ZA200205707B - Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use. - Google Patents
Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use. Download PDFInfo
- Publication number
- ZA200205707B ZA200205707B ZA200205707A ZA200205707A ZA200205707B ZA 200205707 B ZA200205707 B ZA 200205707B ZA 200205707 A ZA200205707 A ZA 200205707A ZA 200205707 A ZA200205707 A ZA 200205707A ZA 200205707 B ZA200205707 B ZA 200205707B
- Authority
- ZA
- South Africa
- Prior art keywords
- lower alkyl
- composition
- independently
- compound
- hydrogen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 253
- 238000000034 method Methods 0.000 title claims description 107
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title claims description 91
- 125000000217 alkyl group Chemical group 0.000 claims description 405
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 343
- 150000001875 compounds Chemical class 0.000 claims description 320
- 229910052739 hydrogen Inorganic materials 0.000 claims description 142
- -1 tri-substituted phenyl Chemical group 0.000 claims description 141
- 239000001257 hydrogen Substances 0.000 claims description 140
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 132
- 125000003545 alkoxy group Chemical group 0.000 claims description 131
- 125000003118 aryl group Chemical group 0.000 claims description 131
- 125000005843 halogen group Chemical group 0.000 claims description 119
- 125000001188 haloalkyl group Chemical group 0.000 claims description 112
- 125000001424 substituent group Chemical group 0.000 claims description 101
- 229960003753 nitric oxide Drugs 0.000 claims description 99
- 229940111134 coxibs Drugs 0.000 claims description 89
- 125000004414 alkyl thio group Chemical group 0.000 claims description 88
- 239000000126 substance Substances 0.000 claims description 80
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 78
- 239000003814 drug Substances 0.000 claims description 67
- 239000003112 inhibitor Substances 0.000 claims description 62
- 125000000623 heterocyclic group Chemical group 0.000 claims description 61
- 125000004429 atom Chemical group 0.000 claims description 58
- 229910052760 oxygen Inorganic materials 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
- 150000002148 esters Chemical class 0.000 claims description 48
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 46
- 125000005842 heteroatom Chemical group 0.000 claims description 46
- 239000002253 acid Substances 0.000 claims description 45
- 230000004054 inflammatory process Effects 0.000 claims description 45
- 238000004519 manufacturing process Methods 0.000 claims description 45
- 206010061218 Inflammation Diseases 0.000 claims description 44
- 125000002950 monocyclic group Chemical group 0.000 claims description 44
- 125000001072 heteroaryl group Chemical group 0.000 claims description 42
- 208000035475 disorder Diseases 0.000 claims description 40
- 229940124597 therapeutic agent Drugs 0.000 claims description 37
- 238000012546 transfer Methods 0.000 claims description 37
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 34
- 229910052799 carbon Inorganic materials 0.000 claims description 34
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 34
- 229920006395 saturated elastomer Polymers 0.000 claims description 34
- 239000000758 substrate Substances 0.000 claims description 34
- 229910002651 NO3 Inorganic materials 0.000 claims description 33
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 33
- 239000000066 endothelium dependent relaxing factor Substances 0.000 claims description 33
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
- 239000001301 oxygen Substances 0.000 claims description 32
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 31
- 239000004215 Carbon black (E152) Substances 0.000 claims description 30
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 30
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 30
- 229910052717 sulfur Inorganic materials 0.000 claims description 29
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 27
- 239000000460 chlorine Substances 0.000 claims description 27
- 230000002496 gastric effect Effects 0.000 claims description 27
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 27
- 229940024606 amino acid Drugs 0.000 claims description 26
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 26
- 125000004043 oxo group Chemical group O=* 0.000 claims description 26
- 125000003342 alkenyl group Chemical group 0.000 claims description 25
- 125000005518 carboxamido group Chemical group 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 239000002464 receptor antagonist Substances 0.000 claims description 24
- 229940044551 receptor antagonist Drugs 0.000 claims description 24
- 208000002193 Pain Diseases 0.000 claims description 23
- 230000036407 pain Effects 0.000 claims description 23
- 125000003282 alkyl amino group Chemical group 0.000 claims description 22
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 22
- 206010037660 Pyrexia Diseases 0.000 claims description 21
- 125000001931 aliphatic group Chemical group 0.000 claims description 21
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 229930195733 hydrocarbon Natural products 0.000 claims description 21
- 150000002430 hydrocarbons Chemical class 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 19
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 18
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 18
- 239000011593 sulfur Substances 0.000 claims description 18
- 208000025865 Ulcer Diseases 0.000 claims description 17
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 17
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 16
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 16
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 16
- 230000001624 sedative effect Effects 0.000 claims description 16
- 231100000397 ulcer Toxicity 0.000 claims description 16
- 230000029663 wound healing Effects 0.000 claims description 16
- 125000005596 alkyl carboxamido group Chemical group 0.000 claims description 15
- 125000004104 aryloxy group Chemical group 0.000 claims description 15
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 15
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- 125000005001 aminoaryl group Chemical group 0.000 claims description 14
- 229940034982 antineoplastic agent Drugs 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 14
- 239000004093 hydrolase inhibitor Substances 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 14
- UFPQIRYSPUYQHK-WAQVJNLQSA-N leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 14
- 239000000612 proton pump inhibitor Substances 0.000 claims description 14
- 241000590002 Helicobacter pylori Species 0.000 claims description 13
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 13
- 125000000747 amidyl group Chemical group [H][N-]* 0.000 claims description 13
- 229940127218 antiplatelet drug Drugs 0.000 claims description 13
- 125000001769 aryl amino group Chemical group 0.000 claims description 13
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 13
- 150000001767 cationic compounds Chemical class 0.000 claims description 13
- 239000000850 decongestant Substances 0.000 claims description 13
- 229940037467 helicobacter pylori Drugs 0.000 claims description 13
- 229910001411 inorganic cation Inorganic materials 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims description 12
- 239000002934 diuretic Substances 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 150000002535 isoprostanes Chemical class 0.000 claims description 12
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims description 12
- 125000001624 naphthyl group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 150000002892 organic cations Chemical class 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 125000005110 aryl thio group Chemical group 0.000 claims description 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 206010052428 Wound Diseases 0.000 claims description 10
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 10
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 10
- 125000005533 aryl carboxamido group Chemical group 0.000 claims description 10
- 150000001721 carbon Chemical group 0.000 claims description 10
- 125000004986 diarylamino group Chemical group 0.000 claims description 10
- 229910052700 potassium Inorganic materials 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- FQWRAVYMZULPNK-UHFFFAOYSA-N N(5)-[(Z)-amino(hydroxyimino)methyl]ornithine Chemical compound OC(=O)C(N)CCCNC(N)=NO FQWRAVYMZULPNK-UHFFFAOYSA-N 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- KWDSFGYQALRPMG-UHFFFAOYSA-N delta-N-Hydroxy-L-orginin Natural products OC(=O)C(N)CCCN(O)C(N)=N KWDSFGYQALRPMG-UHFFFAOYSA-N 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 9
- 231100000419 toxicity Toxicity 0.000 claims description 9
- 230000001988 toxicity Effects 0.000 claims description 9
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims description 8
- 125000005421 aryl sulfonamido group Chemical group 0.000 claims description 8
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 8
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims description 7
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 7
- 201000006549 dyspepsia Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 7
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 claims description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000007882 Gastritis Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical class 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 230000009826 neoplastic cell growth Effects 0.000 claims description 6
- 208000016557 Acute basophilic leukemia Diseases 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 206010006811 Bursitis Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 5
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 5
- 206010020601 Hyperchlorhydria Diseases 0.000 claims description 5
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 5
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 5
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 5
- 206010036600 Premature labour Diseases 0.000 claims description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 claims description 5
- 206010042220 Stress ulcer Diseases 0.000 claims description 5
- 201000008736 Systemic mastocytosis Diseases 0.000 claims description 5
- 208000000491 Tendinopathy Diseases 0.000 claims description 5
- 206010043255 Tendonitis Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 229910052770 Uranium Inorganic materials 0.000 claims description 5
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 230000003872 anastomosis Effects 0.000 claims description 5
- 230000033115 angiogenesis Effects 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 208000000718 duodenal ulcer Diseases 0.000 claims description 5
- 230000008694 endothelial dysfunction Effects 0.000 claims description 5
- 201000000052 gastrinoma Diseases 0.000 claims description 5
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 5
- 208000001288 gastroparesis Diseases 0.000 claims description 5
- 230000008595 infiltration Effects 0.000 claims description 5
- 238000001764 infiltration Methods 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 210000000440 neutrophil Anatomy 0.000 claims description 5
- 208000026440 premature labor Diseases 0.000 claims description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 5
- 125000005504 styryl group Chemical group 0.000 claims description 5
- 201000004415 tendinitis Diseases 0.000 claims description 5
- 230000002485 urinary effect Effects 0.000 claims description 5
- 208000014001 urinary system disease Diseases 0.000 claims description 5
- BDFFOEAQENGFSK-UHFFFAOYSA-N 5-[cyano(nitroso)amino]-2-hydroxypentanamide Chemical compound NC(=O)C(O)CCCN(N=O)C#N BDFFOEAQENGFSK-UHFFFAOYSA-N 0.000 claims description 4
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 4
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 4
- 108010001742 S-Nitrosoglutathione Proteins 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 4
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 4
- 150000003857 carboxamides Chemical class 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- QTJKCQPXTOYYHJ-BYPYZUCNSA-N (2r)-2-acetamido-3-nitrososulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSN=O QTJKCQPXTOYYHJ-BYPYZUCNSA-N 0.000 claims description 3
- QWPCKAAAWDCDCW-VKHMYHEASA-N (2s)-2-amino-4-nitrososulfanylbutanoic acid Chemical compound OC(=O)[C@@H](N)CCSN=O QWPCKAAAWDCDCW-VKHMYHEASA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 claims description 3
- UOHAKHBEJRPHQZ-VKHMYHEASA-N S-nitroso-L-cysteinylglycine Chemical compound O=NSC[C@H](N)C(=O)NCC(O)=O UOHAKHBEJRPHQZ-VKHMYHEASA-N 0.000 claims description 3
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 claims description 3
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 229960002173 citrulline Drugs 0.000 claims description 3
- 235000013477 citrulline Nutrition 0.000 claims description 3
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000005516 coenzyme A Substances 0.000 claims description 3
- 229940093530 coenzyme a Drugs 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical class 0.000 claims description 3
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 229960002743 glutamine Drugs 0.000 claims description 3
- 229960003104 ornithine Drugs 0.000 claims description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- HNIULCDUASSKOM-RQJHMYQMSA-N (2s)-1-[(2s)-2-methyl-3-nitrososulfanylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound O=NSC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O HNIULCDUASSKOM-RQJHMYQMSA-N 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 2
- 150000001204 N-oxides Chemical class 0.000 claims description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 2
- 125000005605 benzo group Chemical group 0.000 claims description 2
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 claims description 2
- AZLYZRGJCVQKKK-UHFFFAOYSA-N dioxohydrazine Chemical compound O=NN=O AZLYZRGJCVQKKK-UHFFFAOYSA-N 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- CUKIPZCSRWOROY-VHEBQXMUSA-N ethyl (2z)-2-[(4-chlorophenyl)-(4-methylsulfonylphenyl)methylidene]-4-nitrooxybutanoate Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(=C(\CCO[N+]([O-])=O)C(=O)OCC)/C1=CC=C(Cl)C=C1 CUKIPZCSRWOROY-VHEBQXMUSA-N 0.000 claims description 2
- CHZCDHHNSOWMDF-UHFFFAOYSA-N ethyl 6-chloro-8-(nitrooxymethyl)-2-(trifluoromethyl)-2h-chromene-3-carboxylate Chemical compound ClC1=CC(CO[N+]([O-])=O)=C2OC(C(F)(F)F)C(C(=O)OCC)=CC2=C1 CHZCDHHNSOWMDF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004991 fluoroalkenyl group Chemical group 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 230000002040 relaxant effect Effects 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 24
- 208000010643 digestive system disease Diseases 0.000 claims 24
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 24
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 208000011906 peptic ulcer disease Diseases 0.000 claims 4
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 3
- 229940124036 Hydrolase inhibitor Drugs 0.000 claims 3
- 229940119568 Inducible nitric oxide synthase inhibitor Drugs 0.000 claims 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 3
- 230000001387 anti-histamine Effects 0.000 claims 3
- 239000000739 antihistaminic agent Substances 0.000 claims 3
- 230000001882 diuretic effect Effects 0.000 claims 3
- 125000002345 steroid group Chemical group 0.000 claims 3
- 229940080328 Arginase inhibitor Drugs 0.000 claims 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 2
- BNIGSLAHGMGZOT-FMQUCBEESA-N (2z)-2-[(4-chlorophenyl)-(4-methylsulfonylphenyl)methylidene]-4-hydroxy-n-(2-methyl-2-nitrososulfanylpropyl)butanamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(=C(\CCO)C(=O)NCC(C)(C)SN=O)/C1=CC=C(Cl)C=C1 BNIGSLAHGMGZOT-FMQUCBEESA-N 0.000 claims 1
- BTXVQDAXMZKMKC-UHFFFAOYSA-N 2-[4-benzyl-3-(4-methylsulfonylphenyl)pyrazol-1-yl]ethanol Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NN(CCO)C=C1CC1=CC=CC=C1 BTXVQDAXMZKMKC-UHFFFAOYSA-N 0.000 claims 1
- JLBKZBWPLNACHN-UHFFFAOYSA-N 2-[4-benzyl-5-(4-methylsulfonylphenyl)pyrazol-1-yl]ethyl nitrate Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(N(N=C1)CCO[N+]([O-])=O)=C1CC1=CC=CC=C1 JLBKZBWPLNACHN-UHFFFAOYSA-N 0.000 claims 1
- NJYXVNXTMBGDNG-UHFFFAOYSA-N 2-methyl-1-(2-methyl-2-nitrososulfanylpropyl)-5-(4-methylsulfonylphenyl)pyrrole Chemical compound O=NSC(C)(C)CN1C(C)=CC=C1C1=CC=C(S(C)(=O)=O)C=C1 NJYXVNXTMBGDNG-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- ZULIOBXIKKKYSL-UHFFFAOYSA-N 3-methyl-n-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl-3-nitrososulfanylbutanamide Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(=O)(=O)NC(=O)CC(C)(C)SN=O)C=C1 ZULIOBXIKKKYSL-UHFFFAOYSA-N 0.000 claims 1
- 101000608750 Arachis hypogaea Alpha-methyl-mannoside-specific lectin Proteins 0.000 claims 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims 1
- 206010056740 Genital discharge Diseases 0.000 claims 1
- 101000771730 Tropidolaemus wagleri Waglerin-3 Proteins 0.000 claims 1
- ZGNZZQCPNXJOIS-QURGRASLSA-N [(z)-3-(4-fluorophenyl)-4-[methyl-(2-methyl-2-nitrososulfanylpropyl)amino]-2-(4-methylsulfonylphenyl)-4-oxobut-2-enyl] acetate Chemical compound C=1C=C(F)C=CC=1/C(C(=O)N(CC(C)(C)SN=O)C)=C(/COC(C)=O)C1=CC=C(S(C)(=O)=O)C=C1 ZGNZZQCPNXJOIS-QURGRASLSA-N 0.000 claims 1
- HKOZPTSLPOOADL-UHFFFAOYSA-N [1-cyclohexyl-5-(4-methylsulfonylphenyl)pyrazol-3-yl]methanol Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(CO)=NN1C1CCCCC1 HKOZPTSLPOOADL-UHFFFAOYSA-N 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- QVFWZNCVPCJQOP-UHFFFAOYSA-N chloralodol Chemical compound CC(O)(C)CC(C)OC(O)C(Cl)(Cl)Cl QVFWZNCVPCJQOP-UHFFFAOYSA-N 0.000 claims 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 230000002175 menstrual effect Effects 0.000 claims 1
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- 239000000243 solution Substances 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 40
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- 239000000047 product Substances 0.000 description 34
- 238000001819 mass spectrum Methods 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- 239000007787 solid Substances 0.000 description 30
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- 239000002904 solvent Substances 0.000 description 25
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 23
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 18
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 18
- 239000002840 nitric oxide donor Substances 0.000 description 17
- 241000894007 species Species 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 229940035676 analgesics Drugs 0.000 description 13
- 239000000730 antalgic agent Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 12
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- KEJOCWOXCDWNID-UHFFFAOYSA-N Nitrilooxonium Chemical compound [O+]#N KEJOCWOXCDWNID-UHFFFAOYSA-N 0.000 description 11
- 150000003431 steroids Chemical class 0.000 description 11
- 229940124581 decongestants Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 10
- 229960000201 isosorbide dinitrate Drugs 0.000 description 10
- 229940005483 opioid analgesics Drugs 0.000 description 10
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 10
- 102000010906 Cyclooxygenase 1 Human genes 0.000 description 9
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 9
- 229940030606 diuretics Drugs 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 231100000417 nephrotoxicity Toxicity 0.000 description 9
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 9
- CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 239000000938 histamine H1 antagonist Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 150000003573 thiols Chemical class 0.000 description 8
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 7
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 125000003709 fluoroalkyl group Chemical group 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229960001802 phenylephrine Drugs 0.000 description 5
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- LUOUCHOLMUUZBO-SVSXJNCISA-N [4-[(1e,3e)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate Chemical compound C1=C(OC)C(OC(=O)OCC)=CC=C1\C=C\C=C\C(=O)NCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 LUOUCHOLMUUZBO-SVSXJNCISA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- ZEYYDOLCHFETHQ-JOCHJYFZSA-N (2r)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Chemical compound C1([C@@H](C(=O)O)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)CCCC1 ZEYYDOLCHFETHQ-JOCHJYFZSA-N 0.000 description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001308 poly(aminoacid) Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JENWDDCMEATQSR-ONSKYXJOSA-N (2r)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-3-(4-hydroxyphenyl)-2-(methylamino)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]-met Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N(C)[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC(C)C)C(=O)NCC)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC)C1=CC=CC=C1 JENWDDCMEATQSR-ONSKYXJOSA-N 0.000 description 2
- DTQNEFOKTXXQKV-HKUYNNGSSA-N (2s,3s)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 DTQNEFOKTXXQKV-HKUYNNGSSA-N 0.000 description 2
- BUMMZWFWCNQFPS-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[5-(4-carbamimidoylphenoxy)pentoxy]-3-methoxy-n,n-di(propan-2-yl)benzamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 BUMMZWFWCNQFPS-BTJKTKAUSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- MBPAUMHSIFBANF-UHFFFAOYSA-N 1-amino-2-methylpropane-2-thiol Chemical compound CC(C)(S)CN MBPAUMHSIFBANF-UHFFFAOYSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- JKYJSFISYHSNOE-UHFFFAOYSA-N 2-[3-[1-[[2-(3,4-dichlorophenyl)-1-oxoethyl]-methylamino]-2-(1-pyrrolidinyl)ethyl]phenoxy]acetic acid Chemical compound C=1C=C(Cl)C(Cl)=CC=1CC(=O)N(C)C(C=1C=C(OCC(O)=O)C=CC=1)CN1CCCC1 JKYJSFISYHSNOE-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- YWYUQSGYKDEAMJ-QFIPXVFZSA-N 3-[(2s)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2h-chromen-2-yl]propanoic acid Chemical compound O([C@H](CCC(O)=O)CCC=1C=C2)C=1C(CCC)=C2OCCCOC1=CC=C(C(=O)NC)C(OC)=C1CC1CC1 YWYUQSGYKDEAMJ-QFIPXVFZSA-N 0.000 description 2
- KRCUWCAUDKTMPB-UHFFFAOYSA-N 4-[[n-[(3-fluorophenyl)methyl]-4-(quinolin-2-ylmethoxy)anilino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN(C=1C=CC(OCC=2N=C3C=CC=CC3=CC=2)=CC=1)CC1=CC=CC(F)=C1 KRCUWCAUDKTMPB-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- JOPSSWGWLCLPPF-RUDMXATFSA-N 5-[2-(2-carboxyethyl)-3-[(e)-6-(4-methoxyphenyl)hex-5-enoxy]phenoxy]pentanoic acid Chemical compound C1=CC(OC)=CC=C1\C=C\CCCCOC1=CC=CC(OCCCCC(O)=O)=C1CCC(O)=O JOPSSWGWLCLPPF-RUDMXATFSA-N 0.000 description 2
- UDYUIWXQUBNDHC-UHFFFAOYSA-N 6-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 UDYUIWXQUBNDHC-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- YFIZRWPXUYFCSN-UHFFFAOYSA-N LY293111 Chemical compound C1=CC=C(OC=2C(=CC=CC=2)C(O)=O)C(CCC)=C1OCCCOC(C(=C1)CC)=CC(O)=C1C1=CC=C(F)C=C1 YFIZRWPXUYFCSN-UHFFFAOYSA-N 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 229930195725 Mannitol Chemical class 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
- HDURYNMDIDGIMT-HNENSFHCSA-N [(z)-2-(4-fluorophenyl)-4-hydroxy-3-(4-methylsulfonylphenyl)but-2-enyl] acetate Chemical compound C=1C=C(F)C=CC=1C(/COC(=O)C)=C(/CO)C1=CC=C(S(C)(=O)=O)C=C1 HDURYNMDIDGIMT-HNENSFHCSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960002133 almotriptan Drugs 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229950010033 ebselen Drugs 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000594 mannitol Chemical class 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 2
- 150000002826 nitrites Chemical class 0.000 description 2
- 150000002829 nitrogen Chemical class 0.000 description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229950006862 rilopirox Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000004059 squalene synthase inhibitor Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000000542 sulfonic acid group Chemical group 0.000 description 2
- 125000004354 sulfur functional group Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XKKGMVDIONCFKP-UHFFFAOYSA-N (2-butyl-4-methoxynaphthalen-1-yl) acetate Chemical compound C1=CC=CC2=C(OC(C)=O)C(CCCC)=CC(OC)=C21 XKKGMVDIONCFKP-UHFFFAOYSA-N 0.000 description 1
- IQMNSYSWLJMVCP-FMQUCBEESA-N (2z)-2-[(4-chlorophenyl)-(4-methylsulfonylphenyl)methylidene]-4-hydroxy-n-(2-methyl-2-sulfanylpropyl)butanamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(=C(\CCO)C(=O)NCC(C)(S)C)/C1=CC=C(Cl)C=C1 IQMNSYSWLJMVCP-FMQUCBEESA-N 0.000 description 1
- IFYUDIRJWINNFY-WUKNDPDISA-N (2z)-2-[(4-chlorophenyl)-(4-methylsulfonylphenyl)methylidene]-4-nitrooxybutanoic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(=C(/CCO[N+]([O-])=O)C(O)=O)\C1=CC=C(Cl)C=C1 IFYUDIRJWINNFY-WUKNDPDISA-N 0.000 description 1
- HFKKMXCOJQIYAH-YFKPBYRVSA-N (S)-2-amino-6-boronohexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCB(O)O HFKKMXCOJQIYAH-YFKPBYRVSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- ZTXDHEQQZVFGPK-UHFFFAOYSA-N 1,2,4-tris(oxiran-2-ylmethyl)-1,2,4-triazolidine-3,5-dione Chemical compound C1OC1CN1C(=O)N(CC2OC2)C(=O)N1CC1CO1 ZTXDHEQQZVFGPK-UHFFFAOYSA-N 0.000 description 1
- QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- NVQSZIPWICDNLW-UHFFFAOYSA-N 1-(4-methylsulfonylphenyl)pentane-1,4-dione Chemical compound CC(=O)CCC(=O)C1=CC=C(S(C)(=O)=O)C=C1 NVQSZIPWICDNLW-UHFFFAOYSA-N 0.000 description 1
- KMNLXCBYBKHKSK-BKMJKUGQSA-N 1-[(3s,4r)-4-hydroxy-3-[(4-phenylphenyl)methyl]-3,4-dihydro-2h-chromen-7-yl]cyclopentane-1-carboxylic acid Chemical compound C([C@@H]1[C@H](C2=CC=C(C=C2OC1)C1(CCCC1)C(O)=O)O)C(C=C1)=CC=C1C1=CC=CC=C1 KMNLXCBYBKHKSK-BKMJKUGQSA-N 0.000 description 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- JMBYBVLCYODBJQ-HFMPRLQTSA-N 2-(1-benzofuran-4-yl)-n-methyl-n-[(5r,7s,8s)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=3C=COC=3C=CC=2)C[C@]21CCCO2 JMBYBVLCYODBJQ-HFMPRLQTSA-N 0.000 description 1
- KUXUHSZZXWMMSU-UHFFFAOYSA-N 2-(1-methyl-4-nitrososulfanylpiperidin-4-yl)ethanol Chemical compound CN1CCC(CCO)(SN=O)CC1 KUXUHSZZXWMMSU-UHFFFAOYSA-N 0.000 description 1
- SYOPRZWROBOKGX-ZJSXRUAMSA-N 2-(3,4-dichlorophenyl)-n-[(1r,2r)-5-methoxy-2-pyrrolidin-1-yl-1,2,3,4-tetrahydronaphthalen-1-yl]-n-methylacetamide Chemical compound N1([C@H]2[C@@H](C=3C=CC=C(C=3CC2)OC)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CCCC1 SYOPRZWROBOKGX-ZJSXRUAMSA-N 0.000 description 1
- IWSVLBKHBJGMAA-UHFFFAOYSA-M 2-(3-benzyl-4-methyl-1,3-thiazol-3-ium-5-yl)ethanol;chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CC=CC=C1 IWSVLBKHBJGMAA-UHFFFAOYSA-M 0.000 description 1
- RVAQGJXYUJRFFK-UHFFFAOYSA-N 2-(4-benzylsulfanyl-1-methylpiperidin-4-yl)ethanol Chemical compound C1CN(C)CCC1(CCO)SCC1=CC=CC=C1 RVAQGJXYUJRFFK-UHFFFAOYSA-N 0.000 description 1
- UIJWMSUSZQORDJ-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 UIJWMSUSZQORDJ-UHFFFAOYSA-N 0.000 description 1
- AHUVYKWQXYVARC-UHFFFAOYSA-N 2-[1-[(4-chlorophenyl)methyl]-5-methoxy-2-methylindol-3-yl]ethanol Chemical compound CC1=C(CCO)C2=CC(OC)=CC=C2N1CC1=CC=C(Cl)C=C1 AHUVYKWQXYVARC-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- 125000002856 2-fluorophenylethyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- AFFARTYCDZPMRS-UHFFFAOYSA-N 2-methyl-1-[2-methyl-5-(4-methylsulfonylphenyl)pyrrol-1-yl]propane-2-thiol Chemical compound CC(S)(C)CN1C(C)=CC=C1C1=CC=C(S(C)(=O)=O)C=C1 AFFARTYCDZPMRS-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- XNWFXTOHNKPYMK-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydrocyclopenta[c]dioxole Chemical compound C1OOC2CCCC21 XNWFXTOHNKPYMK-UHFFFAOYSA-N 0.000 description 1
- LMGHUTIUVKVZNH-UHFFFAOYSA-N 3,4-difluoro-2-methylbenzonitrile Chemical compound CC1=C(F)C(F)=CC=C1C#N LMGHUTIUVKVZNH-UHFFFAOYSA-N 0.000 description 1
- ZTKJKZVEZUKEAD-UHFFFAOYSA-N 3-(2-bromoethyl)-1-[(4-chlorophenyl)methyl]-5-methoxy-2-methylindole Chemical compound CC1=C(CCBr)C2=CC(OC)=CC=C2N1CC1=CC=C(Cl)C=C1 ZTKJKZVEZUKEAD-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- YWYUQSGYKDEAMJ-UHFFFAOYSA-N 3-[7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2h-chromen-2-yl]propanoic acid Chemical compound C1=CC=2CCC(CCC(O)=O)OC=2C(CCC)=C1OCCCOC1=CC=C(C(=O)NC)C(OC)=C1CC1CC1 YWYUQSGYKDEAMJ-UHFFFAOYSA-N 0.000 description 1
- LZVBMKDVEPGGFK-DQEYMECFSA-N 3-[[2-[2-(4-chlorophenyl)sulfanylethoxy]-3-methoxy-5-[(2s,5s)-5-(3,4,5-trimethoxyphenyl)oxolan-2-yl]phenyl]methyl]-1-hydroxy-1-methylurea Chemical compound COC1=CC([C@H]2O[C@@H](CC2)C=2C=C(OC)C(OC)=C(OC)C=2)=CC(CNC(=O)N(C)O)=C1OCCSC1=CC=C(Cl)C=C1 LZVBMKDVEPGGFK-DQEYMECFSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 1
- JLKUMSHHQYQLSG-UHFFFAOYSA-N 3-carboxy-3,5-dihydroxy-5-oxopentanoate;dimethyl-[2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethyl]azanium Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=NN1C JLKUMSHHQYQLSG-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- BPQAYMFGBGMJRY-UHFFFAOYSA-N 4,6-dimethyl-2-(6-phenylhexylamino)pyrimidin-5-ol;phosphoric acid Chemical compound OP(O)(O)=O.CC1=C(O)C(C)=NC(NCCCCCCC=2C=CC=CC=2)=N1 BPQAYMFGBGMJRY-UHFFFAOYSA-N 0.000 description 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 description 1
- FIKVYIRIUOFLLR-UHFFFAOYSA-N 4-[4-(2,4-difluorophenyl)phenyl]-2-methyl-4-oxobutanoic acid Chemical compound C1=CC(C(=O)CC(C)C(O)=O)=CC=C1C1=CC=C(F)C=C1F FIKVYIRIUOFLLR-UHFFFAOYSA-N 0.000 description 1
- UJSFKTUZOASIPA-UHFFFAOYSA-N 4-[5-(hydroxymethyl)-3-phenyl-1,2-oxazol-4-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(CO)ON=C1C1=CC=CC=C1 UJSFKTUZOASIPA-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- HZUIZEPUKSIFOK-UHFFFAOYSA-N 4-methylsulfanylbenzaldehyde 1-(4-methylsulfanylphenyl)pentane-1,4-dione Chemical compound CSC1=CC=C(C=O)C=C1.CSC1=CC=C(C=C1)C(CCC(C)=O)=O HZUIZEPUKSIFOK-UHFFFAOYSA-N 0.000 description 1
- BVXIPVGMZNDIPW-UHFFFAOYSA-N 4-methylsulfonyl-3-phenyl-3h-furan-2-one Chemical class CS(=O)(=O)C1=COC(=O)C1C1=CC=CC=C1 BVXIPVGMZNDIPW-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- OUTUZEBQXNEVGY-UHFFFAOYSA-N 5,5-diethyl-1,3-diazinane-2,4,6-trione;4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O.O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 OUTUZEBQXNEVGY-UHFFFAOYSA-N 0.000 description 1
- JOPSSWGWLCLPPF-UHFFFAOYSA-N 5-[2-(2-carboxyethyl)-3-[6-(4-methoxyphenyl)hex-5-enoxy]phenoxy]pentanoic acid Chemical compound C1=CC(OC)=CC=C1C=CCCCCOC1=CC=CC(OCCCCC(O)=O)=C1CCC(O)=O JOPSSWGWLCLPPF-UHFFFAOYSA-N 0.000 description 1
- LECUGLHMNZTZQB-XNIJJKJLSA-N 5-amino-1-[(2r,3r,4s,5r)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CNCC=2C=CC=CC=2)O1 LECUGLHMNZTZQB-XNIJJKJLSA-N 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- ZVVCSBSDFGYRCB-UHFFFAOYSA-N 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound C1=CC(C(C)=O)=C(OC)C(CCC)=C1OCCCOC1=CC=C(CCC(O2)C(O)=O)C2=C1CCC ZVVCSBSDFGYRCB-UHFFFAOYSA-N 0.000 description 1
- NFHKAMAWIQHXAT-UHFFFAOYSA-N 7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(1,3-thiazol-4-yl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound C1=CC=2CCC(C(O)=O)OC=2C(CCC)=C1OCCCOC(C(=C1OC)CC2CC2)=CC=C1C1=CSC=N1 NFHKAMAWIQHXAT-UHFFFAOYSA-N 0.000 description 1
- PBDRPBFECGUOAU-UHFFFAOYSA-N 7-[4-[[4-(carbamoylamino)phenyl]methyl]phenyl]heptanoic acid Chemical compound C1=CC(NC(=O)N)=CC=C1CC1=CC=C(CCCCCCC(O)=O)C=C1 PBDRPBFECGUOAU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 description 1
- PBZVIYIWLYRXNM-ZGRMKTROSA-N Acanthifolicin Chemical compound O([C@@]12[C@@H]3S[C@]3(C)C[C@H](O2)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)C(O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]1O PBZVIYIWLYRXNM-ZGRMKTROSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000945 Amylopectin Chemical class 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 108010039478 BPC 157 Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- HEEWEZGQMLZMFE-RKGINYAYSA-N CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H]1N(C(=O)[C@H]2N(CCC2)C(=O)[C@H]2N(CCC2)C(=O)[C@H](CCC(O)=O)NC(=O)CN)CCC1 Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H]1N(C(=O)[C@H]2N(CCC2)C(=O)[C@H]2N(CCC2)C(=O)[C@H](CCC(O)=O)NC(=O)CN)CCC1 HEEWEZGQMLZMFE-RKGINYAYSA-N 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100024066 Coiled-coil and C2 domain-containing protein 1A Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 101000594607 Conus magus Omega-conotoxin MVIIA Proteins 0.000 description 1
- 229920002261 Corn starch Chemical class 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- IONAQTGMWFXHIX-UHFFFAOYSA-N E3040 Chemical compound CC1=C(O)C(C)=C2SC(NC)=NC2=C1CC1=CC=CN=C1 IONAQTGMWFXHIX-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000910423 Homo sapiens Coiled-coil and C2 domain-containing protein 1A Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 101100490479 Lactococcus lactis subsp. lactis (strain IL1403) addA gene Proteins 0.000 description 1
- 101100000975 Lactococcus lactis subsp. lactis (strain IL1403) rexB gene Proteins 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KWKZCGMJGHHOKJ-ZKWNWVNESA-N Methyl Arachidonyl Fluorophosphonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCP(F)(=O)OC KWKZCGMJGHHOKJ-ZKWNWVNESA-N 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- 206010034344 Peptic ulcer haemorrhage Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 1
- 108091005623 S-nitrosylated proteins Proteins 0.000 description 1
- 241001486234 Sciota Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 1
- 108020003891 Squalene monooxygenase Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LWKUJMVWHTVMLC-HNENSFHCSA-N [(z)-3-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-4-oxobut-2-enyl] acetate Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(/COC(=O)C)=C(/C=O)C1=CC=C(F)C=C1 LWKUJMVWHTVMLC-HNENSFHCSA-N 0.000 description 1
- VYPUXNRDLGIBRW-HNENSFHCSA-N [(z)-3-(4-fluorophenyl)-4-hydroxy-2-(4-methylsulfonylphenyl)but-2-enyl] acetate Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(/COC(=O)C)=C(/CO)C1=CC=C(F)C=C1 VYPUXNRDLGIBRW-HNENSFHCSA-N 0.000 description 1
- OILIHSBVKGKIBV-UHFFFAOYSA-N [3-phenyl-4-(4-sulfamoylphenyl)-1,2-oxazol-5-yl]methyl nitrate Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(CO[N+]([O-])=O)ON=C1C1=CC=CC=C1 OILIHSBVKGKIBV-UHFFFAOYSA-N 0.000 description 1
- CQWOCXFNVYBQAP-GAGCPXRHSA-M [Li+].C(=C\C=C\CCCCCCCCCC)/C1C(O1)C1=C(C(=O)[O-])C=CC=C1 Chemical compound [Li+].C(=C\C=C\CCCCCCCCCC)/C1C(O1)C1=C(C(=O)[O-])C=CC=C1 CQWOCXFNVYBQAP-GAGCPXRHSA-M 0.000 description 1
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 description 1
- 229960003000 acadesine Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950001003 anaxirone Drugs 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229950006427 bunaprolast Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- OFAIGZWCDGNZGT-UHFFFAOYSA-N caramiphen Chemical compound C=1C=CC=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 OFAIGZWCDGNZGT-UHFFFAOYSA-N 0.000 description 1
- 229960004160 caramiphen Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- SUAJWTBTMNHVBZ-UHFFFAOYSA-N clonitrate Chemical compound [O-][N+](=O)OCC(CCl)O[N+]([O-])=O SUAJWTBTMNHVBZ-UHFFFAOYSA-N 0.000 description 1
- 229950004347 clonitrate Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008120 corn starch Chemical class 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229950010961 enadoline Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- VCFGXLWRLVJHKK-UHFFFAOYSA-N ethyl 2-(1-methylpiperidin-4-ylidene)acetate Chemical compound CCOC(=O)C=C1CCN(C)CC1 VCFGXLWRLVJHKK-UHFFFAOYSA-N 0.000 description 1
- FVCATMMWRMZOST-UHFFFAOYSA-N ethyl 2-(4-benzylsulfanyl-1-methylpiperidin-2-yl)acetate Chemical compound C1CN(C)C(CC(=O)OCC)CC1SCC1=CC=CC=C1 FVCATMMWRMZOST-UHFFFAOYSA-N 0.000 description 1
- FJKGJDCQUXITNS-UHFFFAOYSA-N ethyl 6-chloro-8-(hydroxymethyl)-2-(trifluoromethyl)-2h-chromene-3-carboxylate Chemical compound ClC1=CC(CO)=C2OC(C(F)(F)F)C(C(=O)OCC)=CC2=C1 FJKGJDCQUXITNS-UHFFFAOYSA-N 0.000 description 1
- VDMUQNZYCVYKMP-UHFFFAOYSA-N ethyl 6-chloro-8-formyl-2-(trifluoromethyl)-2h-chromene-3-carboxylate Chemical compound ClC1=CC(C=O)=C2OC(C(F)(F)F)C(C(=O)OCC)=CC2=C1 VDMUQNZYCVYKMP-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- KFSXLIJSXOJBCB-HZMBPMFUSA-N filenadol Chemical compound N1([C@@H]([C@@H](O)C)C=2C=C3OCOC3=CC=2)CCOCC1 KFSXLIJSXOJBCB-HZMBPMFUSA-N 0.000 description 1
- 229950003056 filenadol Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229950006000 flezelastine Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- RVRATNAADXHAQO-ZJSKVYKZSA-M lithium;(e)-3-[6-[(3-aminophenyl)sulfinylmethyl]-3-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]prop-2-enoate Chemical compound [Li+].C1=CC(OC)=CC=C1CCCCCCCCOC(C(=N1)\C=C\C([O-])=O)=CC=C1CS(=O)C1=CC=CC(N)=C1 RVRATNAADXHAQO-ZJSKVYKZSA-M 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- DGMJZELBSFOPHH-KVTDHHQDSA-N mannite hexanitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)CO[N+]([O-])=O DGMJZELBSFOPHH-KVTDHHQDSA-N 0.000 description 1
- 229960001765 mannitol hexanitrate Drugs 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
- 229960000365 meptazinol Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- JCDWETOKTFWTHA-UHFFFAOYSA-N methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=CC=C1 JCDWETOKTFWTHA-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- RVXKHAITGKBBAC-SFHVURJKSA-N n-[(1s)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine Chemical compound C([C@H](NC=1OC2=CC=C(C=C2N=1)C)C=1N=CC=CC=1)C1CCCCC1 RVXKHAITGKBBAC-SFHVURJKSA-N 0.000 description 1
- ZBOYHAZRFJBUEL-UHFFFAOYSA-N n-[2-(4-benzhydryloxypiperidin-1-yl)ethyl]-3-hydroxy-5-(pyridin-3-ylmethoxy)naphthalene-2-carboxamide Chemical compound C1=CC=C2C=C(C(=O)NCCN3CCC(CC3)OC(C=3C=CC=CC=3)C=3C=CC=CC=3)C(O)=CC2=C1OCC1=CC=CN=C1 ZBOYHAZRFJBUEL-UHFFFAOYSA-N 0.000 description 1
- YAYBWZFZDMHVDH-UHFFFAOYSA-N n-amino-n-hydroxynitrous amide Chemical class NN(O)N=O YAYBWZFZDMHVDH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KXMAIWXPZGQNCR-KRWDZBQOSA-N n-propyl-10-[(2s)-1-pyrrolidin-1-ylpropan-2-yl]phenothiazine-2-carboxamide Chemical compound C([C@H](C)N1C2=CC=CC=C2SC2=CC=C(C=C21)C(=O)NCCC)N1CCCC1 KXMAIWXPZGQNCR-KRWDZBQOSA-N 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000013315 neuromuscular junction disease Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 108091005622 nitrosylated proteins Proteins 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical class ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229950010666 ontazolast Drugs 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- VVNCNSJFMMFHPL-UHFFFAOYSA-N penicillamine Chemical compound CC(C)(S)C(N)C(O)=O VVNCNSJFMMFHPL-UHFFFAOYSA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960003436 pentoxyverine Drugs 0.000 description 1
- BRBAEHHXGZRCBK-UHFFFAOYSA-N pentrinitrol Chemical compound [O-][N+](=O)OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O BRBAEHHXGZRCBK-UHFFFAOYSA-N 0.000 description 1
- 229950006286 pentrinitrol Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229920001592 potato starch Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- WDTHDAAJSPBIKY-QZQOTICOSA-N propyl (Z)-4-acetyloxy-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)but-2-enoate Chemical compound C=1C=C(F)C=CC=1/C(C(=O)OCCC)=C(/COC(C)=O)C1=CC=C(S(C)(=O)=O)C=C1 WDTHDAAJSPBIKY-QZQOTICOSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000005470 propylenyl group Chemical group 0.000 description 1
- 229960000786 propylhexedrine Drugs 0.000 description 1
- JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229950010450 pseudophedrine Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
- 229960000425 rizatriptan Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 229960003320 roxatidine Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- 229950009638 tepoxalin Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229960000833 xylometazoline Drugs 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
BR WO 81/45703 PCT/US00/35014
NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS,
COMPOSITIONS AND METHODS OF USE
This application claims priority to U.S. Provisional Application No. 60/171,623 filed December 23, 1999, and U.S. Provisional Application No. : 60/226,085 filed August 18, 2000.
The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one COX-2 inhibitor. The present invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.
Nonsteroidal anti-inflammatory compounds (NSAIDs) are widely used for the treatment of pain, inflammation, and acute and chronic inflammatory disorders such as osteoarthritis and rheumatoid arthritis. These compounds inhibit the activity of the enzyme cyclooxygenase (COX), also known as prostaglandin G/H synthase, which is the enzyme that converts arachidonic acid into prostanoids. The
NSAIDs also inhibit the production of other prostaglandins, especially prostaglandin G,, prostaglandin H, and prostaglandin E,, thereby reducing the prostaglandin-induced pain and swelling associated with the inflammation process. The chronic use of NSAIDs has been associated with adverse effects, such as gastrointestinal ulceration and renal toxicity. The undesirable side effects are also due to the inhibition of prostaglandin in the affected organ.
Recently two isoforms of cyclooxygenase, encoded by two distinct genes (Kujubu et al, J. Biol. Chem., 266, 12866-12872 (1991)), have been identified — a x WO 01/45703 PCT/US00/35014 constitutive form, cyclooxygenase-1 (COX-1), and an inductive form, cyclooxygenase-2 (COX-2). It is thought that the antiinflammatory effects of
NSAIDs are mediated by the inhibition of COX-2, whereas the side effects seem to be caused by the inhibition of COX-1. The NSAIDs currently on the market either inhibit both isoforms of COX with little selectivity for either isoform or are COX-1 selective. Recently compounds that are selective COX-2 inhibitors have been developed and marketed. These selective COX-2 inhibitors have the desired therapeutic profile of an antiinflammatory drug without the adverse effects commonly associated with the inhibition of COX-1. However, these compounds can result in dyspepsia and can cause gastropathy (Mohammed et al, N. Engl. J.
Med., 340(25) 2005 (1999)).
Selective COX-2 inhibitors are disclosed in, for example, U. S. Patent Nos. 5,681,842, 5,750,558, 5,756,531, 5,776,984 and in WO 97/41100, WO 98/39330, WO 99/10331, WO 99/10332 and WO 00/24719 assigned to Abbott Laboratories; and in
WO 98/50075, WO 00/29022 and WO 00/29023 assigned to Algos Pharmaceutical
Corporation; and in WO 99/15205 assigned to Almirall Prodesfarma S.A.; and in U.
S. Patent No. 5,980,905 assigned to AMBI Inc. ; and in U. S. Patent No. 5,945,538 assigned to American Cyanamid Company; and in U. S. Patent Nos. 5,776,967, + 5,824,699, 5,830,911 and in WO 98/04527 and WO 98/21195 assigned to American
Home Products Corporation; and in WO 98/22442 assigned to Angelini Richerche
S. P. A. Societa Consortile; and in U. S. Patent No. 6,046,191 and in WO 99/18960 and WO 00/00200 assigned to Astra Pharmaceuticals Ltd.; and in U. S. Patent No. 5,905,089 assigned to Board of Supervisors of Louisiana State University; and in
WO 97/13767 assigned to Chemisch Pharmazeutische Forschungsgesellschaft
MBH; and in WO 98/57924 and WO 99/61436 assigned to Chugai Seiyaku
Kabushiki Kaisha; and in WO 00/13685 assigned to Cornell Research Foundation
Inc.; and in WO 96/10021 assigned to The Du Pont Merck Pharmaceutical
Company; and in EP 0 087 629 B1 assigned to E.I. Du Pont de Nemours and
Company; and in WO 99/13799 assigned to Euro-Celtique; and in U. S. Patent No. 5,134,142 and in WO 91/19708, WO 97/13755, WO 99/15505, WO 99/25695 and in
EP 0 418 845 B1 and EP 0 554 829 A2 assigned to Fujisawa Pharmaceutical Co. Ltd.; and in U. S. Patent Nos. 5,344,991, 5,393,790, 5,434,178, 5,466,823, 5,486,534, : 5,504,215, 5,508,426, 5,510,496, 5,516,907, 5,521,207, 5,563,165, 5,580,985, 5,596,008,
RN WO 01/45703 PCT/US00/35014 5,616,601, 5,620,999, 5,633,272, 5,643,933, 5,668,161, 5,686,470, 5,696,143, 5,700,816, 5,719,163, 5,753,688, 5,756,530, 5,760,068, 5,859,257, 5,908,852, 5,935,990, 5,972,986, 5,985,902, 5,990,148, 6,025,353, 6,028,072, 6,136,839 and in WO 94/15932, WO 94/27980, WO 95/11883, WO 95/15315, WO 95/15316, WO 95/15317, WO 95/15318, WO 95/21817, WO 95/30652, WO 95/30656, WO 96/03392, WO 96/03385, WO 96/03387, WO 96/03388, WO 96/09293, WO 96/09304, WO 96/16934, WO 96/25405, WO 96/24584, WO 96/24585, WO 96/36617, WO 96/38418, WO 96/38442, WO 96,/41626, WO 96/41645, WO 97/11704, WO 97/27181, WO 97/29776, WO 97 /38986, WO 98/06708, WO 98/43649, WO 98/47509, WO 98/47890, WO 98/52937, WO 99/22720, WO 00/23433, WO 00/37107, WO 00/38730, WO 00/38786 and WO 00/53149 assigned to G.D. Searle & Co.; and in WO 96/31509, WO 99/12930, WO 00/26216 and WO 00/52008 - assigned to Glaxo Group Limited; and in EP 1 006 114 Al and in WO 98/46594 assigned to Grelan Pharmaceutical Co. Ltd.; and in WO 97/34882 assigned to
Grupo Farmaceutico Almirall; and in WO 97/03953 assigned to Hafslund
Nycomed Pharma AG; and in WO 98/32732 assigned to Hoffmann-La Roche AG; and in U. S. Patent Nos. 5,945,539, 5,994,381, 6,002,014 and in WO 96/19462, WO 96/19463 and in EP 0 745 596 Al assigned to Japan Tobacco, Inc.; and in U. S.
Patent Nos. 5,686,460, 5,807,873 and in WO 97/37984, WO 98/05639, WO 98/11080 and WO 99/21585 assigned to Laboratories USPA; and in WO 99/62884 assigned to :
Laboratories Del Dr. Esteve, S. A.; and in WO 00/08024 assigned to Laboratorios
S.ALV.AT,S. A; and in U.S. Patent Nos. 5,585,504, 5,840,924, 5,883,267, 5,925,631, 6,001,843, 6,080,876 and in WO 97/44027, WO 97 /44028, WO 97 /45420,
WO 98/00416, WO 98/47871, WO 99/15503, WO 99/15513, WO 99/ 201 10, WO 99/45913, WO 99/55830, WO 00/25779 and WO 00/27382 assigned to Merck & Co.
Inc; and in U. S. Patent Nos. 5,409,944, 5,436,265, 5,474,995, 5,536,752, 5,550,142, 5,510,368, 5,521,213, 5,552,422, 5,604,253, 5,604,260, 5,639,780, 5,677,318, 5,691,374, 5,698,584, 5,710,140, 5,733,909, 5,789,413, 5,817,700, 5,840,746, 5,849,943, 5,861,419, 5,981,576, 5,994,379, 6,020,343, 6,071,936, 6,071,954 and in EP 0 788 476 B1, EP 0 863 134 A1, EP 0 882 016 B1 and in WO 94/20480, WO 94/13635, WO 94/26731, WO ’ 95/00501, WO 95/18799, WO 96/06840, WO 96/13483, WO 96/19469, WO 96/21667, WO 96/23786, WO 96/36623, WO 96/37467, WO 96/37468, WO 96/37469, WO 97/14691, WO 97/16435, WO 97/28120, WO 97/28121, WO i WO 01/45703 PCT/US00/35014 97/36863, WO 98/03484, WO 98/41511, WO 98/41516, WO 98/43966, WO 99/14194, WO 99/14195, WO 99/23087, WO 99/41224 and WO 00/68215 assigned to Merck Frosst Canada & Co., and in WO 99/59635 assigned to Merck Sharp &
Dohme Limited; and in U. S. Patent No. 5,380,738 assigned to Monsanto Company; and in WO 00/01380 assigned to A. Nattermann & Co.; and in WO 99/61016 assigned to Nippon Shinyaku Co. Ltd.; and in WO 99/33796 assigned to Nissin
Food Products Co. Ltd.; and in WO 99/11605 assigned to Novartis AG; and in WO 98/33769 assigned to Nycomed Austria GMBH; and in U. S. Patent Nos. 6,077,869 and 6,083,969 and in WO 00/51685 assigned to Ortho-McNeil Pharmaceutical, Inc.; and in U. S. Patent No. 5,783,597 assigned to Ortho Pharmaceutical Corporation; and in WO 98/07714 assigned to Oxis International Inc.; and in WO 00/10993 assigned to Pacific Corporation; and in EP 0937 722 Al and in WO 98/50033, WO 99/05104, WO 99/35130 and WO 99/64415 assigned to Pfizer Inc.; and in WO 00/48583 assigned to Pozen Inc.; and in U. S. Patent No. 5,908,858 assigned to
Sankyo Company Limited; and in WO 97/25045 assigned to SmithKline Beecham
Corporation; and in U.S. Patent No. 5,399,357 assigned to Takeda Chemical
Industries, Ltd.; and in WO 99/20589 assigned to The University of Sydney; and in :
U. S. Patent No. 5,475,021 and WO 00/40087 assigned to Vanderbilt University; and in WO 99 /59634 assigned to Wakamoto Pharmaceutical Co. Ltd., the : disclosures of each of which are incorporated by reference herein in their entirety.
There is still a need in the art for COX-2 inhibitor compounds that have gastroprotective properties, facilitate wound healing, decreased renal toxicity and dyspepsia, and that can be used at low dosages. The present invention is directed to these, as well as other, important ends.
The present invention provides novel nitrosated and/or nitrosylated COX-2 inhibitors, which are COX-2 inhibitors linked to at least one nitrogen monoxide group (NO), and/or at least one nitrogen dioxide group (NO,) (i.e., nitrosylated : and/or nitrosated group, respectively). The resulting compounds are potent analgesics, have antiinflammatory properties and have an unexpected potential for facilitating wound healing. The novel compounds also have unexpected properties in the treatment and/or prevention of renal toxicity. The COX-2 inhibitors can be nitrosated and/or nitrosylated through one or more sites, such as oxygen oy WO 01/45703 PCT/US00/35014 (hydroxyl condensation), sulfur (sulfhydryl condensation) and/or nitrogen. The
COX-2 inhibitor can be, for example, a sulfonamide containing 1,5-diarylpyrazole derivative, such as, for example, CELEBREX® (4-(5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, Celecoxib). The COX-2 ‘ 5 inhibitor can also be, for example, a methylsulfonylphenyl-furanone derivative, such as, for example, Rofecoxib (VIOXX®, 4-(4'-methylsulfonylphenyl)-3-phenyl-2- (5H)-furanone). The present invention also provides compositions comprising such compounds in a pharmaceutically acceptable carrier.
The present invention is also based on the discovery that administering at 10 least one nitrosated and/or nitrosylated COX-2 inhibitor and at least one nitric oxide donor reduces the gastrointestinal distress induced by COX-2 inhibitors. A nitric oxide donor is a compound that contains a nitric oxide moiety and which releases or chemically transfers nitric oxide to another molecule. Nitric oxide . donors include, for example, S-nitrosothiols, nitrites, nitrates, N-oxo-N- 15 nitrosamines, and substrates of the various isozymes of nitric oxide synthase.
Thus, another aspect of the invention provides compositions comprising at least one COX-2 inhibitor that is substituted with at least one NO and/or NO, group (i.e., nitrosylated and/or nitrosated), and at least one compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO") or 20 nitroxyl (NO-), or as the neutral species, nitric oxide (NOe), and/or stimulates endogenous production of nitric oxide or EDRF in vivo and/or is a substrate for nitric oxide synthase.
Yet another aspect of the invention provides compositions comprising at least one COX-2 inhibitor that is substituted with at least one NO and/or NO, 25 group (i.e., nitrosylated and/or nitrosated), and, optionally, at least one compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO") or nitroxyl (NO-), or as the neutral species, nitric oxide (NOe), and/or stimulates endogenous production of nitric oxide or EDRF in vivo and/or is a : substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, 30 including but not limited to, steroids, nonsteroidal antiinflammatory compounds ) (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B,(LTB,) receptor antagonists, leukotriene A, (LTA) hydrolase inhibitors, 5-HT agonists, HMG CoA inhibitors, H, antagonists, antineoplastic agents, antiplatelet agents, decongestants,
oo WO 01/45703 PCT/US00/35014 diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, : isoprostane inhibitors, and the like.
Another aspect of the invention provides compositions comprising at least ‘ 5 one parent COX-2 inhibitor and at least one compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO) or nitroxyl (N O-), or as the neutral species, nitric oxide (NOe), and/or stimulates endogenous production of nitric oxide or EDRF in vivo and / or is a substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, including but not limited to, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B,(LTB,) receptor antagonists, leukotriene A, (LTA) hydrolase inhibitors, 5-HT agonists, HMG CoA inhibitors, H, antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non- sedating antij-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and the like.
Yet another aspect of the present invention provides methods for treating and/or preventing inflammation, pain and fever; for treating and/or improving gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing COX- 2 mediated disorders (i.e., disorders resulting from elevated levels of COX-2) in a patient in need thereof which comprises administering to the patient a therapeutically effective amount of at least one nitrosated and/or nitrosylated
COX-2 inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO) or nitroxyl | : (NIO-), or as the neutral species, nitric oxide (NOe), and/or stimulates endogenous production of nitric oxide or EDRF in vivo and/or is a substrate for nitric oxide : synthase and/or stimulates endogenous production of NO or EDRF in vivo and/or is a substrate for nitric oxide synthase (i.e., NO donors). The method can optionally ) further comprise the administration of at least one therapeutic agent, such as, for example, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5- lipoxygenase (5-LO) inhibitors, leukotriene B, (LTB,) receptor antagonists,
LT WO 01/45703 PCT/US00/35014 leukotriene A, (LTA,) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) inhibitors, H, antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti- histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, - 5 Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. In this aspect of the invention, the methods can involve administering nitrosated and/or nitrosylated COX-2 inhibitors, administering nitrosated and/or nitrosylated COX-2 inhibitors and NO donors, administering nitrosated and/or nitrosylated COX-2 inhibitors and therapeutic agents, or administering nitrosated and/or nitrosylated COX-2 inhibitors, NO donors and therapeutic agents. The nitrosated and/or nitrosylated COX-2 inhibitors, nitric oxide donors, and/or therapeutic agents can be administered separately or as components of the same composition in one or more pharmaceutically acceptable carriers.
Another aspect of the present invention provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or : preventing renal toxicity; and for treating and/or preventing other cyclooxygenase- 2 mediated disorders comprising administration of at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one ; therapeutic agent.
Yet another aspect of the present invention provides kits comprising at least one nitrosated and/or nitrosylated COX-2 inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO) or nitroxyl (NO-), or as the neutral species, nitric oxide (NOs), and/or stimulates endogenous production of nitric oxide or EDRF in vivo and/or is a substrate for nitric oxide synthase. The kit can further comprise at least one therapeutic agent. The nitrosated and/or nitrosylated COX-2 inhibitor, the nitric : oxide donor and/or therapeutic agent, can be separate components in the kit or can be in the form of a composition in one or more pharmaceutically acceptable i carriers.
Yet another aspect of the present invention provides kits comprising at least one parent COX-2 inhibitor and at least one compound that donates, transfers or
SE WO 61/45703 PCT/US00/35014 releases nitric oxide as a charged species, i.e., nitrosonium (NO") or nitroxyl (NO-), or as the neutral species, nitric oxide (NOo), and / or stimulates endogenous production of nitric oxide or EDRF in vivo and/or is a substrate for nitric oxide synthase. The kit can further comprise at least one therapeutic agent. The parent . 5 COX-2 inhibitor, the nitric oxide donor and/or therapeutic agent, can be separate components in the kit or can be in the form of a composition in one or more pharmaceutically acceptable carriers.
These and other aspects of the present invention are explained in detail herein.
Fig. 1 shows the relaxation of rat aortic smooth muscle rings by (a) isosorbide dinitrate (ISDN, open triangles); (b) Example la (non-nitrosated compound, open circles); and (c) Example 1b (nitrosated compound, open squares).
The non-nitrosated compound of Example la did not relax the tissue. At higher concentrations, the relaxation of the nitrosated compound of Example 1b was similar to that obtained with ISDN. Total number of samples tested varied from a minimum of 5 to a maximum of 12. In the x axis, log M corresponds to ten fold increases of the test compound from 100 nM (107) to 100 uM (10*). Results are expressed as the mean + standard error of the mean of the percentage of total relaxation induced by 10 pM phenylephrine.
Fig. 2 shows the relaxation of rat aortic smooth muscle rings by (a) isosorbide dinitrate (ISDN, open triangles); (b) Example 2a (non-nitrosated compound, open squares); and (c) Example 2b (nitrosated compound, open circles).
The non-nitrosated compound of Example 2a did not relax the tissue. At higher concentrations, the relaxation of the nitrosated compound of Example 2b was comparable to that obtained with ISDN. Total number of samples tested varied from a minimum of 6 to a maximum of 12. In the x axis, log M corresponds to ten fold increases of the test compound from 100 nM (107) to 100 uM (10*). Results are . expressed as the mean + standard error of the mean of the percentage of total relaxation induced by 10 uM phenylephrine.
Fig. 3 shows the relaxation of rat aortic smooth muscle rings by (a) S- nitrosoglutathione (GSNG, open triangles); (b) Example 3e (non-nitrosylated compound, open squares); and (c) Example 3g (nitrosylated compound, open
LY, WO 01/45703 PCT/US00/35014 circles). The non-nitrosylated compound of Example 3e did not relax the tissue. At higher concentrations, the relaxation of the nitrosylated compound of Example 3g was comparable to that obtained with GSNO. Total number of samples tested varied from a minimum of 4 to a maximum of 12. In the x axis, log M corresponds . 5 to ten fold increases of the test compound from 100 nM (107) to 100 uM (10).
Results are expressed as the mean + standard error of the mean of the percentage of total relaxation induced by 10 uM phenylephrine.
Fig. 4 shows the relaxation of rat aortic smooth muscle rings by (a) isosorbide dinitrate (ISDN, open circles); (b) Example 20c (non-nitrosated compound, open inverted triangles); and (c) Example 20d (nitrosated compound, open squares). The non-nitrosated compound of Example 20c did not relax the tissue. At higher concentrations, the relaxation of the nitrosated compound of
Example 20d was comparable to that obtained with ISDN. Total number of samples tested varied from a minimum of 4 to a maximum of 16. In the x axis, log
M corresponds to ten fold increases of the test compound from 100 nM (107) to 100 pM (10%). Results are expressed as the mean + standard error of the mean of the percentage of total relaxation induced by 10 uM phenylephrine.
Fig. 5 shows that anti-inflammatory effect of (a) Celecoxib (open bars); (b)
Example 2a (non-nitrosated compound, horizontal stripped bars); and (c) Example 2b (nitrosated compound, hatched bars) using the carrageenan-induced paw edema test. Total samples, 5 for each concentration of test compound. The x axis corresponds to the dose of the test compounds in pmol/kg body weight of the rats.
The y axis corresponds to the increase in the paw volume (mL). Results are expressed as the mean = standard error of the change in paw volume. Data was analyzed by AVONA analysis followed by Student Newmann-Keuls post-hoc test.
As used throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings. "NSAID" refers to a nonsteroidal anti-inflammatory compound or a nonsteroidal anti-inflammatory drug. NSAIDs inhibit cyclooxygenase, the enzyme responsible for the biosyntheses of the prostaglandins and certain autocoid inhibitors, including inhibitors of the various isozymes of cyclooxygenase (including but not limited to cyclooxygenase-1 and -2), and as inhibitors of both cyclooxygenase and lipoxygenase. “Cyclooxygenase-2 (COX-2) inhibitor” refers to a compound that selectively : inhibits the cyclooxygenase-2 enzyme over the cyclooxygenase-1 enzyme.
Preferably, the compound has a cyclooxygenase-2 IC, of less than about 0.5 uM, : 5 and also has a selectivity ratio of cyclooxygenase-2 inhibition over cyclooxygenase- 1 inhibition of at least 50, and more preferably of at least 100. Even more preferably, the compound has a cyclooxygenase-1 IC, of greater than about 1 pM, and more preferably of greater than 20 pM. The compound can also inhibit the enzyme, lipoxygenase and/or phosphodiestase. Such preferred selectivity may indicate an ability to reduce the incidence of common NSAID-induced side effects. “Parent COX-2 inhibitor “ refers to a non-nitrosated and/or non- nitrosylated COX-2 inhibitor and includes those described in the prior art, including those described in the patents and publications cited herein, as well as the novel compounds described herein. “Parent COX-2 inhibitor” includes the compounds of formulas I to XVI before they are nitrosated and/or nitrosylated by the methods described herein. “Therapeutic agent” includes any therapeutic agent that can be used to treat or prevent the diseases described herein. “Therapeutic agents” include, for example, steroids, nonsteroidal antiinflammatory compounds, 5-lipoxygenase inhibitors, leukotriene B, receptor antagonists, leukotriene A, hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A inhibitors, H, antagonists, : antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non- sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, : analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and the like. Although NO donors have therapeutic activity, the term “therapeutic agent” does not include the NO donors described herein, since NO donors are separately defined. “Patient” refers to animals, preferably mammals, most preferably humans, ’ and includes males and females, and children and adults. “Therapeutically effective amount" refers to the amount of the compound and/or composition that is effective to achieve its intended purpose. "Transdermal" refers to the delivery of a compound by passage through the skin and into the blood stream.
SE WO 01/45703 PCT/US00/35014 "Transmucosal” refers to delivery of a compound by passage of the compound through the mucosal tissue and into the blood stream. "Penetration enhancement” or "permeation enhancement" refers to an increase in the permeability of the skin or mucosal tissue to a selected : 5 pharmacologically active compound such that the rate at which the compound permeates through the skin or mucosal tissue is increased. "Carriers" or "vehicles" refers to carrier materials suitable for compound administration and include any such material known in the art such as, for example, any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non-toxic and which does not interact with any components of the composition in a deleterious manner. "Nitric oxide adduct” or "NO adduct" refers to compounds and functional groups which, under physiological conditions, can donate, release and/or directly or indirectly transfer any of the three redox forms of nitrogen monoxide (NO', NO,
NOe), such that the biological activity of the nitrogen monoxide species is expressed at the intended site of action. "Nitric oxide releasing" or "nitric oxide donating" refers to methods of donating, releasing and/or directly or indirectly transferring any of the three redox forms of nitrogen monoxide (NO”, NO-, NOe), such that the biological activity of the nitrogen monoxide species is expressed at the intended site of action. "Nitric oxide donor" or "NO donor" refers to compounds that donate, release and/or directly or indirectly transfer a nitrogen monoxide species, and/or stimulate the endogenous production of nitric oxide or endothelium-derived relaxing factor (EDRF) in vivo and/or elevate endogenous levels of nitric oxide or
EDREF in vivo. “NO donor” also includes compounds that are substrates for nitric oxide synthase. "Alkyl" refers to a lower alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkenyl group, an alkynyl group, a bridged cycloalkyl group, a cycloalkyl : group or a heterocyclic ring, as defined herein. An alkyl group may also comprise one or more radical species, such as, for example a cycloalkylalkyl group or a heterocyclicalkyl group. "Lower alkyl" refers to a branched or straight chain acyclic alkyl group comprising one to about ten carbon atoms (preferably one to about eight carbon
. ) v WO 01/45703 PCT/US00/35014 atoms, more preferably one to about six carbon atoms). Exemplary lower alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, neopentyl, iso-amy], hexyl, octyl, and the like. "Substituted lower alkyl" refers to a lower alkyl group, as defined herein, : 5 wherein one or more of the hydrogen atoms have been replaced with one or more
R"™ groups, wherein each R'” is independently a hydroxy, an oxo, a carboxyl, a carboxamido, a halo, a cyano or an amino group, as defined herein. "Haloalkyl" refers to a lower alkyl group, an alkenyl group, an alkynyl group, a bridged cycloalkyl group, a cycloalkyl group or a heterocyclic ring, as defined herein, to which is appended one or more halogens, as defined herein.
Exemplary haloalkyl groups include trifluoromethyl, chloromethyl, 2-bromobutyl, 1-bromo-2-chloro-pentyl, and the like. "Alkenyl" refers to a branched or straight chain C,-C,, hydrocarbon (preferably a C,-C; hydrocarbon, more preferably a C,-C, hydrocarbon) which can comprise one or more carbon-carbon double bonds. Exemplary alkenyl groups include propylenyl, buten-1-yl, isobutenyl, penten-1-yl, 2,2-methylbuten-1-yl, 3- : methylbuten-1-yl, hexan-1-yl, hepten-1-yl, octen-1-yl, and the like. "Lower alkenyl" refers to a branched or straight chain C,-C, hydrocarbon . which can comprise one or two carbon-carbon double bonds. "Substituted alkenyl" refers to arbranched or straight chain C,-C,, : hydrocarbon (preferably a C,-C, hydrocarbon, more preferably a C,-C, hydrocarbon) which can comprise one or more carbon-carbon double bonds, wherein one or more of the hydrogen atoms have been replaced with one or more
R™ groups, wherein each R™ is independently a hydroxy, an oxo, a carboxyl, a carboxamido, a halo, a cyano or an amino group, as defined herein. "Alkynyl" refers to an unsaturated acyclic C,-C,, hydrocarbon (preferably a
C,-C; hydrocarbon, more preferably a C,-C, hydrocarbon) which can comprise one or more carbon-carbon triple bonds. Exemplary alkynyl groups include ethynyl, y propynyl, butyn-1-yl, butyn-2-yl, pentyl-1-yl, pentyl-2-yl, 3-methylbutyn-1-yl, hexyl-1-yl, hexyl-2-yl, hexyl-3-yl, 3,3-dimethyl-butyn-1-yl, and the like. "Bridged cycloalkyl" refers to two or more cycloalkyl groups, heterocyclic groups, or a combination thereof fused via adjacent or non-adjacent atoms.
Bridged cycloalkyl groups can be unsubstituted or substituted with one, two or
‘ nL WO 01/45703 PCT/US06/35014 three substituents independently selected from alkyl, alkoxy, amino, alkylamino, dialkylamino, hydroxy, halo, carboxyl, alkylcarboxylic acid, aryl, amidyl, ester,
alkylcarboxylic ester, carboxamido, alkylcarboxamido, oxo and nitro.
Exemplary bridged cycloalkyl groups include adamantyl, decahydronapthyl, quinuclidyl, 2,6-
dioxabicyclo[3.3.0]octane, 7-oxabycyclo[2.2.1]heptyl, 8-azabicyclo[3,2,1]oct-2-enyl and the like.
"Cycloalkyl" refers to a saturated or unsaturated cyclic hydrocarbon comprising from about 3 to about 10 carbon atoms.
Cycloalkyl groups can be unsubstituted or substituted with one, two or three substituents independently selected from alkyl, alkoxy, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylarylamino, aryl, amidyl, ester, hydroxy, halo, carboxyl, alkylcarboxylic acid, alkylcarboxylic ester, carboxamido, alkylcarboxamido, oxo, alkylsulfinyl, and nitro.
Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cyclohepta,1,3-dienyl, and the like.
"Heterocyclic ring or group" refers to a saturated or unsaturated cyclic hydrocarbon group having about 2 to about 10 carbon atoms (preferably about 4 to about 6 carbon atoms) where 1 to about 4 carbon atoms are replaced by one or more nitrogen, oxygen and/or sulfur atoms.
Sulfur maybe in the thio, sulfinyl or :
sulfonyl oxidation state.
The heterocyclic ring or group can be fused to an aromatic : hydrocarbon group.
Heterocyclic groups can be unsubstituted or substituted with ~~ one, two or three substituents independently selected from alkyl, alkoxy, amino, alkylthio, aryloxy, arylthio, arylalkyl, hydroxy, oxo, thial, halo, carboxyl, carboxylic ester, alkylcarboxylic acid, alkylcarboxylic ester, aryl, arylcarboxylic acid,
arylcarboxylic ester, amidyl, ester, alkylcarbonyl, arylcarbonyl, alkylsulfinyl, carboxamido, alkylcarboxamido, arylcarboxamido, sulfonic acid, sulfonic ester, sulfonamido and nitro.
Exemplary heterocyclic groups include pyrrolyl, 3- pyrrolinyl 4,5,6-trihydro-2H-pyranyl, pyridinyl, 1,4-dihydropyridinyl, pyrazolyl,
: triazolyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, imidazolyl, indolyl,
thiophenyl, furany], tetrhydrofuranyl, tetrazolyl, pyrrolinyl, pyrrolindinyl,
oxazolindinyl 1,3-dioxolanyl, imidazolinyl, imidazolindinyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3 ,4- thiadiazolyl, 2H-pyranyl, 4H-pyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-
dithianyl, thiomorpholinyl, pyrazinyl, piperazinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, benzo(b)thiophenyl, benzimidazolyl, benzothiazolinyl, quinolinyl, and the like.
: "Heterocyclic compounds" refer to mono- and polycyclic compounds comprising at least one aryl or heterocyclic ring.
: 5 "Aryl" refers to a monocyclic, bicyclic, carbocyclic or heterocyclic ring system comprising one or two aromatic rings.
Exemplary aryl groups include phenyl, pyridyl, napthyl, quinoyl, tetrahydronaphthyl, furanyl, indanyl, indenyl, indoyl, and the like.
Aryl groups (including bicyclic aryl groups) can be unsubstituted or substituted with one, two or three substituents independently selected from alkyl,
alkoxy, alkylthio, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylarylamino, halo, cyano, alkylsulfinyl, hydroxy, carboxyl, carboxylic ester, alkylcarboxylic acid, alkylcarboxylic ester, aryl, arylcarboxylic acid, arylcarboxylic ester, alkylcarbonyl, arylcarbonyl, amidyl, ester, carboxamido, alkylcarboxamido, carbomy], sulfonic acid, sulfonic ester, sulfonamido and nitro.
Exemplary substituted aryl groups include tetrafluorophenyl, pentafluorophenyl, sulfonamide, alkylsulfonyl, arylsulfonyl, and the like.
“Cycloalkenyl” refers to an unsaturated cyclic C,-C,, hydrocarbon (preferably a C,-C, hydrocarbon, more preferably a C.-C; hydrocarbon) which can comprise one or more carbon-carbon triple bonds.
“Arylalkyl” refers to an aryl radical, as defined herein, attached to an alkyl radical, as defined herein.
Exemplary arylalkyl groups include benzyl, - phenylethyl, 4-hydroxybenzyl, 3-fluorobenzyl, 2-fluorophenylethyl, and the like.
: “ Arylalkenyl” refers to an aryl radical, as defined herein, attached to an alkenyl radical, as defined herein.
Exemplary arylalkenyl groups include styryl,
propenylphenyl, and the like.
“Cycloalkylalkyl” refers to a cycloalkyl radical, as defined herein, attached to an alkyl radical, as defined herein. “Cycloalkylalkoxy” refers to a cycloalkyl radical, as defined herein,
: attached to an alkoxy radical, as defined herein.
“Cycloalkylalkylthio” refers to a cycloalkyl radical, as defined herein,
attached to an alkylthio radical, as defined herein.
“Heterocyclicalkyl” refers to a heterocyclic ring radical, as defined herein, attached to an alkyl radical, as defined herein.
"Arylheterocyclic ring" refers to a bi- or tricyclic ring comprised of an aryl ring, as defined herein, appended via two adjacent carbon atoms of the aryl ring to a heterocyclic ring, as defined herein. Exemplary arylheterocyclic rings include dihydroindole, 1,2,3,4-tetra-hydroquinoline, and the like. "Alkoxy" refers to R,;O-, wherein R_, is an alkyl group, as defined herein (preferably a lower alkyl group or a haloalkyl group, as defined herein).
Exemplary alkoxy groups include methoxy, ethoxy, t-butoxy, cyclopentyloxy, trifluoromethoxy, and the like. "Aryloxy" refers to R,;O-, wherein R,, is an aryl group, as defined herein.
Exemplary aryloxy groups include napthyloxy, quinolyloxy, isoquinolizinyloxy, and the like. “Alkylthio” refers to R,,S-, wherein R,; is an alkyl group, as defined herein. "Arylalkoxy or alkoxyaryl” refers to an alkoxy group, as defined herein, to which is appended an aryl group, as defined herein. Exemplary arylalkoxy groups include benzyloxy, phenylethoxy, chlorophenylethoxy, and the like. "Alkoxyalkyl" refers to an alkoxy group, as defined herein, appended to an alkyl group, as defined herein. Exemplary alkoxyalkyl groups include methoxymethyl, methoxyethyl, isopropoxymethyl, and the like. "Alkoxyhaloalkyl” refers to an alkoxy group, as defined herein, appended to a haloalkyl group, as defined herein. Exemplary alkoxyhaloalkyl groups include 4- methoxy-2-chlorobutyl and the like. "Cycloalkoxy" refers to R,,O-, wherein R,, is a cycloalkyl group or a bridged cycloalkyl group, as defined herein. Exemplary cycloalkoxy groups include cyclopropyloxy, cyclopentyloxy, cyclohexyloxy, and the like. "Cycloalkylthio" refers to R,S-, wherein R;, is a cycloalkyl group or a bridged cycloalkyl group, as defined herein. Exemplary cycloalkylthio groups include cyclopropylthio, cyclopentylthio, cyclohexylthio, and the like. "Haloalkoxy" refers to an alkoxy group, as defined herein, in which one or : more of the hydrogen atoms on the alkoxy group are substituted with halogens, as defined herein. Exemplary haloalkoxy groups include 1,1,1-trichloroethoxy, 2- bromobutoxy, and the like. "Hydroxy" refers to -OH. "Oxo " refers to =O.
"Oxy "refers to -O R, wherein R,, is an organic or inorganic cation. "Organic cation" refers to a positively charged organic ion.
Exemplary : organic cations include alkyl substituted ammonium cations, and the like. "Inorganic cation" refers to a positively charged metal ion.
Exemplary : 5 inorganic cations include Group I metal cations such as for example, sodium, potassium, and the like. "Hydroxyalkyl" refers to a hydroxy group, as defined herein, appended to an alkyl group, as defined herein. "Nitrate" refers to -O-NO,. "Nitrite" refers to -O-NO. "Thionitrate" refers to -S-NO,. "Thionitrite" and "nitrosothiol" refer to -S-NO. "Nitro" refers to the group -NO, and "nitrosated" refers to compounds that have been substituted therewith.
"Nitroso" refers to the group -NO and "nitrosylated" refers to compounds that have been substituted therewith. : "Nitrile" and "cyano" refer to -CN. "Halogen" or "halo" refers to iodine (I), bromine (Br), chlorine (Cl), and/or . fluorine (F).
"Amino "refers to -NH,, an alkylamino group, a dialkylamino group, an arylamino group, a diarylamino group, an alkylarylamino group or a heterocyclic ring, as defined herein.
"Alkylamino" refers to R,NH-, wherein R,; is an alkyl group, as defined herein.
Exemplary alkylamino groups include methylamino, ethylamino,
butylamino, cyclohexylamino, and the like.
"Arylamino" refers to R,,NH-, wherein Ry, is an aryl group, as defined herein. "Dialkylamino” refers to R,R,;N-, wherein R;, and R;, are each independently ) an alkyl group, as defined herein.
Exemplary dialkylamino groups include dimethylamino, diethylamino, methyl propargylamino, and the like. "Diarylamino" refers to RR, N-, wherein R; and R, are each independently an aryl group, as defined herein. "Alkylarylamino or arylalkylamino" refers to R,,R,;N-, wherein R,, is an alkyl group, as defined herein, and Ris an aryl group, as defined herein.
"Alkylarylalkylamino " refers to RR, N-, wherein R,, is an alkyl group, as
: defined herein, and Ris an arylalkyl group, as defined herein.
"Alkylcycloalkylamino " refers to R,R;;N-, wherein R, is an alkyl group, as defined herein, and Ris an cycloalkyl group, as defined herein.
"Aminoalkyl " refers to an amino group, an alkylamino group, a dialkylamino group, an arylamino group, a diarylamino group, an alkylarylamino group or a heterocyclic ring, as defined herein, to which is appended an alkyl group, as defined herein.
Exemplary aminoalkyl groups include dimethylaminopropyl, diphenylaminocyclopentyl, methylaminomethyl, and the like.
"Aminoaryl " refers to an aryl group to which is appended an alkylamino group, a arylamino group or an arylalkylamino group.
Exemplary aminoaryl groups include anilino, N-methylanilino, N-benzylanilino, and the like.
"Thio" refers to -S-.
"Sulfinyl" refers to -S(O)-.
"Methanthial" refers to -C(S)-.
“Thial" refers to =S.
"Sulfonyl" refers to -S(O),
“Sulfonic acid" refers to -5(0),0R,,, wherein R, is a hydrogen, an organic : cation or an inorganic cation, as defined herein.
“ Alkylsulfonic acid” refers to a sulfonic acid group, as defined herein, appended to an alkyl group, as defined herein.
“ Arylsulfonic acid” refers to an sulfonic acid group, as defined herein,
appended to an aryl group, as defined herein
"Sulfonic ester" refers to -S(O),0R,,, wherein R,; is an alkyl group, an aryl group or an aryl heterocyclic ring, as defined herein.
"Sulfonamido" refers to -5(O),-N(R,,)(R,;), wherein R;, and R,, are each
: independently a hydrogen atom, an alkyl group, an aryl group or an arylheterocyclic ring, as defined herein, or R;, and R,, when taken together are a heterocyclic ring, a cycloalkyl group or a bridged cycloalkyl group, as defined herein. “ Alkylsulfonamido” refers to a sulfonamido group, as defined herein,
appended to an alkyl group, as defined herein. “Arylsulfonamido” refers to a sulfonamido group, as defined herein, appended to an aryl group, as defined herein. "Alkylthio" refers to R,,S-, wherein R,, is an alkyl group, as defined herein © 5 (preferably a lower alkyl group, as defined herein). "Arylthio" refers to R,S-, wherein R; is an aryl group, as defined herein. "Arylalkylthio” refers to an aryl group, as defined herein, appended to an alkylthio group, as defined herein. "Alkylsulfinyl" refers to R,-S(O)-, wherein R,; is an alkyl group, as defined herein. "Alkylsulfonyl” refers to R,-5(O),-, wherein R,| is an alkyl group, as defined herein. "Alkylsulfonyloxy" refers to R,-S(0),-O-, wherein R,, is an alkyl group, as defined herein. "Arylsulfinyl" refers to R,.-5(O)-, wherein R is an aryl group, as defined herein. "Arylsulfonyl" refers to R-5(0),-, wherein R; is an aryl group, as defined : herein. "Arylsulfonyloxy" refers to R..-5(0),-O-, wherein R; is an aryl group, as defined herein. "Amidyl" refers to R, C(O)N(R,,)- wherein R;, and R;, are each independently a hydrogen atom, an alkyl group, an aryl group or an arylheterocyclic ring, as defined herein. "Ester" refers to R,,C(O)O- wherein R;, is a hydrogen atom, an alkyl group, an aryl group or an arylheterocyclic ring, as defined herein. "Carbamoyl" refers to -O-C(O)N(R,,)(R,,), wherein R,, and R,, are each independently a hydrogen atom, an alkyl group, an aryl group or an arylheterocyclic ring, as defined herein, or R;, and R;, taken together are a : heterocyclic ring, a cycloalkyl group or a bridged cycloalkyl group, as defined herein. "Carboxyl" refers to -C(O)OR,,, wherein R, is a hydrogen, an organic cation or an inorganic cation, as defined herein. “Carbonyl” refers to ~C(O)-.
“Alkylcarbonyl” refers to R.-C(O)-, wherein R,, is an alkyl group, as defined herein. “Arylcarbonyl” refers to R,,-C(O)-, wherein R,, is an aryl group, as defined herein. . 5 “Arylalkylcarbonyl” refers to R,-R,-C(O)-, wherein Ry; is an aryl group, as defined herein, and R, is an alkyl group, as defined herein. “Alkylarylcarbonyl” refers to R,,-R.-C(O)-, wherein Ry; is an aryl group, as defined herein, and R;, is an alkyl group, as defined herein. "Heterocyclicalkylcarbonyl" refer to R,,C(O)- wherein R ; is a heterocyclicalkyl group, as defined herein. "Carboxylic ester" refers to -C(O)OR,,, wherein R; is an alkyl group, an aryl group or an aryl heterocyclic ring, as defined herein. "Alkylcarboxylic acid" and "alkylcarboxyl" refer to an alkyl group, as defined herein, appended to a carboxyl group, as defined herein. "Alkylcarboxylic ester” refers to an alkyl group, as defined herein, appended to a carboxylic ester group, as defined herein. : "Arylcarboxylic acid" refers to an aryl group, as defined herein, appended to L a carboxyl group, as defined herein. : "Arylcarboxylic ester” and "arylcarboxyl" refer to an aryl group, as defined herein, appended to a carboxylic ester group, as defined herein. : "Carboxamido" refers to -C(ON(R,))(R,,), wherein R,, and R, are each independently a hydrogen atom, an alkyl group, an aryl group or an arylheterocyclic ring, as defined herein, or R; and R,, when taken together are a heterocyclic ring, a cycloalkyl group or a bridged cycloalkyl group, as defined herein. "Alkylcarboxamido" refers to an alkyl group, as defined herein, appended to a carboxamido group, as defined herein. "Arylcarboxamido" refers to an aryl group, as defined herein, appended to a carboxamido group, as defined herein. "Urea" refers to -N(R,,)-C(O)N(R,))(R,,) wherein R;,, R,,, and R, are each ' independently a hydrogen atom, an alkyl group, an aryl group oran arylheterocyclic ring, as defined herein, or R;, and R;, taken together are a heterocyclic ring, a cycloalkyl group or a bridged cycloalkyl group, as defined herein. "Phosphoryl" refers to -P(R, }(R,)(R,,), wherein R,, is a lone pair of electrons, thial or oxo, and R,, and R,, are each independently a covalent bond, a hydrogen, a lower alkyl, an alkoxy, an alkylamino, a hydroxy, an oxy or an aryl, as defined «5 herein. “Silyl” refers to -Si(R,,)(R,)(R,;), wherein R,, R,, and R, are each independently a covalent bond, a lower alkyl, an alkoxy, an aryl or an arylalkoxy, as defined herein.
Compounds that donate, transfer or release nitric oxide species in vivo have been recognized as having a wide spectrum of advantages and applications. The present invention is based on the unexpected discovery of the effects of such compounds alone and together with one or more COX-2 inhibitors directly or indirectly linked with one or more nitric oxide moieties. Treatment or prevention of inflammation, pain and fever; treatment and/or improvement of the gastrointestinal properties of COX-2 inhibitors; facilitation of wound healing; and treatment and /or prevention of renal toxicity and cyclooxygenase-2 mediated disorders can be obtained by the use of the nitrosated and/or nitrosylated COX-2 inhibitors of the present invention; or by the use of the nitrosated and/or nitrosylated COX-2 inhibitors in conjunction with one or more compounds that donate, release or transfer nitric oxide and/or stimulate endogenous production of
NO and/or EDRF in vivo and/or is a substrate for nitric oxide synthase, and, optionally, with one or more therapeutic agents.
In one embodiment, the present invention describes nitrosated and/or nitrosylated COX-2 inhibitors of Formula (I):
R RY
= ’ XX | c 7!
R2 a =X
I wherein: when side b is a double bond, and sides a and ¢ are single bonds, -X'-Y'-Z'- : is: (a) -CRYR)-CR’(R*)-CR'(R%)-;
SE: (b) -C(O)-CR(R*)-CR(R")-; (0) -CR(RY)-CR(R)-C(0)-; (d) «(CR (R™)),-0-C(O)-; (e) -C(O)-O-(CR(R™),~; (f) - CRYR")-NR*-CR’(R™)-; (g) -CR°(R")-NR*-C(O)-; (h) -CR'=CR"-S-; (i) -S-CR*=CR"~; (G) -5-N=CR*; (k) -CR*=N-S-; (1) -N=CR-O-; (m) -O-CR*=N-; (n) -NR*-CR*=N-; (0) -N=CR*S-; (p) -S-CR*=N-; (9) -C(O)-NR’-CR"(R™)-; (r) RN-CR’=C R°-; (s) -CR*=CR’-NR’; (t) -O-N=CR*-; (1) -CR*=N-O-; (v) -N=N-5-; (w) -5-N=N-; (x) -R’N-CR*=N-; (y) -N=CR*NR’; : (z) RN-N=N-; (aa) -N=N-NR’-; (bb) -CR(R*)-O-CR(R*)-; (cc) -CR(R*)-S-CR¥(R™)-; (dd) -CR*(R*)- C(O)-CR’(R™)~;
(ee) -CR(R")-CR’(R*)-C(S)-; (ff) «(CR*(R™)),-O-C(S)~ : (88) -C(S)-O-(CR’(R™)),-; (hh) ~(CR’(R™)),-NR*-C(S)-; © 5 (ii) -C(S)-NR*-(CR’(R™)),~; (i) ~(CR°(R™)),-5-C(O)-; (kk) -C(O)-S-(CR’(R™)),; (11) -O-CR'=CR’-; (mm) -CR*=CR>-O-; (nn) -C(O)- NR*-5-; (00) -S-NR>-C(0)-; (pp) ~C(O)-NR*-O-; (qq) -O-NR-C(O)-; (rr) -NR>-CR*=CR’-; (ss) -CR'=N-NR’-; (tt) -NR-N=CR; (uu) -C(O)-NR*-NR’-; (vv) -NR-NR-C(O)-; (ww) -C(0)-O-NR*; 2 (x) -NR*-O-C(O)-; (yy) -CR'R*CRR’; (zz) -C(O)-CR'R*- (aaa) -CR'R*-C(O)-; (bbb) -C(S)-CR'R*-; (ccc) -CR*R*-C(S)-; (ddd) -C(=NRY)-CRR*; or (eee) -CR'R*-C(=NR’)-; when sides 4 and ¢ are double bonds and side b is a single bond, -X'-Y'-Z is: : (a) =CR’-O-CR’=; (b) =CR*NR’-CR’=; : (c) =N-6-CR'=; (d) =CR-S-N=; (e) =N-O-CR's;
(f) =CR*-O-N=; (g) =N-S-N=; (h) =N-O-N=; (i) =N-NR-CR’=; . 5 (j) =CR*-NR’-N=; (k) =N-NR*-N=; (1) =CR*-S-CR’=; or (m) =CR*-CR*(R*)-CR’=;
R'is: (a) -5(0),-CH,; (b) -S(0),-NRY(D"); (c) -5(0),-N(D')-C(O)-CF;; (d) -8(0)-(NH)-NH(D'); (e) -8(O)-(NH)-N(D)-C(O)-CF;; () -P(O)(CH,)NH(D"); (8) -P(O)(CH); (h) -C(S)-NH(D"); (i) -S(O)(INH)CHL; (j) -P(O)(CH,)OD’; or (K) -P(O)(CH,)NH(D");
RY is: (a) hydrogen; (b) halogen; (c) methyl; or (d) CH,OH;
R'is: (a) lower alkyl; (b) cycloalkyl; : (c) mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently: (1) hydrogen; (2) halo; (3) alkoxy;
v . WO 01/45703 PCT/US00/35014 (4) alkylthio; (5) CN; (6) haloalkyl, preferably CF; (7) lower alkyl; ‘ 5 (8) N,; (9)-CO,D"; (10) -CO,- lower alkyl; (11) {C(R)(RY), OD; (12) «(C(R*)(R"),-O-lower alkyl; (13) lower alkyl-CO,-R’; (14) -ODY; (15) haloalkoxy; (16) amino; : (17) nitro; (18) alkylsulfinyl; or (19) heteroaryl; (d) mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is : a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, .
O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, : optionally, 1, 2, 3, or 4 additional N atoms; wherein the substituents are each independently: (1) hydrogen; (2) halo; (3) lower alkyl; (4) alkoxy; (5) alkylthio; (6) CN; : (7) haloalkyl, preferably CF; (8) N,; (9) -C(R’)(R)-OD’; (10) -C(R°)(R®)-O-lower alkyl; or (11) alkylsulfinyl;
~ . WO 01/45703 PCT/US00/35014 (e) benzoheteroaryl which includes the benzo fused analogs of (d); (f)-NR" RY;
: (g) SRY; (h) -OR™;
- 5 @) -RY;
(j) alkenyl;
(k) alkynyl;
(1) unsubstituted, mono-, di-, tri- or tetra-substituted cycloalkenyl, wherein the substituents are each independently:
(1) halo; (2) alkoxy; (3) alkylthio; (4) CN; (5) haloalkyl, preferably CF,; : (6) lower alkyl; (7)N, (8) -CO,D’; (9) -CO,-lower alkyl; (10) -C(R¥)(R®)-OD’; (11) -C(R®)(R®)-O-lower alkyl; : (12) lower alkyl-CO,-R”; (13) benzyloxy; (14) -O-(lower alkyl)-CO,R*; (15) -O-(lower alkyl)-NR” R”; or (16) alkylsulfinyl;
(m) mono-, di-, tri- or tetra-substituted heterocycloalkyl group of 5, 6 or 7 members, or a benzoheterocycle, wherein said heterocycloalkyl or benzoheterocycle contains 1 or 2 heteroatoms selected from O, S, or N and,
: optionally, contains a carbonyl group or a sulfonyl group, and wherein said substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy;
~ ” WO 01/45703 PCT/US00/35014 (4) alkylthio; (5) CN; : (6) haloalkyl, preferably CF; (MIN; (8) -C(R*)(R")-OD; (9) -C(R*)(R")-O-lower alkyl; or (10) alkylsulfinyl; (n) styryl, mono or di-substituted styryl, wherein the substituent are each independently: (1) halo; (2) alkoxy; (3) alkylthio; 4) CN; (5) haloalkyl, preferably CF, (6) lower alkyl; (7) N;; (8) -CO,D’; : 9) -COlower alkyl; . (10) -C(R*(R®)-OD’; (11) -C(R®*)(R®)-O-lower alkyl; - (12) lower alkyl-CO,-R”; (13) benzyloxy; (14) -O-(lower alkyl)-CO,R”; or (15) -O-(lower alkyl)-NR"R"; (0) phenylacetylene, mono- or di-substituted phenylacetylene, wherein the substituents are each independently: (1) halo; (2) alkoxy; : (3) alkylthio; (4) CN; (5) haloalkyl, preferably CF; (6) lower alkyl; (7) N,;
(8) -CO,D; (9) -CO,-lower alkyl; (10) -C(R®(R®)-OD"; (11) -C(R*)(R")-O-lower alkyl; , 5 (12) lower alkyl-CO,-R*> (13) benzyloxy; : (14) -O-(lower alkyl)-CO,R"; or (15) -O-(lower alkyl)-NR"R"; (p) fluoroalkenyl; (g) mono- or di-substituted bicyclic heteroaryl of 8, 9 or 10 members, containing 2, 3, 4 or 5 heteroatoms, wherein at least one heteroatom resides on each ring of said bicyclic heteroaryl, said heteroatoms are each independently O, S and
N and said substituents are each independently: (1) hydrogen; (2) halo; (3) lower alkyl; (4) alkoxy; : (5) alkylthio; (6) CN; (7) haloalkyl, preferably CF,; (8) Ny; (9) -C(R°)(R°)-OD"; or (10) -C(R)(R%)-O-lower alkyl; () K; (s) aryl; . (t) arylalkyl; (u) cycloalkylalkyl; (v) CORY; (u) hydrogen; (v) arylalkenyl; (w) arylalkoxy; (x) alkoxy; (y) aryloxy;
v . WO 01/45703 PCT/USO0/35014 (z) cycloalkoxy; : (aa) arylthio; (bb) alkylthio; (cc) arylalkylthio; or . 5 (dd) cycloalkylthio;
R’is: (a) hydrogen; (b) haloalkyl, preferably CF; (c) CN; (d) lower alkyl; (6) -(CRIR),-U-V;
OK
(g) unsubstituted or substituted: (1) lower alkyl-Q; (2) lower alkyl-O- lower alkyl-Q; (3) lower alkyl-S-lower alkyl-Q; (4) lower alkyl-O-Q; (5) lower alkyl-S-Q; . (6) lower alkyl-O-V; (7) lower alkyl-S-V; (8) lower alkyl-O-K; or (9) lower alkyl-S-K; wherein the substituent(s) reside on the lower alkyl group; hQ (i) alkylcarbonyl; (j) arylcarbonyl; : (k) alkylarylcarbonyl; (1) arylalkylcarbonyl; : (m) carboxylic ester; (n) carboxamido; (0) cycloalkyl; (p) mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently:
(1) hydrogen; (2) halo; . (3) alkoxy; (4) alkylthio; (5) CN; (6) haloalkyl, preferably CF; (7) lower alkyl; (8) Ny (9) -CO,D; (10) -CO,-lower alkyl; (11) ~(C(R)(RY),-OD; (12) (C(R)(R%)),-O-lower alkyl; (13) lower alkyl-CO,-R’; (14) -OD%; (15) haloalkoxy; : (16) amino; (17) nitro; or (18) alkylsulfinyl; g (q) alkenyl; (r) alkynyl; (s) arylalkyl; (t) lower alkyl-OD%; (u) alkoxyalkyl; : (v) aminoalkyl; . (w) lower alkyl-CO,R"; (x) lower alkyl-C(O)NR*(R™); (y) heterocyclicalkyl; or (z) heterocyclic ring-C(O)-; ) R’, R*, Rand R” are each independently: (a) hydrogen; ] (b) amino; (©) CN; (d) lower alkyl;
(e) haloalkyl; (f) alkoxy; ; (g) alkylthio; . (h) Q; (i) -0-Q (4) -5-Q
WK; (I) cycloalkoxy; (m) cycloalkylthio; (n) unsubstituted, mono-, or di-substituted phenyl or unsubstituted, mono-, or di-substituted benzyl, wherein the substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; (5) CN; (6) haloalkyl, preferably CF; E (7)N,; @) (9) nitro; or (10) amino; (0) unsubstituted, mono-, or di-substituted heteroaryl or unsubstituted, mono-, or di-substituted heteroarylmethyl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S,
O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroarylis a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1, 2, 3, or 4 additional N atoms; said substituents are each -independently: (1) halo; (2) lower alkyl; : (3) alkoxy; (4) alkylthio; (5) CN;
N . WO 01/45703 PCT/US00/35014 (6) haloalkyl, preferably CF; (7) N,; (8) -C(R)(R")-OD’; (9) -C(R")(R")-O-lower alkyl; or : 5 (10) alkylsulfinyl (p) ~CON(R’)(R®); (q) - CH,OR’; (r) -CH,OCN; (s) unsubstituted or substituted: (1) lower alkyl-Q; (2) -O-lower alkyl-Q; (3) -S-lower alkyl-Q; (4) lower alkyl-O-lower alkyl-Q; (5) lower alkyl-S-lower alkyl-Q; (6) lower alkyl-O-Q; (7) lower alkyl-S-Q; (8) lower alkyl-O-K; (9) lower alkyl-S-K; (10) lower alkyl-O-V; or (11) lower alkyl-S-V; : wherein the substituent(s) resides on the lower alkyl; : (t) cycloalkyl; (u) aryl; (v) arylalkyl; (w) cycloalkylalkyl; © (x) aryloxy; (y) arylalkoxy; (z) arylalkylthio; (aa) cycloalkylalkoxy; (bb) heterocycloalkyl; ) (cc) alkylsulfonyloxy; (dd) alkylsulfonyl; (ee) arylsulfonyl;
(ff) arylsulfonyloxy; (88) COR"; . (hh) nitro; (ii) amino; (jj) aminoalkyl; (kk) -C(O)-alkyl-heterocyclic ring; (11) halo; (mm) heterocyclic ring; (nn) -CO,D’; (oo) carboxyl; (pp) amidyl; or (qq) alkoxyalkyl; alternatively, R* and R’ together with the carbons to which they are attached are: (a) cycloalkyl; (b) aryl; or : (c) heterocyclic ring; alternatively, Rand R* or R’ and R” taken together with the carbon to which they are attached are: : (a) cycloalkyl; or (b) heterocyclic ring; alternatively, R*and R®, Rand R®, R*and R’, or R*and R® when substituents on adjacent carbon atoms taken together with the carbons to which they are attached are: (a) cycloalkyl; (b) heterocyclic ring; or (c) aryl;
R® and R’ are each independently: (a) hydrogen; (b) unsubstituted, mono- or di-substituted phenyl; unsubstituted, ’ mono- or di-substituted benzyl; unsubstituted, mono- or di-substituted heteroaryl; mono- or di-substituted heteroarylmethyl, wherein said substituents are each independently:
y o WO 01/45703 PCT/US00/35014 (1) halo; (2) lower alkyl; i (3) alkoxy; (4) alkylthio; «5 (5) CN; (6) haloalkyl, preferably CF,; (7) N,; (8) -C(R*)(R")-OD"; or (9) -C(R*)(R*)-O-lower alkyl; (c) lower alkyl; (d) -CH,OR’; (e) CN; (f) -CH,CN; (g) haloalkyl, preferably fluoroalkyl; : (h) -CON(R®)(R®); (i) halo; or () -OR’;
R’ is: (a) hydrogen; (b) K; or
OR’; alternatively, R°and R”, R® and R” or R’ and R’ together with the carbon to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms; optionally containing up to two heteroatoms selected from oxygen, S(O), or NR;
R’ is: (a) lower alkyl; (b) lower alkyl-CO,D}; (c) lower alkyl-NHD'; (d) phenyl or mono-, di- or tri-substituted phenyl, wherein the substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy;
BN . WO 01/45703 PCT/US00/3501+4 (4) alkylthio; (5) lower alkyl-CO,D’; . (6) lower alkyl-NHD'; (7) CN; <5 (8) CO,D’; or (9) haloalkyl, preferably fluoroalkyl; (e) benzyl, mono-, di- or tri-substituted benzyl, wherein the substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; (5) lower alkyl-CO,D’; (6) lower alkyl-NHD’; (7) CN; (8) -CO,D’; or (9) haloalkyl, preferably CF; (f) cycloalkyl; (8) K; or (h) benzoyl, mono-, di-, or trisubstituted benzoyl, wherein the substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; (5) lower alkyl-CO,D'; (6) lower alkyl-NHD’; (7) CN; : (8) -CO,D’; or (9) haloalkyl, preferably CF;
R* and R' are each independently: (a) hydrogen; or (b) RY;
R" is: (a) lower alkyl; . (b) cycloalkyl; : (c) unsubstituted, mono-, di- or tri-substituted phenyl or naphthyl, . 5 wherein the substituents are each independently: (1) halo; (2) alkoxy; (3) alkylthio; (4) CN; (5) haloalkyl, preferably CF,; (6) lower alkyl; : (7) N,; (8) -CO,D; (9) -CO,-lower alkyl; (10) -C(R*)(R")-OD'; (11) -C(R®)(R")-O-lower alkyl; (12) lower alkyl-CO,D’; (13) lower alkyl-CO,R”; (14) benzyloxy; (15) -O-(lower alkyl)-CO,D"; ) (16) -O-(lower alkyl)-CO,R"; or (17) -O-(lower alkyl)-NR"R"; (d) unsubstituted, mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or said heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally 1, 2, or 3 additional N atoms, and wherein said substituents are each independently: (1) halo; (2) lower alkyl; ; (3) alkoxy; (4) alkylthio; (6) CN; ]
(6) haloalkyl, preferably CF; (7) N;; } (8) -C(R*)(R*¥)-OD"; or (9) -CR®)R")-O-lower alkyl; . 5 (e) unsubstituted, mono- or di-substituted benzoheterocycle, wherein the benzoheterocycle is a 5, 6, or 7-membered ring which contains 1 or 2 heteroatoms independently selected from O, S, or N, and, optionally, a carbonyl group or a sulfonyl group, wherein said substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; : 6) CN; (6) haloalkyl, preferably CF; (7) N,; (8) -C(R*)(R")-OD'; or (9) -C(R*)(R")-O-lower alkyl]; (f) unsubstituted, mono- or di-substituted benzocarbocycle, wherein B the carbocycle is a 5, 6, or 7-membered ring which optionally contains a carbonyl group, wherein said substituents are each independently : (1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; (5) CN; (6) haloalkyl, preferably CF,; (7) N,; (8) -C(R*)(R*)-OD’; or (9) -C(R®*)(R®)-O-lower alkyl; (8) hydrogen; or ' hh K
R” and R” are each independently: (a) hydrogen;
(b) lower alkyl; or (c) aryl; or : R” and R” together with the atom to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms; . 5 R* and R” are each independently : : (a) hydrogen; or : (b) lower alkyl; or
R* and R” together with the atom to which they are attached form a carbonyl, a thial, or a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms;
D'is: (a) hydrogen or (b) D;
Dis: (a V; or (b) K;
Uis: (a) oxygen; (b) sulfur; or (© -NR)R)-
Vis: (a) -NO; (b) -NO,; or (c) hydrogen
K is -W,-EACR IR), EACRIRY),W(CR)R)),-WE-WCR)R))-U-
V; wherein aa, b, ¢, d, g, i and j are each independently an integer from 0 to 3; p, X, y and z are each independently an integer from 0 to 10;
W at each occurrence is independently: : (a) -C(O); (b) -C(S)-; (© -T-; (d) ~(CRIRY),~ (e) alkyl;
(f) aryl; (g) heterocyclic ring; (h) arylheterocyclic ring, or (i) -(CHCH,0), : 5 E at each occurrence is independently: (a) -T-; (b) alkyl (c) aryl; (d) -(CRIR)), (e) heterocyclic ring; (f) arylheterocyclic ring; or (8) -(CHCHO)+ h is an integer form 1 to 10; q is an integer from 1 to 5;
R, and R, are each independently: (a) hydrogen; (b) alkyl; (c) cycloalkoxy; (d) halogen; (e) hydroxy; (f) hydroxyalkyl; (g) alkoxyalkyl; (h) arylheterocyclic ring; (i) cycloalkylalkyl; (j) heterocyclicalkyl; (k) alkoxy; (1) haloalkoxy; (m) amino; : (n) alkylamino; (0) dialkylamino; : (p) arylamino; (q) diarylamino; (r) alkylarylamino;
(s) alkoxyhaloalkyl; (t) haloalkoxy; (u) sulfonic acid; (v) alkylsulfonic acid; . 5 (w) arylsulfonic acid; (x) arylalkoxy; (y) alkylthio; (z) arylthio; (aa) cyano; (bb) aminoalkyl; (cc) aminoaryl; (dd) alkoxy; (ee) aryl; (ff) arylalkyl; (gg) carboxamido; (hh) alkylcarboxamido; (if) arylearboxamido; B (jj) amidyl; . (kk) carboxyl; (I) carbamoyl; (mm) alkylcarboxylic acid; (nn) arylcarboxylic acid; (oo) alkylcarbonyl; (pp) arylcarbonyl; (qq) ester; (rr) carboxylic ester; (ss) alkylcarboxylic ester; (tt) arylcarboxylic ester; : (uu) haloalkoxy; (vv) sulfonamido; ) (ww) alkylsulfonamido; (xx) arylsulfonamido; (yy) alkylsulfonyl,
(zz) alkylsulfonyloxy, (aaa) arylsulfonyl, : (bbb) arylsulphonyloxy (ccc) sulfonic ester; : 5 (ddd) carbamoyl; (eee) urea; (fff) nitro; or (ggg) -U-V; or
R, and R, taken together are: (a) oxo; (b) thial; or
R, and R; taken together with the carbon to which they are attached are: (a) heterocyclic ring; (b) cycloalkyl group; or (c) bridged cycloalkyl group; k is an integer from 1 to 2;
T at each occurrence is independently: (a) a covalent bond, (b) carbonyl, (c) an oxygen, : (d) -S(O)-; or (e) NR)R)- o is an integer from 0 to 2;
Qis: (a) -C(O)-U-D; (b) -CO,- lower alkyl; (c) tetrazolyl-5-yl; (d) CR)R)SDY; : (e) -CRHR)O-DY); or (f) -CR)(R’)(O-lower alkyl); ’ R, is: (a) alone pair of electron; (b) hydrogen; or
(c) lower alkyl;
R, is: . (a) hydrogen; (b) alkyl; : 5 (c) aryl; (d) alkylcarboxylic acid; (e) arylcarboxylic acid; (f) alkylcarboxylic ester; (g) arylcarboxylic ester; (h) alkylcarboxamido; (i) arylcarboxamido; (j) alkylsulfinyl; (k) alkylsulfonyl; (1) alkylsulfonyloxy, (m) arylsulfinyl; (n) arylsulfonyl; : (0) arylsulphonyloxy; (p) sulfonamido; : (q) carboxamido; (r) carboxylic ester; (s) aminoalkyl; (t) aminoaryl; (w) -CH-C(U-V)R)R); (v) a bond to an adjacent atom creating a double bond to that atom; or (Ww) -(N,O,-) *M’, wherein M" is an organic or inorganic cation; with the proviso that the compounds of Formula I must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
In cases where R, and R, are a heterocyclic ring or R, and R, taken together with the carbon atoms to which they are attached are a heterocyclic ring, then R, can be a substituent on any disubstituted nitrogen contained within the radical where R. is as defined herein.
In cases where multiple designations of variables which reside in sequence are chosen as a "covalent bond" or the integer chosen is 0, the intent is to denote a single covalent bond connecting one radical to another. For example, E, would denote a covalent bond, while E, denotes (E-E) and (C(R_)(R))), denotes -C(R)R)-
CRIR,)-
Another embodiment of the present invention provides compounds of the . 5 Formula (II):
R! RY et
Nt oz 0 ase 2” dX
II wherein:
A-Bis: (a) N-C; (b) C-Nj; or (c) N-N; when sides d and f are double bonds, and sides e and g are single bonds, -XP-Y*-Z2- is: (a) =CR*-CR"=CR*; : (b) =N-CR'=CR*-; (c) =N-CR’=N-; (d) =CR*-N=CR"~; (e) =CR*-N=N-; : (f) =N-N=CR*-; (8) =N-N=N-; (h) =CR*CR’=N-; or . (i) =CR*-CR’=N-;
Rand R? taken together are:
(a)
TTT or oo SF fT (b) xX £1) Mr
ZN or R” and R’ taken together with the carbon atoms to which they are attached are: (a) cycloalkyl; or (b) heterocyclic ring;
R” is: (a) hydrogen; : (b) alkylthio; (c) alkylsulfinyl; } (d) alkylsulfonyl; (e) cyano; (f) carboxyl; (g) amino; (h) lower alkyl; (i) haloalkyl; (j) hydroxy; (k) alkoxy; : (1) haloalkoxy; (m) alkylarylalkylamino; ) (n) aminoalkyl; (0) aminoaryl; (p) sulfonamido;
(9) alkylsulfonamido; (r) arylsulfonamido; : (s) heterocyclic ring; (t) hydroxyalkyl; or . 5 (u) nitro; a is an integer from 1 to 3; when sides e and g are double bonds, and sides d and f are single bonds, -X-YA-Z- is: : (a) -CR*=N-N=; (b) -N=N-CR’=; (c) -CR'=N-CR"=; (d) -N=CR*-N=; (e) -CR*=CR“-N=; (f) -N=CR'-CR’=; (g) -CR*=CR’-CR’=; or (h) -N=N-N=; when side g is a double bond, and sides d, e and f are single bonds,
XYZ is: (a) -C(0)-O-CR's; (b) -C(O)-NR-CR'=; B (c) -C(O)-S-CR’=; or (d) -C(H)R*-C(OCH)R-N=; when sides d is a double bond, and sides ¢, f and g are single bonds,
XYZ is: : (a) =CR*-O-C(O); (b) =CR-NR’-C(O)~; (c) =CR*-S-C(O)-; or (d) =N-C(OH)R*-C(H)R’-; : when sides f is a double bond, and sides 4, e and g are single bonds,
XYZ is: ’ (a) -CH(R’)-CR’=N-; or (b) -C(O)-CR*=CR’~; when sides e is a double bond, and sides d, f and g are single bonds,
XYZ is: (a) -N=CR*-CH(R’-; or . (b) -CR'=CR-C(O)-; when sides 4, ¢, f and g are single bonds, . 5 XYZ is: (a) -C(O)-CRY(R")-C(O)~
R), RY, R}, R®, R*, RY, R® and R” are as defined herein; with the proviso that the compounds of Formula II must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Another embodiment of the present invention provides compounds of the
Formula (II):
R
Qu.
R? x mI wherein:
XPis: (a) -C(O)-U-D’; (b) -CH,-U-D’; (0) -CH,-C(O)-CH; (d) -CH,-CH,-C(O)-U-D'; (e) -CH,-O-D’; or (f) -C(OH
Yis: (a) -(CR'(R")),-U-D’; : (b) -CH,; (c) -CH,OC(O)R’; or (d) -C(O)H; alternatively, X* and Y° taken together are -CR*(R*)-CR*(R*)~;
R” R¥, R® and R” are each independently: (a) hydrogen; . (b) hydroxy; (c) alkyl; ’ 5 (d) alkoxy; (e) lower alkyl-OD"; (f) alkylthio; (8) CN; (h) -C(O)R*; or (i) -OC(O)R®;
Ris: (a) hydrogen; (b) lower alkyl; or (c) alkoxy;
R® is: (a) lower alkyl; (b) alkoxy (c) unsubstituted, mono-, di- or tri-substituted phenyl or pyridyl, wherein the substituents are each independently: : (1) halo; (2) alkoxy; (3) haloalkyl; (4) CN; (5) -C(O)R*; (6) lower alkyl; (7) -S(O),-lower alkyl; or (8)-OD; alternatively, R* and R® or R* and R* taken together are: : (a) oxo; (b) thial; i (c) =CR*R¥; or (d)=NR%;
R* and R” are each independently:
(a) hydrogen; (b) lower alkyl; (c) lower alkyl-OD"; (d) CN; or - 5 (e)-C(O)R™,
R* is: (a) OD; (b) alkoxy; (c) lower alkyl; or (d) unsubstituted, mono-, di- or tri-substituted phenyl or pyridyl, wherein the substituents are each independently: : (1) halo; (2) alkoxy; (3) haloalkyl; (4) CN; (5) CORY; (6) lower alkyl; : (7) -5(0) lower alkyl; or (8) -OD';
R, RR’, R”, R%, U, D', 0 and k are as defined herein; with the proviso that the compounds of Formula III must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Another embodiment of the present invention provides compounds of the
Formula (IV)
R20 2 4
R XT XN
] R2!" 7 RZ
Iv wherein:
X* and Z' are each independently: (2) N; or : (b) CR*;
R” is: os (a) S(0)-CH (b) -S(0),-NR*(D"); or (c) -S(0),-N(D")-C(O)-CF,;
R" and R™ are each independently: - (a) hydrogen; (b) lower alkyl; (c) alkoxy; (d) alkylthio; (e) haloalkyl, preferably fluoroalkyl; (f) haloalkoxy, preferably fluoroalkoxy; (g) CN; (h) -CO,D} (i) -CO,R™; (j) lower alkyl-O-D’; (k) lower alkyl-CO,D’; (1) lower alkyl-CO,R™; (m) halo; (n)-O-D} (0) -N,; (p) -NO;, (q) -NR"D}; (1) -N(D)C(O)RY; (s) -NHK; (t) aryl; : (u) arylalkylthio; (v) arylalkoxy; : (w) alkylamino; (x) aryloxy; (y) alkylarylalkylamino;
(2) cycloalkylalkylamino; or (aa) cycloalkylalkoxy;
Ris: (a) mono-, di- or tri-substituted phenyl or pyridinyl (or the N-oxide , 5 thereof), wherein the substituent are each independently: (1) hydrogen; (2) halo; (3) alkoxy; (4) alkylthio; (5) CN; (6) lower alkyl; (7) haloalkyl, preferably fluoroalkyl; (8) N; (9) -CO,D}; (10) -CO,-lower alkyl; (11) -C(R*)(R")-OD’; (12) -OD%; (13) lower alkyl-CO,-R"; or (14) lower alkyl-CO,-D’; (b) -T-CR®)R*)~CR*)(R*)),-CR*)(R*)-U-D’; (0) 2
TT Ho)
Hao—Y® (d) arylalkyl; or (e) cycloalkylalkyl; wherein:
R" and R" are each independently: (a) hydrogen; or (b) lower alkyl; '
R® R* R® R* RY, R* are each independently: (a) hydrogen; or (b) lower alkyl; or
R® and R”, or R” and R” together with the atoms to which they are attached . 5 form a carbocyclic ring of 3, 4, 5, 6 or 7 atoms, or R* and Rare joined to form a covalent bond;
Y? is: (a) CR*R”; (b) oxygen; or (c) sulfur;
R” and R” are each independently: (a) hydrogen; (b) lower alkyl; (0) (CH) OD; (d) halo; or
R” and R” taken together are an oxo group; s is an integer from 2 to 4; :
R’, DY, T, U, K and o are as defined herein; with the proviso that the compounds of Formula IV must contain at least one nitrite, nitrate, thionitrite or thionitrate group. )
Another embodiment of the present invention provides compounds of the
Formula (V):
» RS R¥ RS x5 aN 71 by J . A | ln Ny—K
R3 R%® R¥
N R38 40 Rr ~ \ 0%
R41
Vv wherein: xX is: (a) oxygen; or i (b) sulfur;
R* is: (a) alkoxy; } (b) haloalkoxy preferably -OCH,F, -OCHF, or -OCHF,; (c) alkylthio; : (d) haloalkyl, preferably CF,; (e) halo; or (f) lower alkyl;
R%, R* R* R® R* and R are each independently : (a) hydrogen; (b) halo, preferably F or Cl; (c) lower alkyl; (d) cycloalkyl; (e) haloalkyl, preferably CF,, CF,H or CFH,; (f) -OD’; (g) ORY;
(h) -SD’; (i) -SR%; () -SO)R®; (k) -S(O).R”; : 5 (1) unsubstituted, mono- or di-substituted benzyl, wherein the substituents are each independently: (1) haloalkyl, preferably CF,; (2) CN; (3) halo; 0 (4) lower alkyl; (5) -OR%; (6) -SR*; (7) -S(O)R”; or (8) -S(O).R"; (m) phenyl or mono- or di-substituted phenyl, wherein the substituents are each independently: : (1) haloalkyl, preferably CF,; (2) CN; (3) halo; (4) lower alkyl; (5) OR"; (6) -SR; (7) -S(O)R*; or’ (8) -S(O),R"; or
R* together with R” form an oxo group; or
R* together with R” form an oxo group; or :
R* together with R” form an oxo group; or
R* and R” are joined so that, together with the carbon atom to which they are attached, they form a saturated monocyclic ring of 3, 4, 5, 6 or 7 members, and, optionally, contain one heteroatom which is preferably oxygen; or
R* and R* are joined so that, together with the carbon atoms to which they are attached, they form a saturated or aromatic monocyclic ring of 3,4, 5, 6 or 7 members; or
R” and R* are joined so that, together with the carbon atoms to which they are attached, they form a saturated or aromatic monocyclic ring of 3,4, 5,6 or 7 ] members; or
R* and R” are joined so that, together with the carbon atom to which they . 5 are attached, they form a saturated monocyclic ring of 3, 4, 5, 6 or 7 members, and optionally, contain one heteroatom which is preferably oxygen; or
R* and R* are joined so that, together with the carbon atoms to which they are attached, they form a saturated or aromatic monocyclic ring of 3, 4,5, 6 or 7 members; or
R* and RY are joined so that, together with the carbon atom to which they are attached, they form a saturated monocyclic ring of 3, 4, 5, 6 or 7 members, and, optionally, contain one heteroatom which is preferably oxygen;
R® and R” are hydrogen or R® and R” when taken together are oxo;
R¥, R" and R* are each independently: (a) hydrogen; (b) halo; (c) lower alkyl; (d) alkoxy; (e) alkylthio; 2 (9 -S(O)-lower alkyl; '(g) haloalkyl, preferably CF,; (h) CN; (B) -Ny (G) -NO,; (k) -SCF;; or (1) -OCF;;
Ris: (a) lower alkyl; or : (b) benzyl, optionally mono- or di-substituted, wherein the substituents are each independently: ) (1) haloalkyl, preferably CF; (2) CN; (3) halo; or
(4) lower alkyl; alternatively, X° and U taken together with the carbon atom to which they . are attached form a 5-, 6-, or 7-membered heterocyclic ring; n at each occurrence is an integer from 0 to 1; and . 5 D', U and KX are as defined herein; with the proviso that the compounds of Formula V must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Another embodiment of the present invention provides compounds of the Formula (VI): i 45___ 6
CI o
AN
R48 :
RY
VI
‘wherein:
X* is: (a) oxygen; (b) sulfur; (c) CH, : (d) -5(0).; (e) -NH; or (f) -C(O);
Z' is: (a) K; (b) -C(O)CH,; or (c) hydrogen;
R” is: (a) lower alkyl; or
(b) mono-, di-, tri-, tetra- or per-substituted lower alkyl, wherein the substituent is halo, preferably fluoro; . R* is: (a) mono or disubstituted aromatic ring of 5 atoms containing one O, d 5 Sor N atom, and, optionally, 1, 2 or 3 additional N atoms, wherein the substituents are each independently: (1) hydrogen; (2) lower alkyl; (3) halo; (4) -O-lower alkyl; (5) -S-lower alkyl; (6) haloalkyl, preferably CE; (7) -COCH,; or (8) -S(O),-lower alkyl; (b) mono or disubstituted aromatic ring of 6 atoms containing 0, 1, 2, 3 or 4 nitrogen atoms, wherein the substituents are each independently: (1) hydrogen; (2) lower alkyl; (3) halo; (4) -O-lower alkyl; (5) -S-lower alkyl; (4) -O-haloalkyl; (5) -S-haloalkyl; (6) haloalkyl, preferably CF, (7) CN; (8) -Ny (9) -COCH,; (10) -S(O),-lower alkyl; : (11) alkenyl; or (12) alkynyl; (c) cycloalkylalkyl; (d) unsubstituted, mono-, di-, tri-, or tetra substituted phenyl or naphthyl, wherein the substituents are each independently:
(1) halo; (2) CN; ; (3) haloalkyl, preferably CF,; (4) -N,; - 5 (6) vinyl; (6) acetylenyl; (7) lower alkyl, (8) alkoxy; (9) haloalkoxy; (10) alkylthio; or (11) haloalkylthio; (e) unsubstituted, mono-, di-, tri-, or tetra substituted benzoheteroaryl, wherein the substituents are each independently: (1) halo; (2) CN; or (3) haloalkyl, preferably CF,; (f) substituted lower alkyl; (g) substituted alkenyl; (h) cycloalkyl; or (i) lower alkyl-O-lower alkyl;
RY is: (a) -C(O)-lower alkyl; (b) -CN; (c) -CO,D} (d) -CO,-lower alkyl ester; (e) -C(O)-NHD'; (f) -S(O)-lower alkyl; (g) -S(O), lower alkyl; (h) -NO,; (i) haloalkyl, preferably CF; : ’ (j) halo; k) K; (1) -S(O) NR*R"; or
(m) -S(O) NR"R*;
R¥ is: : (a) hydrogen; or (b) lower alkyl; or . 5 R” and R” taken together with the atoms to which they are attached form a 5, 6, or 7-membered unsubstituted, mono-, di-, or trisubstituted saturated or unsaturated cyclic ring optionally containing a —5(O),-group, wherein the substituents are each independently: (a) oxo; (b) lower alkyl; (c) OD} or : (d) =N-OD’;
R”,R", R%? R® K, D' and o are as defined herein; with the proviso that the compounds of Formula VI must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Another embodiment of the present invention provides compounds of
Formula (VII): }
R! v 7 ~ RS’
XX XN ;
RO 7 No
X7 vil wherein:
X' is: (a) oxygen; - (b) sulfur; (c) NR”; (d) -N-O-R*; or (e) -N-NR*R%,; a 57
Y is: (a) hydrogen; (b) halo; (c) lower alkyl; ‘ 5 (d) alkenyl; or (e) alkynyl;
Z is: (a) -C(O) (b) oxygen; 0 (©) S(O), (d) -NR”-; or " (e) covalent bond;
R” is: : (a) R’ or : (LR
R® and R” are each independently: (a) hydrogen; (b) halo; (c) lower alkyl; (d) aryl; (e) arylalkyl; (f) cycloalkyl; (g) cycloalkylalkyl; (h) -OD’; (i) lower alkyl-OD’; : (j) carboxamido; (k) amidyl; or 0) K; : R” is: (a) lower alkyl; ) (b) alkenyl; (c) cycloalkyl; (d) cycloalkylalkyl;
(e) aryl; (f) arylalkyl; . (g) heterocyclic ring; or (h) lower alkyl-heterocyclic ring; +5 R™ and R” are each independently: (a) lower alkyl; (b) cycloalkyl; (c) cycloalkylalkyl; (d) aryl; 0 (e) arylalkyl; (f) heterocyclic ring; or (g) heterocyclicalkyl;
R*is: (a) hydrogen; or ’ (b) lower alkyl;
R, R’, RY, K, D' and o are as defined herein; with the proviso that the compounds of Formula VII must contain at least : one nitrite, nitrate, thionitrite or thionitrate group. :
Another embodiment of the present invention provides compounds of the
Formula (VIII):
R56 1 R55 p27 X pad UY
A Ny x8 R54 vil wherein:
Xt is:
L025 (a) oxygen; (b) sulfur; (c) NR; or (d) -CR*R%;
A’, A’, A’, and Aare each independently carbon or nitrogen, with the provise that at least two of A", A?, A®, and A’are carbon atoms; ; R* is: (a) haloalkylalkyl, preferably fluoroalkylalkyl; - - 5 (b) halo; (c) alkylthio; (d) alkoxy; (e) -NO,; (f) CN; 0 (g) lower alkyl-CN; (h) heterocyclic ring; (i) lower alkyl; (j) arylalkyl; (k) cycloalkyl; or (1) phenyl or mono- or di-substituted phenyl, wherein the substituents are each independently: | : (1) alkylthio; (2) nitro; or (3) alkylsulfonyl;
R” is: (a) -CO,DY (b) -CO-NR)R); (c) -CO,-lower alkyl; (d) -C(O)-NDY)-S(O)~(CR)R),-U-V; or (e) -CO,-lower alkyl-U-V;
R*is: (a) hydrogen; (b) phenyl; : (¢) thienyl; (d) alkynyl; ’ (e) alkenyl; or (f) alkyl;
R,is:
(a) hydrogen; (b) lower alkyl; . (c) arylalkyl; (d) alkoxy; - 5 (e) aryloxy; (f) arylalkoxy; (g) haloalkyl; (h) haloalkoxy; (i) alkylamino; 0 (j) arylamino; (k) arylalkylamino; (1) nitro; (m) sulfonamido; (n) carboxamido; (0) aryl; (p) -C(O)-aryl; or (q) -C(O)-alkyl; alternatively, R_ and the monocyclic ring radical of which A’, A?, A® and A* comprise four of the six atoms are: 0 (a) naphthyl; (b) quinolyl; (c) isoquinolyl; (d) quinolizinyl; (e) quinoxalinyl; or 5 (f) dibenzofuryl;
R* and R” are each independently: (a) hydrogen; (b) lower alkyl; (c) lower alkyl-phenyl; (d) haloalkyl, preferably fluoroalkyl; ’ (e) halo; (f) -NO,; (5) CN;
(h) lower alkyl-CN; (i) alkoxy; , (j) alkylthio; or (k) alkenyl; ; 5 alternatively, R*and R” taken together along with the atoms to which they are attached are cycloalkyl;
R’,R,R,R,D!, U,V,aand p are as defined herein; with the proviso that the compounds of Formula VIII must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Another embodiment of the present invention provides compounds of the
Formula (IX): 1 yo
R? x9
IX wherein:
X’ is -C(O) UD" and Y’ is -CH, CR*(R*)-U-D%; or
X’ is -CH, CR’ (R”)UD' and Y’ is -C(O) UD; or
X’ and Y’ taken together are: (a) -C(O)-O-CR'(R")-CR*(R"); (b) -(CR(RY)),-CR(R")-CR'(R’)-; (c) -C(O)-(CR!(R"),-CR(R*)-; (d) -(CRY(R))-CR(R")-C(O)-; or . (e) -C(O)-CR(R*) -CR’(R")-; : wherein X is the first carbon atom of a,b, c,d and €; : ’ RL R%L RY RY, RR”, U, D' and k are as defined herein; with the proviso that the compounds of Formula IX contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Another embodiment of the present invention provides compounds of the
Formula (X):
R
J _z10 ] WW
A a2 7 x10
X
. 5 : wherein: when side k, k, and j are single bonds, and side i and I are a double bond, -
Xoy_ze_ is: (a) ail ps i J
Ni) / k
Qi0 a1 or
XX ON
R60 \\ V/A (b)
Jj 10 ~ Ngo i id NC ZC" ] h k D! when sides i , k and I are single bonds, and sides kz and j are double bonds, -
XO-Y-Z- is:
A 4
PN gi i / po va . R607 J Rot when side / and j are single bonds, and side k and i is a single or a double bond, -X"°-Y"-Z"- is; (a)
LA
\ giv’ or l
EN pe (0) 61 ade i \~Z 3 ~~ oe
PYis: (a) -N=; (b) -NR’; (c)-O-; or (d)-5-
Q" and Q" are each independently: (a) CR®; or © 15 (b) nitrogen;
A =B®-C*D"- is: (a) -CR*=CR*-CR’=CR’-; (b) -CR'(R")-CR'(R")-CR'(R)-C(O)-; (c) -CRY(R*)-CR*(R®)-C(O)-CR'(R")-;
(d) -CR{R")-C(O)-CR{(R")-CR(R®)-; (e) -C(O)-CRR")-CRY(R*)-CR*(R*)-; a (f) -CRY(R*)-CR(R")-C(O)-; (g) -CRYR")-C(0)-CR’(R’)-; ' 5 (h) -C(O)-CRR*)-CR’(R’) ~; (i) -CR(R*)-CR(R*)-O-C(O)-; (j) -CRY(R")-O-C(O)-CR’(R) -; (k) -O-C(O)-CR*(R"-CR’(R’) -; (1) -CR(R*)-CR*(R%)-C(O)-O-; (m) -CR*(R*)-C(O)-O-CR’(R®)-; (n) -C(O)-O-CR(R*)-CR’(R*)-; (0) -CR*([R")-O-C(O)-; (p) -C(O)-O-CR*(R")-; (9) -O-C(O)-CR*(R")-; (r) -CR®*(R®)-C(O)-O-; (s) N=CR-CR=CR"-; (t) -CR*=N-CR*=CR*-; (1) -CR'=CR*-N=CR’-; (v) -CR=CR*-CR°=N-; 2 (w) N=CR-CR*=N-; (x) -N=CR*-N=CR*~; (y) -CR*=N-CR*=N-; (2) S-CR'=N-; (aa) -S-N=CR*-; (bb) -N=N-NR’- (cc) -CR*=N-5-; (dd) -N=CR“-S-; (ee) -O-CR'=N-; ) (ff) -O-N=CR*; or (gg) -N=CR*-O-; ’ -AVB=D > is; (a) -CR*=CR°-CR°= (b) -CRY(R*)-CR(R*)-CR'(R")~;
A WO 01/45703 PCT/US00/35014 (0) -C(O)-CRYR")-CR’(R")-; (d) -CRY(R)-CR*(R*)-C(O)-; . (e) N=CR-CR’=; (8) -N=N-CR'=; ’ 5 (h) -N=N-NR*; (i) -N=N-N=; (j) -N=CR-NR’-; (k) -N=CR*-N=; (I) -CR*=N-NR*; (m) -CR*=N-N=; (n) -CR*=N-CR’=; (0) -CR'=CR*-NR’-; (p) -CR*=CR*N=; (q) -S-CR'=CR*; (r) -O-CR'=CR%; (s) -CR*=CR’>-O-; (t) -CR*=CR>-S-; (1) -CR‘=N-S-; : (v) -CR*=N-O-; (w) -N=CR"-S-; (x) -N=CR"-O-; (y) -S-CR'=N-; (z) -O-CR*=N-; (aa) -N=N-S-; (bb) -N=N-O-; (cc) -S-N=N-; (dd) -O-N=N-; (ee) -CR*=CR’-S; . (ff) -CR*(R*)-CR’(R*)-S-; (gg) -CR'(R")-CR’(R")-O-; ’ (hh) -5-CRY(R*)-CR*(R®)-; or (ii) -O-CR*(R*)-CR(R%)~;
R” and R" are each independently: _ 66
(a) lower alkyl; (b) haloalkyl, preferably fluoroalkyl; , (c) alkoxy; (d) alkylthio; boos (e) lower alkyl-OD, (f) -CO)H; (h) -(CH,)-CO,-lower alkyl; (i) -(CH,)-CO,D} () -O-(CH,)-S-lower alkyl; (k) ~(CH,)S-lower alkyl; (1) -5(0),-lower alkyl; (m) -(CH,) -NR"R"; or (n) -CONR)(RY);
RL,RL RRL RY RR RS RY RYT, D' and q are as defined herein; with the proviso that the compounds of Formula X must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Another embodiment of the present invention provides compounds of the
Formula (XI):
RE? 11
R63 es | R66 ° _—K
Dn! wherein: ' X* is: (a) oxygen; or (b) CH,;
iy y WO 01/45703 PCT/US00/35034
Ys: (a) oxygen; (b) -H,; (c) -N-OD"; : 5 (d) -N-O-lower alkyl; (e) -N-O-aryl; (f) -N-C(O)-O-lower alkyl; (8) -N-N(R)(R); or (h) -N-N(R)-S(O), lower alkyl;
R? R®, R* and R” are each independently: (a) hydrogen; (b) lower alkyl; (c) alkoxy; (d) halo; (e) CN; (f) OD’; (g) aryloxy; (h) -NR"R”; (i) -CF; (G) -NO,; (k) alkylthio; (1) -S(0)-lower alkyl; (m) -CONR’)(R); (n) -CO,D' (0) -CO,-lower alkyl; or (p) -NR*-C(O)-lower alkyl;
R¥is: (a) hydrogen; . (b) lower alkyl; (c) alkenyl; ‘ (d) alkoxyalkyl; or (e) cycloalkylalkyl;
R% R? R®, o,K and D' are as defined herein;
K
Lo WO 01/45703 PCT/US00/35014 with the proviso that the compounds of Formula XI must contain at least one nitrite, nitrate, thionitrite or thionitrate group. } Another embodiment of the present invention provides compounds of the
Formula (XII): y 5 y12
ON \ ® a Zz"
FG 12
XI wherein:
X* is: (a)
Re R70 (b) 1 .
R70 R69 (c) NR;
Y* is:
(a)
JOR? sr _ R70 (b)
N R72 ——(CHam—0" hi
R70 : (©) 0 0)
D'o . (d) : 0
A R77
R80 Rel (e) -NRP[R™); (f) hydrogen; or (eK;
ZP is: (a) (b) RY;
R” is: (a) hydrogen; . (b) lower alkyl; (c) lower alkyl-OD’; , 5 (d) -OD% : : (e) haloalkyl; or 3) x5
Pt R75 (CHI
R* is: (a) lower alkyl; (b) halo; (c) alkoxy (d) haloalkyl; ; (e) alkylthio; : (f) haloalkylthio; (g) -OCH.- . (h) unsubstituted, mono-, or di-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or said heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally 1, 2, or 3 additional N atoms, and wherein said substituents are each independently: (1) halo; or (2) lower alkyl : 25 (i) -S(0),-lower alkyl; (j) -S(O),-lower haloalkyl; ) (k) amino; (1) alkylamino; : (m) dialkylamino;
(n) -N(H)SO,-lower alkyl; (0) N(H)SO,-lower haloalkyl}; : . (p) nitro; (q) cyano; (r) -CO,D} (s) carboxylic ester; (t) lower alkyl-OD%; (q) carboxamide; or (r) -C(ONR™)D’;
R® is: ; (a) lower alkyl; (b) hydrogen; (c) alkoxy (d) mono-, di-, tri, tetra- or penta-substituted phenyl, wherein the substituent are each independently: (1) hydrogen; (2) halo; (3) alkoxy; (4) alkylthio; (5) -S(O) -lower alkyl; (6) lower alkyl; : (7) haloalkyl; (8) -CO,D; (9) -lower alkyl-CO,D’; (10) -OD}; (11) -lower alkyl-OD’; or (12) haloalkoxy; : (e) mono-, di-, or tri-substituted heteroaryl, wherein the heteroaryl is ' a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S,.
O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroarylis a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1, 2, 3, or 4 additional N atoms; wherein the substituents are each independently:
(1) hydrogen; (2) halo; . (3) lower alkyl; (4) alkoxy; ‘ 5 (5) alkylthio; (6) aryloxy; (7) arylthio; ) (8) -CO,D’; (9) -C(O)NH(D") (10) haloalkyl; or (11) -OD%;
R” is: (a) lower alkyl; (b) hydrogen; or (c) mono- or di-substituted phenyl], wherein the substituent are each independently: (1) hydrogen; : . (2) halo; (3) alkoxy; (4) haloalkyl; or : : (5) lower alkyl;
R" is: (a) benzoyl, or mono-, or disubstituted benzoyl, wherein the substituents are each independently: (1) halo; (2) lower alkyl; or (3) alkoxy; (b) benzyl, mono- or disubstituted benzyl, wherein the substituents ’ are each independently: (1) halo; ) (2) lower alkyl; or (3) alkoxy; (c) lower alkyl-pyridinyl, or unsubstituted, mono-, or disubstituted pyridinyl, wherein the substituents are each independently: (1) halo; ) (2) lower alkyl; or (3) alkoxy; (d) -C(O)-pyridinyl, or mono-, or disubstituted —C(O)-pyridinyl wherein the substituents are each independently: (1) halo; (2) lower alkyl; or (3) alkoxy; (e) hydrogen; (f) aryl; (g) cycloalkyl; (h) cycloalkylalkyl;
Ris: (a) lower alkenyl-CO,D’; or (b) K;
R” is unsubstituted or mono substituted lower alkyl, wherein the substituents are each independently: (a) hydroxy; (b) alkoxy; : (c) nitro; (c) -NH,; (d) alkylamino; (e) dialkylamino; (f) carboxyl; (g) carboxylic ester; or : (h) carboxamide;
R™ is: - (a) hydrogen; (b) lower alkyl; or (c) -C(OR”;
R” is: (a) lower alkyl;
(b) haloalkyl (c) substituted lower alkyl; : (d) cycloalkyl; * (e) unsubstituted, mono-, di- or tri-substituted phenyl or naphthyl, : 5 wherein the substituents are each independently: (1) halo; (2) alkoxy; (3) -5(O) lower alkyl; (4) hydroxy; (5) -S(O),-haloalkyl; (6) lower alkyl; (7) haloalkyl; (8) -CO,D’; (9) -CO;-lower alkyl; (10) -S(O),NR¥(D'); (11) -lower alkyl-O-lower alkyl; (12) -CN; (13) lower alkyl-OD’; (14) arylalkoxy; (15) -C(O)NR* (DY); or (16) aryl; (f) mono-, di- or tri-substituted heteroaryl, wherein the heteroarylisa monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is selected from S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1, 2, 3, or 4 additional N atoms; wherein the substituents are each independently: (1) halo; » (2) alkoxy; (3) -S(O) lower alkyl; ’ (4) hydroxy; (5) -5(0) haloalkyl; (6) lower alkyl;
(7) haloalkyl; (8) -CO,D; : } (9) -CO,-lower alkyl; (10) -S(O),NR’(D"); ; 5 (11) -lower alkyl-O-lower alkyl; (12) -N(D")S(0),- lower alkyl; (13) lower alkyl-OD’; (14) -N(D")S(O),-haloalky]; (15) -C(O)NR¥D"; or (16) aryl; :
R*is: (a) alkyl; (b) substituted alkyl; (c) alkyl-N(D")S(O),-aryl; (d) substituted alkyl-cycloalkyl; (e) substituted alkyl-heterocyclic ring; or (f) arylalkoxy;
R”is: (a) -ODj; (b) alkoxy; or 3 (c) -NR"R”;
R™ and R” are each independently: (a) hydrogen; (b) hydroxy; (c) alkoxy; (d) lower alkyl; or (e) substituted lower alkyl; or
R” and R” taken together with the nitrogen to which they are attached form . a heterocyclic ring; R"and R" are each independently: : (a) hydrogen; (b) lower alkyl; or (c) halo;
R” and R” are each independently: (a) hydrogen; or } (b) lower alkyl; or
R” and R* taken together with the carbon to which they are attached form a : 5 cycloalkyl ring; m is an integer from 0 to 6;
D, R,R’,R% K, X’, a, p and o are as defined herein; and with the proviso that the compounds of Formula XII must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Another embodiment of the present invention provides compounds of the
Formula (XIII): . x13 - we yz y13 \
RY!
Xi wherein:
X” and Y” are each independently: (a) =C(H)-; or (b) =N-;
R” is: (a) lower alkyl; (b) lower alkyl-OD'; (c) alkenyl; " (d) lower alkyl-CN; (e) lower alkyl-CO,D’; ’ (f) aryl; (8) heterocyclic ring; or
C5 (i) heterocyclicalkyl;
R” is: (a) mono-, di- or tri-substituted phenyl, wherein the substituents are each independently: (1) hydrogen; ] (2) halo; (3) alkoxy; : 5 (4) alkylthio; (5) CN; (6) haloalkyl; (7) lower alkyl; (8) -CO,D; (9) -CO,-lower alkyl; (10) lower alkyl-OD"; (11) lower alkyl-NR"R"; (12) lower alkyl-CO,D’ ; or (13) -OD}; (b) mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S,
O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a : monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, ’ optionally, 1, 2, 3, or 4 additional N atoms; wherein the substituents are each independently: (1) hydrogen; (2) halo; (3) alkoxy; (4) alkylthio; (5) CN; (6) haloalkyl; (7) lower alkyl; (8) -CO,DY; : (9) -CO,-lower alkyl; (10) lower alkyl-OD; : (11) lower alkyl-NR"R"; (12) lower alkyl-CO,D’ ; or (13) -OD%;
D', R', R? and R”, are as defined herein; and with the proviso that the compounds of Formula must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Another embodiment of the present invention provides compounds of the ‘ 5. Formula (XIV):
R
C 1 pl [So A. : 2 14 Ae
XIV wherein:
X* is: (a) -C(O)-; or (b) -C)
Y* is: (a) -O-; or : (b) 5;
AM=B"=D" is: (a) -CR*=CR*-CR’=CR’-; (b) -CR'(R")-CR(R")-C(O); (c) -CRY(R")-C(O)-CR’(R%)~; (d) -C(O)-CRR)-CR'(R’) ~ (e) -CR}R’)-O-C(O)-; (f) -C(O)-O-CR'(R)~; (8) -O-C(O)-CR(R’)-; (h) -S-N=CR*; : (i) -O-N=CR’~; (j) -CRYR’)-NR*-C(O)-; (k) -C(O)-NR*-CR'(R’)-;
(1) -NR’-C(O)-CR*(R’)-; = (m) -CRURY)-S-CO); (n) -C(0)-5-CR(R")—; (0) -5-C(O)-CR'(R)-; : 5 (p) -CR*=CR*-C(O)-; (9) -C(O)- CR’=CR*-; (r) -O-CR*=CR*-; (s) -S-CR*=CR*-; (t) -NR’-CR'=CR’-; (u) -S-NR>*-C(O)-; (v) -O-NR’-C(O)-; or (w) -NR’-N=CR*;
RL, RR}, RY RY R’and R® are as defined herein; and with the proviso that the compounds of Formula XIV must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Another embodiment of the present invention provides compounds of the :
Formula (XV): . X 1 A eo sol
XV . wherein:
X® is: (a) -C(O) (b) -CH,-; . (c) -CH(OD')+; (d) -C=N-O-lower alkyl; ‘ 25 (e)-O-~; (H) -5(0)~ (g) -NR*; or oo 80
(g) covalent bond;
Y” is: (a) aryl; or (b) cycloalkyl; . 5 Zs: (a) hydrogen; (b) alkyl; ‘ (c) haloalkyl; (d) cycloalkyl; (e) alkoxy; (f) alkylthio; (g) cycloalkylalkylthio; (h) cycloalkylalkoxy; (i) -OD’; ~ (j) halo; (k) cyano; (1) -C(O)OD}; (m) -C(O)-lower alkyl; ;
R” is: (a) hydrogen; (b) lower alkyl; (c) -C(O)-lower alkyl; or (d) K;
R', D}, K and o are as defined herein; and with the proviso that the compounds of Formula XV contain at least one. nitrite, nitrate, thionitrite or thionitrate group. a. 81
Another embodiment of the present invention provides compounds of the
Formula (XVI): ’ Z16 ’ ye 0 N rr
Z ©) ' AX .
XVI wherein:
X* is: (a) a (b)
RH
R% R95
EN
N 4
R%
Y* is: (a) hydrogen; . 15 (b) halogen; (c) methyl; or (d) ethyl;
Z" is: (2) hydrogen; or (b) methyl;
R”is: , 5 (a) chloro; or (b) fluoro;
R* and R* are each independently: (a) hydrogen; or (b) fluoro;
R* is: (a) chloro; (b) fluoro; (c) hydrogen; (d) methyl; (e) ethyl; : (f) methoxy; (g) ethoxy; or (i) hydroxy;
R* is: (a) chloro; (b) fluoro; (c) trifluoromethyl; or : (d) methyl;
R* is: (a) lower alkyl; (b) lower alkenyl; (c) alkoxy; or (d) alkylthio; : K and X® are as defined herein; and with the proviso that the compounds of Formula XVI must contain at least one nitrite, nitrate, thionitrite or thionitrate group.
Compounds of the present invention that have one or more asymmetric carbon atoms may exist as the optically pure enantiomers, pure diastereomers,
mixtures of enantiomers, mixtures of diastereomers, racemic mixtures of enantiomers, diastereomeric racemates or mixtures of diastereomeric racemates.
The present invention includes within its scope all such isomers and mixtures thereof. . 5 Another aspect of the present invention provides processes for making the novel compounds of the invention and to the intermediates useful in such processes. The reactions are performed in solvents appropriate to the reagents and materials used are suitable for the transformations being effected. It is understood by one skilled in the art of organic synthesis that the functionality present in the molecule must be consistent with the chemical transformation proposed. This will, on occasion, necessitate judgment by the routineer as to the order of synthetic steps, protecting groups required, and deprotection conditions. Substituents on the starting materials may be incompatible with some of the reaction conditions required in some of the methods described, but alternative methods and substituents compatible with the reaction conditions will be readily apparent to one skilled in the art. The use of sulfur and oxygen protecting groups is well known for protecting thiol and alcohol groups against undesirable reactions during a : synthetic procedure and many such protecting groups are known and described : by, for example, Greene and Wuts, Protective Groups in Organic Synthesis, Third
Edition, John Wiley & Sons, New York (1999).
The chemical reactions described herein are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention.
Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by one skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to one skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, : and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily prepared from known starting materials.
The compounds of Formulas (I), (II), (I), (IV), (V), (VI), (VII), (VII), (IX),
(X), (XT), (XI), (XII), (XIV), (XV) and (XVI) can be synthesized by one skilled in the art following the methods and examples described herein. The synthesis of the ] parent COX-2 inhibitors (i.e. non-nitrosated and/or non-nitrosylated COX-2 inhibitors) are disclosed in, for example, U. S. Patent Nos. 5,344,991, 5,393,790, . 5 5,466,823, 5,474,995, 5,486,534, 5,504,215, 5,508,426, 5,510,496, 5,516,907, 5,521,207, 5,536,752, 5,550,142, 5,563,165, 5,616,601, 5,620,999, 5,677,318, 5,668,161, 5,691,374, 5,698,584, 5,710,140, 5,753,688, 5,859,257, 5,908,858, 5,945,539, 5,994,381, 6,080,876, 6,083,969 and 6,071,954 and in WO 91/19708, WO 94/15932, WO 94 /26731, WO ~ 94/27980, WO 95/00501, WO 95/11883, WO 95/15315, WO 95/15316, WO 95/15317, WO 95/15318, WO 95/18799, WO 95/21817, WO 95/30652, WO 96/30656, WO 96/03387, WO 96/03392, WO 96/03385, WO 96/03387, WO 96/03388, WO 96/09293, WO 96/09304, WO 96/16934, WO 96/19462, WO 96/19463, WO 96/19469, WO 96/25405, WO 96/36617, WO 96/36623, WO 97/11704, WO 97 /13755, WO 97/27181, WO 97/14691, WO 97/16435, WO 97/34882, WO 97/36863, WO 97/40012, WO 97/45420, WO 98/00416, WO 98/11080, WO 98/22422, WO 98/41516, WO 98/46594, WO 98/52937, WO 99/15531, WO 99/23087, WO 99/33796, WO 99/25695, WO 99/61016, WO 99/62884 and WO 99/64415 and in EP 0 745 596 Al, EP 0 087 629 B1, EP 0 418 845 .
B1, EP 0 554 829 A2, EP 0 863 134 Al, EP 1006 114 Al for the parent compounds of
Formulas (I) and (II); and in U. S. Patent Nos. 5,733,909, 5,789,413 and 5,849,943 and : in WO 96/13483, WO 97/28120 and WO 97/28121 for the parent compounds of
Formula (II); and in U. S. Patent No. 5,861,419 and 6,001,843 and in WO 96/10012,
WO 96/16934, WO 96/24585, WO 98/03484, WO 98/24584, WO 98/47871, WO 99/14194 and WO 99/14195 for the parent compounds of Formula (IV); and in U. S.
Patent Nos. 5,436,265, 5,510,368, 5,604,253 and 5,639,780 and in WO 96/37467, WO 96/37468, WO 96/37469, WO 98/39330 and WO 00/40087 for the parent compounds of Formula (V); and in U. S. Patent Nos. 5,409,9444, 5,604,260, 5,968,859, 5,776,984, 5,968,958 and in WO 94/13635, WO 94/20480, WO 96/23786, WO : 97/03953, WO 98/33769 and WO 99/15503 for the parent compounds of Formula (VI); and in WO 98/41511, WO 99/10331, WO 99/10332 and WO 00/24719 for the : parent compounds of Formula (VII); and in WO 98/47890 and WO 00/23443 for the parent compounds of Formula (VIII), and in U. S. 5,807,873 and WO 98/43966 for the parent compounds of Formula (IX); and in U.S. Patent Nos. 5,521,213 and
5,552,422 and in WO 96/06840, WO 96/21667, WO 96/31509, WO 99/12930, WO 00/08024 and WO 00/26216 for the parent compounds of Formula (X); and in U.S.
Patent Nos. 5,776,967, 5,824,699 and 5,830,911 and in WO 98/04527 for the parent compounds of Formula (XI); and in U. S. Patent Nos. 5,750,558 and 5,756,531 and in
WO 97/41100, WO 98/05639, WO 98/21195, WO 98/57924, WO 99 /05104 and WO 99/35130 for the parent compounds of Formula (XII); and in WO 99/61436 for the parent compounds of Formula (XII); and in WO 00/10993 for the parent compounds of Formula (XIV); and in WO 98/32732 for the parent compounds of
Formula (XV); and in WO 97/09977, WO 99/11605 and WO 99 /41224 for the parent compounds of Formula (XVI); the disclosures of each of which are incorporated by reference herein in their entirety. The parent COX-2 inhibitor compounds can then be nitrosated and/or nitrosylated through one or more sites such as oxygen, sulfur and/or nitrogen using the methods described in the examples herein and using conventional methods known to one skilled in the art.
For example, known methods for nitrosating and nitrosylating compounds are described in U.S. Patent Nos. 5,380,758 and 5,703,073; WO 97/27749; WO 98/19672; ; and Oae et al, Org. Prep. Proc. Int., 15(3):165-198 (1983), the disclosures of each of which are incorporated by reference herein in their entirety. The methods of : nitrosating and/or nitrosylating the compounds described in the examples herein and in these references can be applied by one skilled in the art to produce any of the nitrosated and /or nitrosylated COX-2 inhibitors described herein.
The compounds of the present invention include the parent COX-2 : inhibitors, including those described herein, which have been nitrosated and/or nitrosylated through one or more sites such as oxygen (hydroxyl condensation), sulfur (sulfhydryl condensation) and/or nitrogen. The nitrosated and/or nitrosylated COX-2 inhibitors of the present invention donate, transfer or release a biologically active form of nitrogen monoxide (i.e., nitric oxide).
Nitrogen monoxide can exist in three forms: NO- (nitroxyl), NOe : (uncharged nitric oxide) and NO" (nitrosonium). NOs is a highly reactive short- lived species that is potentially toxic to cells. This is critical because the : pharmacological efficacy of NO depends upon the form in which it is delivered. In contrast to the nitric oxide radical (NOe), nitrosonium (NO") does not react with O, or O, species, and functionalities capable of transferring and/or releasing NO" and
Co _ I 86 : SL SE : _
NO- are also resistant to decomposition in the presence of many redox metals.
Consequently, administration of charged NO equivalents (positive and/or negative) is a more effective means of delivering a biologically active NO to the desired site of action.
Compounds contemplated for use in the present invention (e.g., nitrosated and/or nitrosylated COX-2 inhibitors) are, optionally, used in combination with nitric oxide and compounds that release nitric oxide or otherwise directly or indirectly deliver or transfer a biologically active form of nitrogen monoxide to a : site of its intended activity, such as on a cell membrane in vivo.
The term "nitric oxide" encompasses uncharged nitric oxide (NO) and charged nitrogen monoxide species, preferably charged nitrogen monoxide species, such as nitrosonium ion (NO") and nitroxyl ion (NO-). The reactive form of nitric oxide can be provided by gaseous nitric oxide. The nitrogen monoxide releasing, delivering or transfetring compounds have the structure F-NO, wherein Fis a nitrogen monoxide releasing, delivering or transferring moiety, and include any and all such compounds which provide nitrogen monoxide to its intended site of action in a form active for its intended purpose. The term "NO adducts” encompasses any nitrogen monoxide releasing, delivering or transferring : compounds, including, for example, S-nitrosothiols, nitrites, nitrates, S-nitrothiols, sydnonimines, 2-hydroxy-2-nitrosohydrazines, (NONOates), (E)-alkyl-2-[(E)- hydroxyimino}-5-nitro-3-hexene amines or amides, nitrosoamines, furoxans as well as substrates for the endogenous enzymes which synthesize nitric oxide. The "NO adducts" can be mono-nitrosylated, poly-nitrosylated, mono-nitrosated and/or ~ poly-nitrosated at a variety of naturally susceptible or artificially provided binding sites for biologically active forms of nitrogen monoxide.
One group of NO adducts is the S-nitrosothiols, which are compounds that include at least one -S-NO group. These compounds include S-nitroso- polypeptides (the term “polypeptide” includes proteins and polyamino acids that do not possess an ascertained biological function, and derivatives thereof); 5- nitrosylated amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof); S-nitrosylated sugars;
S-nitrosylated, modified and unmodified, oligonucleotides (preferably of at least 5, and more preferably 5-200 nucleotides); straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted S-nitrosylated hydrocarbens; and S-nitrese heterocyclic compounds. S-nitrosothiols and methods for preparing them are described in U.S. Patent Nos. 5,380,758 and 5,703,073; WO 97/27749; WO 98/19672; and Oae et al, Org. Prep. Proc. Int., 15(3):165-198 (1983), the : 5 disclosures of each of which are incorporated by reference herein in their entirety.
Another embodiment of the present invention is S-nitroso amino acids where the nitroso group is linked to a sulfur group of a sulfur-containing amino acid or derivative thereof. Such compounds include, for example, S-nitroso-N- acetylcysteine, S-nitroso-captopril, S-nitroso-N-acetylpenicillamine, S-nitroso- homocysteine, S-nitroso-cysteine, S-nitroso-glutathione, S-nitroso-cysteinyl-glycine, and the like.
Suitable S-nitrosylated proteins include thiol-containing proteins (where the
NO group is attached to one or more sulfur groups on an amino acid or amino acid derivative thereof) from various functional classes including enzymes, such as tissue-type plasminogen activator (TPA) and cathepsin B; transport proteins, such as lipoproteins; heme proteins, such as hemoglobin and serum albumin; and biologically protective proteins, such as immunoglobulins, antibodies and cytokines. Such nitrosylated proteins are described in WO 93/09806, the disclosure of which is incorporated by reference herein in its entirety. Examples include ~~ polynitrosylated albumin where one or more thiol or other nucleophilic centers in the protein are modified.
Other examples of suitable S-nitrosothiols include: ( HS(CR)R),.SNO; (ii) ONS(CR)R))..R;and (ii) HN-CH(CO,H)-(CH,),,-C(O)NH-CH(CH,SNO)-C(O)NH-CH,-CO,H; wherein mm is an integer from 2 to 20; R, and R, are each independently a hydrogen, an alkyl, a cycloalkoxy, a halogen, a hydroxy, an hydroxyalkyl, an alkoxyalkyl, an arylheterocyclic ring, a cycloalkylalkyl, a heterocyclicalkyl an : alkoxy, a haloalkoxy, an amino, an alkylamino, a dialkylamino, an arylamino, a diarylamino, an alkylarylamino, an alkoxyhaloalkyl, a haloalkoxy, a sulfonic acid, a sulfonic ester, an alkylsulfonic acid, an arylsulfonic acid, an arylalkoxy, an alkylthio, an arylthio, a cyano, an aminoalkyl, an aminoaryl, an alkoxy, an aryl, an arylalkyl, a carboxamido, a alkylcarboxamido, an arylcarboxamido, an amidyl, a carboxyl, a carbamoyl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarbonyl, an arylcarbonyl, an ester, a carboxylic ester, an alkylcarboxylic ester, an arylcarboxylic ester, a haloalkoxy, a sulfonamido, an alkylsulfonamido, an arylsulfonamido, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfonyl, an arylsulfonyloxy, a carbamoyl, a urea, a nitro, -T-Q-, or (CRYR),-T-Q, orR, and
R, taken together are an oxo, a methanthial, a heterocyclic ring, a cycloalkyl group or a bridged cycloalkyl group; Q is -NO or -NO,; and T is independently a covalent bond, a carbonyl, an oxygen, -S(O),- or -N(R,)R-, wherein o is an integer from 0 to 2, R, is a lone pair of electrons, a hydrogen or an alkyl group; R, is a hydrogen, an alkyl, an aryl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarboxylic ester, an arylcarboxylic ester, an alkylcarboxamido, an arylcarboxamido, an alkylsulfinyl, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfinyl, an arylsulfonyloxy, an arylsulfonyl, a sulfonamido, a carboxamido, a carboxylic ester, an aminoalkyl, an aminoaryl, -CH,-C(T-Q)(R )(R,), or -(N,O,-) *M’, wherein M" is an organic or inorganic cation; with the proviso that when R, is -CH,-C(T-Q)(R )(R)) or -(N,O,-)*M’; then "-T-Q" can be a hydrogen, an alkyl group, an alkoxyalkyl group, an aminoalkyl group, a hydroxy group or an aryl group.
In cases where R, and R, are a heterocyclic ring or taken together R, and R, : are a heterocyclic ring, then R; can be a substituent on any disubstituted nitrogen : contained within the radical wherein R, is as defined herein. :
Nitrosothiols can be prepared by various methods of synthesis. In general, the thiol precursor is prepared first, then converted to the S-nitrosothiol derivative by nitrosation of the thiol group with NaNO, under acidic conditions (pH is about 2.5) which yields the S-nitroso derivative. Acids which can be used for this purpose include aqueous sulfuric, acetic and hydrochloric acids. The thiol precursor can also be nitrosylated by reaction with an organic nitrite such as tert- butyl nitrite, or a nitrosonium salt such as nitrosonium tetraflurorborate in an inert solvent.
Another group of NO adducts for use in the present invention, where the
NO adduct is a compound that donates, transfers or releases nitric oxide, include } ) compounds comprising at least one ON-O-, ON-N- or ON-C- group. The compounds that include at least one ON-O-, ON-N- or ON-C- group are preferably
ON-O-, ON-N- or ON-C-polypeptides (the term "polypeptide" includes proteins and polyamino acids that do not possess an ascertained biological function, and derivatives thereof); ON-O-, ON-N- or ON-C-amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures); ON-O-, ON-
N- or ON-C-sugars; ON-O-, ON-N- or ON-C- modified or unmodified oligonucleotides (comprising at least 5 nucleotides, preferably 5-200 nucleotides);
ON-O-, ON-N- or ON-C- straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted hydrocarbons; and ON-O-, ON-N- or
ON-C-heterocyclic compounds.
Another group of NO adducts for use in the present invention include nitrates that donate, transfer or release nitric oxide, such as compounds comprising at least one O,N-O-, ON-N-, O,N-5- or O,N-C- group. Preferred among these compounds are O,N-O-, O,N-N-, O,N-5- or O,N-C- polypeptides (the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof); O,N-O-, O,N-N-, O,N-S- or O,N-C- amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures); O,N-O-, O,N-N-, O,N-S- or O,N-C-sugars;
O,N-O-, O,N-N-, O,N-5- or O,N-C- modified and unmodified oligonucleotides ) (comprising at least 5 nucleotides, preferably 5-200 nucleotides); O,N-O-, O,N-N-, :
O,N-5- or O,N-C- straight or branched, saturated or unsaturated, aliphatic or . aromatic, substituted or unsubstituted hydrocarbons; and O,N-O-, O,N-N-, O,N-S- : or O,N-C- heterocyclic compounds. Preferred examples of compounds comprising : at least one O,N-O-, O,N-N-, O,N-S- or O,N-C- group include isosorbide dinitrate, isosorbide mononitrate, clonitrate, erythrityltetranitrate, mannitol hexanitrate, nitroglycerin, pentaerythritoltetranitrate and pentrinitrol. Preferred are those -S-
NO, compounds that are polypeptides or hydrocarbons with a pair or pairs of thiols that are sufficiently structurally proximate, i.e., vicinal, that the pair of thiols will be reduced to a disulfide. Compounds which form disulfide species release nitroxyl ion (NO-) and uncharged nitric oxide (NOs). Compounds where the thiol : groups are not sufficiently close to form disulfide bridges generally provide nitric oxide as the NO- form and not as the uncharged NOe form. : Another group of NO adducts are N-oxo-N-nitrosoamines that donate, transfer or release nitric oxide and are represented by the formula: R'R>N(O-M")-
NO, where R' and R* are each independently a polypeptide, an amino acid, a sugar,
a modified or unmodified oligonucleotide, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted hydrocarbon, or a . heterocyclic group, and where M" is an organic or inorganic cation, such as, for example, an alkyl substituted ammonium cation or a Group I metal cation. - 5 The present invention is also directed to compounds that stimulate endogenous NO or elevate levels of endogenous endothelium-derived relaxing factor (EDRF) in vivo or are substrates for nitric oxide synthase. Such compounds include, for example, L-arginine, L-homoarginine, and N-hydroxy-L-arginine, including their nitrosated and nitrosylated analogs (e.g., nitrosated L-arginine, nitrosylated L-arginine, nitrosated N-hydroxy-L-arginine, nitrosylated N-hydroxy-
L-arginine, nitrosated L-homoarginine and nitrosylated L-homoarginine), precursors of L-arginine and/or physiologically acceptable salts thereof, including, for example, citrulline, ornithine or glutamine, inhibitors of the enzyme arginase (e.g., N-hydroxy-L-arginine and 2(S)-amino-6-boronohexanoic acid) and the substrates for nitric oxide synthase, cytokines, adenosin, bradykinin, calreticulin, bisacodyl, and phenolphthalein. EDRF is a vascular relaxing factor secreted by the - endothelium, and has been identified as nitric oxide (NO) or a closely related g derivative thereof (Palmer et al, Nature, 327:524-526 (1987); Ignarro et al, Proc. Natl.
Acad. Sci. USA, 84:9265-9269 (1987)).
Another embodiment of the present invention provides compositions ; comprising at least one parent COX-2 inhibitor and at least one compound that donates, transfers or releases nitric oxide, or elevates levels of endogenous EDRF or nitric oxide, or is a substrate for nitric oxide synthase. The parent COX-2 inhibitors includes any of those described in the prior art, including those described in the patents and publications cited herein, as well as the novel compounds described herein.
The present invention is also based on the discovery that compounds and compositions of the present invention may also be used in conjunction with other : therapeutic agents for co-therapies, partially or completely, in place of other conventional antiinflammatory compounds, such as, for example, together with ) steroids, NSAIDs, 5-lipoxygenase (5-LO) inhibitors, leukotriene B, (LTB,) receptor antagonists, leukotriene A, (LTA,) hydrolase inhibitors, 5-HT agonists, HMG-CoA inhibitors, H, receptor antagonists, antineoplastic agents, antiplatelet agents, _ 91 decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof.
Leukotriene A, (LTA,) hydrolase inhibitors refers to compounds that : 5 selectively inhibit leukotriene A, hydrolase with an IC, of less than about 10uM, and more preferably with an IC, of less than about 1 pM. Suitable LTA, hydrolase inhibitors include, but are not limited to, RP-64966, (S,5)-3-amino-4-(4- benzyloxyphenyl)-2-hydroxybutyric acid benzyl ester (Scripps Res. Inst.), N-(2(R)- (cyclohexylmethyl)-3-(hydroxycarbamoyl)propionyl)-L-alanine (Searle), 7-(4-(4- ureidobenzyl)phenyl) heptanoic acid (Rhone-Poulenc Rorer), and 3 (3-(1E,3E- tetradecadienyl)-2-oxiranyl)benzoic acid lithium salt (Searle), and mixtures thereof.
Suitable LTB, receptor antagonists include, but are not limited to, ebselen, linazolast, ontazolast; WAY 121006 (American Home Products); Bay-x-1005 (Bayer);
BI-RM-270 (Boehringer Ingleheim); CGS-25019C (Ciba Geigy); ETH-615 (Leo
Denmark); MAFP (Merck); TMK-688 (Terumo); T-0757 (Tanabe); LY 213024, LY : 210073, LY 223982, LY 233469, LY 255283, LY 264086, LY 292728 and LY 293111 (Eli
Lilly); ONO-LB457, ONO-4057, and ONO-LB-448 (ONO), S-2474, calcitrol 2 (Shionogi); PF 10042 (Perdu Frederick); Pfizer 105696 (Pfizer Inc.); RP 66153 . (Rhone-Poulenc); SC-53228, SC-41930, SC-50605, SC-51146 and SC-53228 (Searle);
SB-201146 and SB-209247 (SmithKline Beecham); SKF-104493 (SmithKline &
French); SM 15178 (Sumitamo}); TMK-688 (Terumo); BPC 15, (Warner Lambert); and mixtures thereof. The preferred LTB, receptor antagonists are calcitrol, ebselen,
Bay-x-1005, CGS-25019C, ETH-615, LY-293111, ONO-4057 and TMK-688, and mixtures thereof.
Suitable 5-LO inhibitors include, but are not limited to, A-76745, 78773 and
ABT761 (Abbott compounds); Bay-x-1005 (Bayer); CMI-392 (Cytomed); E-3040 (Eisai); EF-40 (Scotia Pharmaceutical); F-1322 (Fujirebio); ML-3000 (Merckle); PE- 5901 (Purdue Frederick); R-840 (3M Pharmaceuticals); rilopirox, flobufen, : linasolast, lonapolene, masoprocol, ontasolast, tenidap, zileuton, pranlukast, tepoxalin, rilopirox, flezelastine hydrochloride, enazadrem phosphate, and : bunaprolast, and mixtures thereof. Suitable 5-LO inhibitors are also described : more fully in WO 97/29776 assigned to G. D. Searle & Co.
Suitable 5-HT agonists, include, but are not limited to, rizatriptan,
sumatriptan, naratriptan, zolmitroptan, eleptriptan, almotriptan, ergot alkaloids.
ALX 1323, Merck L 741604 SB 220453 and LAS 31416. Suitable 5-HT agonists are described more fully in WO 0025779, assigned to Merck & Co., Inc and in WO 00/48583, assigned to Pozen Inc. 5-HT agonists refers to a compound that is an : 5 agonist to any 5-HT receptor, including but not limited to, 5-HT, agonists, 5-HT; agonists and 5-HT, agonists.
Suitable steroids, include, but are not limited to, budesonide, dexamethasone, corticosterone, prednisolone, and the like. Suitable steroids are described more fully in the literature, such as in the Merck Index on CD-ROM,
Twelfth Edition, Version 12:1, 1996.
Suitable HMG CoA inhibitors, include, but are not limited to, reductase and synthase inhibitors, such as, for example, squalene synthetase inhibitors, benzodiazepine squalene synthase inhibitors, squalene epoxidase inhibitors, acyl- coenzyme A, bile acid sequestrants, cholesterol absorption inhibitors, and the like.
Suitable NSAIDs, include, but are not limited to, acetaminophen, aspirin, diclofenac, ibuprofen, ketoprofen, naproxen and the like. Suitable NSAIDs are described more fully in the literature, such as in Goodman and Gilman, The
Pharmacological Basis of Therapeutics (9th Edition), McGraw-Hill, 1995, Pgs. 617- : 657; and the Merck Index on CD-ROM, Twelfth Edition, Version 12:1, 1996.
Suitable H, receptor antagonists, include, but are not limited to, cimetidine, roxatidine, rantidine and the like. Suitable H, receptor antagonists are described more fully in the literature, such as in Goodman and Gilman, The Pharmacological
Basis of Therapeutics (9th Edition), McGraw-Hill, 1995, Pgs. 901-915; and the Merck
Index on CD-ROM, Twelfth Edition, Version 12:1, 1996.
Suitable antineoplastic agents, include but are not limited to, 5-FU- fibrinogen, acanthifolic acid, aminothiadiazole, altretamine, anaxirone, aclarubicin and the like. Suitable antineoplastic agents are also described more fully in U. S.
Patent No. 6,025,353 and WO 00/38730 assigned to G. D. Searle & Co. : : Suitable antiplatelet agents, include but are not limited to, aspirin, ticlopidine, dipyridamole, clopidogrel, glycoprotein IIb /Illa receptor antagonists, ’ and the like.
Suitable decongestants include, but are not limited to, phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine,
naphazoline, xylometazoline, propylhexedrine, levo-desoxyephedrine, and the like.
Suitable antitussives include, but are not limited to, codeine, hydrocodone, caramiphen, carbetapentane, dextramethorphan, and the like.
Suitable proton pump inhibitors, include, but are not limited to, omeprazole, ; 5 lansoprazole, rabeprazole, pantoprazole, and the like. Suitable proton pump inhibitors are described more fully in the literature, such as in Goodman and
Gilman, The Pharmacological Basis of Therapeutics (9th Edition), McGraw-Hill, 1995, Pgs. 901-915; and the Merck Index on CD-ROM, Twelfth Edition, Version 12:1, 1996.
The compounds and compositions of the present invention, may also be used in combination therapies with opioids and other analgesics, including, but not limited to, narcotic analgesics, Mu receptor antagonists, Kappa receptor antagonists, non-narcotic (i.e. non-addictive) analgesics, monoamine uptake inhibitors, adenosine regulating agents, cannabinoid derivatives, neurokinin 1 receptor antagonists, Substance P antagonists, neurokinin-1 receptor antagonists, sodium channel blockers, N-methyl-D-aspartate receptor antagonists, and mixtures thereof. Preferred combination therapies would be with morphine, meperidine, 3 codeine, pentazocine, buprenorphine, butorphanol, dezocine, meptazinol, hydrocodone, oxycodone, methadone, Tramadol ((+) enantiomer), DuP 747,
Dynorphine A, Enadoline, RP-60180, HN-11608, E-2078, ICI-204448, acetominophen (paracetamol), propoxyphene, nalbuphine, E-4018, filenadol, mirtentanil, amitriptyline, DuP631, Tramadol ((-) enantiomer), GP-531, acadesine, AKI-1, AKI-2,
GP-1683, GP-3269, 4030W92, tramadol racemate, Dynorphine A, E-2078, AXC3742,
SNX-111, ADL2-1294, ICI-204448, CT-3, CP-99,994, CP-99,994, and mixtures thereof.
The compounds and compositions of the present invention can also be used in combination with inducible nitric oxide synthase (iNOS) inhibitors. Suitable iNOS inhibitors are disclosed in U. S. Patent Nos. 5,132,453 and 5,273,875, and in
WO 97/38977 and WO 99/18960, the disclosures of each of which are incorporated : by reference herein in their entirety.
The present invention is also based on the discovery that the administration : of a therapeutically effective amount of the compounds and compositions described herein is effective for treating inflammation, pain (both chronic and acute), and fever, such as, for example, analgesic in the treatment of pain, including
, but not limited to headaches, migraines, postoperative pain, dental pain, muscular pain, and pain resulting from cancer; as an antipyretic for the treatment of fever, : including but not limited to, rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, : 5 headache, toothache, sprains, strains, myositis, neuralgia, synovitis; arthritis, including but not limited to rheumatoid arthritis, degenerative joint disease (osteoarthritis), spondyloarthropathies, gouty arthritis, systemic lupus erythematosus and juvenile arthritis. For example, the patient can be administered a therapeutically effective amount of at least one nitrosated and/or nitrosylated
COX-2 inhibitor of the present invention. In another embodiment, the patient can be administered a therapeutically effective amount of at least one nitrosated and/or nitrosylated COX-2 inhibitor and at least one compound that donates, transfers or releases nitric oxide, or elevates levels of endogenous EDRF or nitric oxide, or is a substrate for nitric oxide synthase. In yet another embodiment, the patient can be administered a therapeutically effective amount of at least one nitrosated and/or nitrosylated COX-2 inhibitor, and, at least one therapeutic agent, including but not limited to, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B, (LTB,) receptor antagonists, leukotriene A, (LTA,) hydrolase inhibitors, 5-HT agonists, 3-hydroxy- 3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H, antagonists, “ antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non- sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and, optionally, at least one compound that donates, transfers or releases nitric oxide, or elevates levels of endogenous EDRF or nitric oxide, or is a substrate for nitric oxide synthase. The compounds can be administered separately or in the form of a composition.
Another embodiment of the invention provides methods for decreasing ‘ and/or preventing gastrointestinal disorders and improving the gastrointestinal properties of the parent COX-2 inhibitor (i.e., non-nitrosated and/or non- ’ nitrosylated COX-2 inhibitor) by administering to the patient in need thereof a therapeutically effective amount of the compounds and/or compositions described herein. Such gastrointestinal disorders refer to any disease or disorder of the upper gastrointestinal tract (e.g., esophagus, stomach, duodenum and jejunum) including, for example, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, peptic ulcers, stress ulcers, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, bacterial infections (including, for example, a Helicobacter Pylori associated disease), short-bowel (anastomosis) syndrome, hypersecretory states associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia, and bleeding peptic ulcers that result, for example, from neurosurgery, head injury, severe body trauma or burns. For example, the patient can be administered a therapeutically effective amount of at least one nitrosated and/or nitrosylated
COX-2 inhibitor of the present invention. In another embodiment, the patient can be administered a therapeutically effective amount of at least one nitrosated and/or nitrosylated COX-2 inhibitor and at least one compound that donates, transfers or releases nitric oxide, or elevates levels of endogenous EDRF or nitric oxide, or is a substrate for nitric oxide synthase. In yet another embodiment, the patient can be administered a therapeutically effective amount of at least one 2 nitrosated and/or nitrosylated COX-2 inhibitor and at least one therapeutic agent, including but not limited to, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B,(LTB,) receptor antagonists, leukotriene A, (LTA,) hydrolase inhibitors, 5-HT agonists, 3-hydroxy- R 3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H, antagonists, ‘ antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non- sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and, optionally, at least one compound that donates, transfers or releases ~ nitric oxide, or elevates levels of endogenous EDRF or nitric oxide, or is a substrate for nitric oxide synthase. The compounds can be administered separately or in the form of a composition.
Yet another embodiment of the invention provides methods for facilitating wound healing (such as, for example, ulcer healing) by administering to the patient in need thereof a therapeutically effective amount of the compounds and/or compositions described herein. Wound refers to, and includes, any lesion that is characterized by loss of tissue, and, includes, but is not limited to, ulcers, cuts,
burns, and the like. Ulcers refers to lesions of the upper gastrointestinal tract lining that are characterized by loss of tissue, and, include, but are not limited to, gastric } ulcers, duodenal ulcets, gastritis, and the like. For example, the patient can be administered a therapeutically effective amount of at least one nitrosated and/or . 5 nitrosylated COX-2 inhibitor of the present invention. In another embodiment, the patient can be administered a therapeutically effective amount of at least one nitrosated and/or nitrosylated COX-2 inhibitor and at least one nitric oxide donor.
In yet another embodiment, the patient can be administered a therapeutically effective amount of at least one nitrosated and/or nitrosylated COX-2 inhibitor and at least one therapeutic agent, and, optionally, at least one nitric oxide donor. The compounds can be administered separately or in the form of a composition.
Another embodiment of the invention provides methods to decrease or reverse renal and other toxicities (such as, for example, kidney toxicity) by administering to a patient in need thereof a therapeutically effective amount of the compounds and/or compositions described herein. For example, the patient can be administered a therapeutically effective amount of at least one nitrosated and/or nitrosylated COX-2 inhibitor of the present invention. In another J embodiment, the patient can be administered a therapeutically effective amount of : at least one nitrosated and/or nitrosylated COX-2 inhibitor and at least one nitric oxide donor. In yet another embodiment, the patient can be administered a ; therapeutically effective amount of at least one nitrosated and/or nitrosylated
COX-2 inhibitor and at least one therapeutic agent, and, optionally, at least one nitric oxide donor. The compounds can be administered separately or in the form of a composition.
Another embodiment of the invention provides methods to treat or prevent disorders resulting from elevated levels of COX-2 by administering to a patient in need thereof a therapeutically effective amount of the compounds and/or compositions described herein. For example, the patient can be administered a : therapeutically effective amount of at least one nitrosated and/or nitrosylated
COX-2 inhibitor of the present invention. In another embodiment, the patient can be administered a therapeutically effective amount of at least one nitrosated and/or nitrosylated COX-2 inhibitor and at least one compound that donates, transfers or releases nitric oxide, or elevates levels of endogenous EDRF or nitric oxide, or is a substrate for nitric oxide synthase. In yet another embodiment, the patient can be administered a therapeutically effective amount of at least one : i nitrosated and/or nitrosylated COX-2 inhibitor and at least one therapeutic agent, including but not limited to, steroids, a nonsteroidal antiinflammatory compounds . 5 (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B, (LTB,) receptor antagonists, leukotriene A, (LTA,) hydrolase inhibitors, 5-HT agonists, 3-hydroxy- 3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H, antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non- sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and, optionally, at least one compound that donates, transfers or releases nitric oxide, or elevates levels of endogenous EDRF or nitric oxide, or is a substrate for nitric oxide synthase. The compounds can be administered separately or in the form of a composition.
Disorders resulting from elevated levels of COX-2 (e.g., COX-2 mediated disorders) include, but are not limited to, for example, angiogenesis, arthritis, asthma, bronchitis, menstrual cramps, premature labor, tendinitis, bursitis; skin- related conditions, such as, for example, psoriasis, eczema, surface wounds, burns and dermatitis; post-operative inflammation including from ophthalmic surgery, such as, for example, cataract surgery and refractive surgery, and the like; treatment of neoplasia, such as, for example, brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma), such as, for example, basal cell carcinoma, adenocarcinoma, gastrointestinal cancer, such as, for example, lip cancer, mouth cancer, esophageal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamus cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that effect epithelial cells throughout the body, benign and cancerous tumors, growths, : polyps, adenomatous polyps, including, but not limited to, familial adenomatous polyposis, fibrusis resulting from radiation therapy, and the like; treatment of ’ inflammatory processes in diseases, such as, for example, vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, theumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis,
gingivitis, nephritis, hypersensitivity, swelling occurring after injury, myocardial ischemia, and the like; treatment of ophthalmic diseases and disorders, such as, for example, retinitis, retinopathies, uveitis, ocular photophobia, acute injury to the eye tissue, glaucoma, inflammation of the eye and elevation of intraocular pressure and the like; treatment of pulmonary inflammation, such as, for example, those associated with viral infections and cystic fibrosis, and the like; treatment of certain central nervous system disorders, such as, for example, cortical dementias including Alzheimer’s disease, vascular dementia, multi-infarct dementia, pre- senile dementia, alcoholic dementia, senile dementia, and central nervous system damage resulting from stroke, ischemia and trauma, and the like; treatment of allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis; treatment of inflammations and / or microbial infections including, t5 for example, inflammations and/or infections of the eyes, ears, nose, throat, and/or skin; treatment and/or prevention of cardiovascular disorders, such as, for : example, coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, including, but not limited to, cardiac transplant atherosclerosis, myocardial infarction, ischemia, embolism, stroke, thrombosis, hypertension, venous thrombosis, thromboembolism, thrombotic occlusion and reclusion, restenosis, : angina, unstable angina, shock, heart failure, coronary plaque inflammation, bacterial-induced inflammation, such as, for example, Chlamydia-induced inflammation, viral induced inflammation, inflammation associated with surgical procedures, such as, for example, vascular grafting, coronary artery bypass surgery, revascularization procedures, such as, for example, angioplasty, stent placement, endarterectomy, vascular procedures involving arteries, veins, capillaries, and the like; treatment and/or prevention of urinary and/or urological disorders, such as, for example, incontinence and the like; treatment and/or : prevention of endothelial dysfunctions, such as, for example, diseases accompanying these dysfunctions, endothelial damage from hypercholesterolemia, ) endothelial damage from hypoxia, endothelial damage from mechanical and chemical noxae, especially during and after drug, and mechanical reopening of stenosed vessels, for example, following percutaneous transluminal angiography
(PTA) and percuntaneous transluminal coronary angiography (PTCA), endothelial damage in postinfarction phase, endothelium-mediated reocclusion following : bypass surgery, blood supply disturbances in peripheral arteries, as well as, cardiovascular diseases, and the like; preservation of organs and tissues, such as, : 5 for example, for organ transplants, and the like; inhibition and/or prevention of activation, adhesion and infiltration of neutrophils at the site of inflammation; inhibition and / or prevention of platelet aggregation. The compounds and compositions of the present invention can also be used as a pre-anesthetic medication in emergency operations to reduce the danger of aspiration of acidic gastric contents.
When administered in vivo, the compounds and compositions of the present invention can be administered in combination with pharmaceutically acceptable carriers and in dosages described herein. When the compounds and compositions of the present invention are administered as a mixture of at least one nitrosated and/or nitrosylated COX-2 inhibitor and at least one nitric oxide donor and/or therapeutic agent, they can also be used in combination with one or more additional compounds which are known to be effective against the specific disease state targeted for treatment. The nitric oxide donors, therapeutic agents and/or other additional compounds can be administered simultaneously with, subsequently to, or prior to administration of the nitrosated and/or nitrosylated :
COX-2 inhibitor.
Another embodiment of the present invention provides methods for treating inflammation, pain and fever; for treating and /or improving the gastrointestinal : properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other cyclooxygenase- 2 mediated disorders comprising administration of at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. For example, the patient can be administered a therapeutically : effective amount of at least one parent COX-2 inhibitor of the present invention and at least one nitric oxide donor. In yet another embodiment, the patient can be ) administered a therapeutically effective amount of at least one parent COX-2 inhibitor, at least one nitric oxide donor and at least one therapeutic agent. The compounds can be administered separately or in the form of a composition. oo 100
The compounds and compositions of the present invention can be administered by any available and effective delivery system including, but not . limited to, orally, bucally, parenterally, by inhalation spray, by topical application, by injection, transdermally, or rectally (e.g., by the use of suppositories) in dosage . 5 unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles, as desired. Parenteral includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
Transdermal compound administration, which is known to one skilled in the art, involves the delivery of pharmaceutical compounds via percutaneous passage of the compound into the systemic circulation of the patient. Topical administration can also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. Other components can be incorporated into the transdermal patches as well. For example, compositions and/or transdermal patches can be formulated with one or more preservatives or bacteriostatic agents including, but not limited to, methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride, and the like. Dosage forms for topical administration of the compounds and compositions can include creams, sprays, lotions, gels, ointments, eye drops, nose drops, ear drops, and the like. In such dosage forms, the compositions of the invention can be mixed to form white, smooth, homogeneous, opaque cream or lotion with, for example, benzyl alcohol ; 1% or 2% (wt/wt) as a preservative, emulsifying wax, glycerin, isopropyl palmitate, lactic acid, purified water and sorbitol solution. In addition, the compositions can contain polyethylene glycol 400.. They can be mixed to form ointments with, for example, benzyl alcohol 2% (wt/wt) as preservative, white petrolatum, emulsifying wax, and tenox II (butylated hydroxyanisole, propyl gallate, citric acid, propylene glycol). Woven pads or rolls of bandaging material, e.g., gauze, can be impregnated with the compositions in solution, lotion, cream, ointment or other such form can also be used for topical application. The - compositions can also be applied topically using a transdermal system, such as one of an acrylic-based polymer adhesive with a resinous crosslinking agent ’ impregnated with the composition and laminated to an impermeable backing.
Solid dosage forms for oral administration can include capsules, tablets, effervescent tablets, chewable tablets, pills, powders, sachets, granules and gels. In such solid dosage forms, the active compounds can be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms can also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, : 5 effervescent tablets, and pills, the dosage forms can also comprise buffering agents.
Soft gelatin capsules can be prepared to contain a mixture of the active compounds or compositions of the present invention and vegetable oil. Hard gelatin capsules can contain granules of the active compound in combination with a solid, pulverulent carrier such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives of gelatin. Tablets and pills canbe - prepared with enteric coatings.
Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
Suppositories for vaginal or rectal administration of the compounds and - compositions of the invention, such as for treating pediatric fever and the like, can be prepared by mixing the compounds or compositions with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are ¥ solid at room temperature but liquid at rectal temperature, such that they will melt in the rectum and release the drug.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing agents, wetting agents and/or suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3- butanediol. Among the acceptable vehicles and solvents that can be used are . water, Ringer’s solution, and isotonic sodium chloride solution. Sterile fixed oils are also conventionally used as a solvent or suspending medium. ; The compositions of this invention can further include conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral application which do not deleteriously react with the active __ 102 ’
compounds. Suitable pharmaceutically acceptable carriers include, for example, water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid . 5 esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, and the like. The pharmaceutical preparations can be sterilized and if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavoring and/or aromatic substances and the like which do not deleteriously react with the active 10 compounds. For parenteral application, particularly suitable vehicles consist of solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants. Aqueous suspensions may contain substances which increase the viscosity of the suspension and include, for example, sodium carboxymethyl cellulose, sorbitol and/or dextran. Optionally, the suspension may also contain 15 stabilizers.
The composition, if desired, can also contain minor amounts of wetting . agents, emulsifying agents and/or pH buffering agents. The composition can be a 2 liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release : formulation, or powder. The composition can be formulated as a suppository, with 20 traditional binders and carriers such as triglycerides. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.
Various delivery systems are known and can be used to administer the compounds or compositions of the present invention, including, for example, encapsulation in liposomes, microbubbles, emulsions, microparticles, microcapsules and the like. The required dosage can be administered as a single unit or in a sustained release form. ‘ The bioavailability of the compositions can be enhanced by micronization of the formulations using conventional techniques such as grinding, milling, spray : drying and the like in the presence of suitable excipients or agents such as phospholipids or surfactants. : The preferred methods of administration of the nitrosated and/or nitrosylated COX-2 inhibitor compositions or the parent COX-2 inhibitor for the treatment of gastrointestinal disorders are orally, bucally or by inhalation. The } preferred methods of administration for the treatment of inflammation and microbial infections are orally, bucally, topically, transdermally or by inhalation. - 5 The compounds and compositions of the present invention can be formulated as pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include, for example, alkali metal salts and addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically- acceptable. Suitable pharmaceutically-acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid and the like. Appropriate organic acids include, but are not limited to, aliphatic, cycloaliphatic, aromatic, heterocyclic, carboxylic and sulfonic classes of organic acids, such as, for example, formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic : ~ (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesuifonic, sulfanilic, stearic, algenic, B- hydroxybutyric, cyclohexylaminosulfonic, galactaric and galacturonic acid and the : like. Suitable pharmaceutically-acceptable base addition salts include, but are not limited to, metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from primary, secondary and tertiary amines, cyclic amines, N,N’-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine; meglumine (N-methylglucamine) and procaine and the like. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the compound.
While individual needs may vary, determination of optimal ranges for effective amounts of the compounds and/or compositions is within the skill of the ‘ art. Generally, the dosage required to provide an effective amount of the compounds and compositions, which can be adjusted by one of ordinary skill in the art, will vary depending on the age, health, physical condition, sex, diet, weight,
extent of the dysfunction of the recipient, frequency of treatment and the nature and scope of the dysfunction or disease, medical condition of the patient, the route } of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound used, whether . 5 a drug delivery system is used, and whether the compound is administered as part of a drug combination.
The amount of a given nitrosated and/or nitrosylated COX-2 inhibitor or the parent COX-2 inhibitor which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques, including reference to
Goodman and Gilman, supra; The Physician's Desk Reference, Medical Economics
Company, Inc., Oradell, N.J., 1995; and Drug Facts and Comparisons, Inc., St.
Louis, MO, 1993. The precise dose to be used in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided by the physician and the patient's circumstances.
The amount of nitric oxide donor in a pharmaceutical composition can be in amounts of about 0.1 to about 10 times the molar equivalent of the COX-2 inhibitor. :
The usual daily doses of nitrosated and/or nitrosylated COX-2 inhibitors are about 0.001 mg to about 140 mg/kg of body weight per day, preferably 0.005 mg to 30 : mg/kg per day, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammations may be effectively treated by the administration of from about 0.01 mg to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day. The compounds may be administered on a regimen of up to 6 times per day, preferably 1 to 4 times per day, and most preferably once per day. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems and are in the same ranges or less than as described for the commercially available compounds in the Physician's Desk Reference, supra. : The present invention also provides pharmaceutical kits comprising one or more containers filled with one or more of the ingredients of the pharmaceutical ; compounds and/or compositions of the present invention, including, at least, one or more of the COX-2 inhibitors optionally substituted with at least one NO and/or
NO, group, described herein and one or more of the NO donors described herein.
Associated with such kits can be additional therapeutic agents or compositions (e.g., steroids, NSAIDs, 5-lipoxygenase (5-LO) inhibitors, leukotriene B,(LTB,) . receptor antagonists and leukotriene A, (LTA,) hydrolase inhibitors, 5-HT agonists,
HMG-CoA inhibitors, H, antagonists, antineoplastic agents, antiplatelet agents, . 5 decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and the like), devices for administering the compositions, and notices in the form prescribed by a governmental agency : regulating the manufacture, use or sale of pharmaceuticals or biological products
Lo which reflects approval by the agency of manufacture, use or sale for humans.
The following non-limiting examples further describe and enable one of ordinary skill in the art to make and use the present invention. In each of the examples, flash chromatography was performed on 40 micron silica gel (Baker).
Example 1: 4-{5-(4-Chlorophenyl)-3-[(nitrooxy)methyl]-3-hydropyrazolyl] benzenesulfonamide. la. 4-[5-(4-Chlorophenyl)-3-(hydroxymethyl)-3-hydropyrazolyl] . benzenesulfonamide. :
This compound was synthesized as described by Penning et al, J. Med. :
Chem., 40: 1347-1365 (1997), (the disclosure of which is incorporated by reference . herein in its entirety), Example 14a. "H NMR (300 MHz, CDCl) 87.87 (d, J = 8.7 :
Hz, 2H), 7.39 (d,] = 8.7 Hz, 2H), 7.33 (d, J = 8.7 Hz, 2 H), 7.15 (d, ] = 8.4 Hz, 2H), 6.54 (s, 1H), 4.79 (s, 2H). 1b. 4-[5-(4-Chlorophenyl)-3-[(nitrooxy)methyl]-3-hydropyrazolyl] benzenesulfonamide.
To a solution of the product of Example la (348 mg, 0.95 mmol) in EtOAc (10 mL) was added over 5 minutes at room temperature a mixture of HNO, (85 ul, fuming 90%) in acetic anhydride (400 uL). The reaction was stirred for 15 minutes . at room temperature. The mixture was poured into excess aqueous Na,CO,. The aqueous layer was extracted with EtOAc. The combined organic layers were dried ) over Na,SO, and concentrated. The residue was chromatographed on silica gel eluting with 2:1 Hex:EtOAc to give 210 mg (54%) of the title compound. "H NMR (300 MHz, CDCL) 87.90 (d,] = 8.2 Hz, 2H), 7.41 (d,] = 8.8 Hz, 2H), 7.34 (d,] = 8.5
Hz, 2H), 7.15 (d, J = 8.5 Hz, 2H), 6.61 (s, 1H), 5.55 (s, 2H), 4.97 (s, 2H); “C NMR (75
MHz, CDCl) § 146.2, 143.8, 142.4, 141.2, 135.4, 130.0, 129.2, 128.2, 127.6, 127.5, 125.1, . 109.2, 67.8.
Example 2: 4-{5-[(Nitrooxy)methyl]-3-phenylisoxazol-4-yl}benzenesulfonamide. . 5 2a. 4-[5-(Hydroxymethyl)-3-phenylisoxazol-4-yl]benzenesulfonamide.
This compound was synthesized as described in patent application WO 96/25405, (the disclosure of which is incorporated by reference herein in its entirety), Example 10. 'H NMR (300 MHz, DMSO-d.) 87.80 (d, J = 8.3 Hz, 2H), 7.32-7.45 (mult, 9H), 5.71 (t,] = 5.3 Hz, 1H), 4.52 (d, ] = 4.5 Hz, 2H); "C NMR (75
MHz, DMSO-d,) 8 69.5, 160.7, 143.5, 132.6, 130.1, 129.8, 128.8, 128.3, 128.2, 126.0, 115.2, 53.3; mass spectrum (API-TIS), m/z 331 (MH). 2b. 4-{5-[(Nitrooxy)methyl]-3-phenylisoxazol-4-yljbenzenesulfonamide.
Concentrated HNO, (40 pL, 0.90 mmol) was added to stirred solution of acetic anhydride (200 nL, 2.1 mmol) in EtOAc (0.3 mL) at 0 °C via a syringe and stirred for 5 minutes at 0 °C. The product of Example 2a (0.1 g, 0.3 mmol) in EtOAc (0.1 mL) was then added and stirred for 5 minutes at 0 °C. The resulting mixture was then subjected to preparative thin layer chromatography (PTLC) eluting with 1:1 Hex:EtOAc to give the title compound (65 mg, 57%).as an oil. The oil was dissolved in CHCl, (5 mL) and solvent was evaporated slowly overnight at room : temperature to give the title compound as white crystals. mp 47-50 °C. "H-NMR 2 (300 MHz, CDCL) 6 7.96 (d, ] = 8.4 Hz, 2H), 7.30-7.45 (mult, 7H), 5.49 (s, 2H), 4.89 : (br s, 2H); "C NMR (75 MHz, CDCl) 8 161.4, 160.5, 142.3, 133.0, 130.4, 130.3, 128.9, 128.4,127.2,127.1, 119.5, 62.7; mass spectrum (API-TIS), m/z 376 (MH")
Example 3: 2-[1-Methyl-4-(nitrosothio)-4-piperidyl]ethyl 3-(N-{[4-(5-methyl-3- phenylisoxazol-4-yl)phenylisulfonyl}carbamoyl)propanoate citrate salt 3a. Ethyl 2-{1-methyl-4-piperidylidene}acetate
A solution of n-BuLi (1.6M in Hex, 58.7 mL, 93.6 mmol) was added to a stirred solution of triethyl phosphonoacetate (17.5 g, 78.0 mmol) in THF (30 mL) at - 78 °C under N, The resulting brownish solution was stirred for 30 min and then a ) solution of 4-N-methylpiperidone (8.8 g, 78.0 mmol) in THF (20 mL) was added.
The cold bath was removed and the mixture was stirred at room temperature for 2 hours. Water (250 mL) was added and the mixture was extracted with EtOAc (3 x100 mL). The combined organic extracts were dried over Na,5O,: The solvent was evaporated to afford the title compound (13.2 g, 92%). 'H NMR (300 MHz, CDCL) 8 . 5.64 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.00 (t, J = 5.1 Hz, 10H), 2.32-2.53 (mult, 5H), 2.29 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H); °C NMR (75 MHz, CDCl) § 1.664, 158.6, 114.2, © 5 59.5,56.7, 56.1, 45.7, 36.7, 29.3, 14.2. 3b. Ethyl 2-{1-methyl-4-(phenylmethylthio)piperidyl}acetate
The product of Example 3a (13.2 g, 72.01 mmol) and benzylmercaptan (8.4 mL, 72.01 mmol) in piperidine (35 mL) were heated at 100 °C for 12 hours and then cooled to room temperature. Water (50 mL) was added and the aqueous layer was 0 extracted with EtOAc (3 x 100 mL). The combined organic layers were dried over
Na,SO,. The solvent was evaporated and the residue was purified by: chromatography on silica gel eluting with 1:9 MleOH:CH,Cl, to afford the title compound (11.7 g, 53%) as a viscous liquid. "H NMR (300 MHz, CDCL,) § 7.18-7.34 (mult, 5H), 4.17(q, J = 7.1 Hz, 2H), 3.71 (s, 2H), 2.64 (s, 2H), 2.46-2.54 (mult, 4H), 2.29
L5 (s, 3H), 1.83-1.95 (mult, 4H), 1.29 (t, J = 7.1 Hz, 3H). 3c. 2-[1-Methyl-4-(phenylmethylthio)-4-piperidyl]ethan-1-ol
A solution of diisobutylaluminium hydride in hexane (83 mL, 83 mmol) was : added to a stirred solution of the product of Example 3b (11.7 g, 38.74 mmol) in :
THF (40 mL) at -78 °C under N,. The cold bath was removed and the mixture was stirred for 1.5 hours. Solid Na,SO,*10H,0 (3 g) was added portionwise with stirring until a thick precipitate was formed. 10% MeOH in CH,CL, (100 mL) was added and the mixture was filtered. The solid was washed with additional 10% MeOH in
CH,C}, (100 mL) .and the solvent was evaporated. The residue was chromatographed on silica gel eluting with 1:9 MeOH:CH,Cl, to give the title compound (5:2 g, 50.6%) as a solid. '"H NMR (300 MHz, CDCl) § 7.20-7.35 (mult, 5H), 3.86 (t,] = 6.4 Hz, 2H), 3.66 (s, 2H), 2.50-2.57 (mult, 4H), 2.29 (s, 3H), 1.88 (t,] = 6.5 Hz, 2H), 1.65-1.84 (mult, 4H). 3d. 2-[1-Methyl-4-(nitrosothio)-4-piperidyl]ethan-1-ol
The product of Example 3c (7.8 g, 29.38 mmol) was dissolved in THF (50 mL) and cooled to -78 °C and liquid NH, (~100 mL) was added. Small pieces of metallic ) sodium (2 g) were added until the blue color persisted for 10 minutes. Solid NH,Cl (~ 5 g) was added to discharge the color and the cold bath was removed and ammonia was evaporated (12 hours). Ether (100 mL) was added to the pale yellow solid and HCl in Et,O (10 mL) was added until the solution became acidic. The mixture was left in a freezer for 30 min. The solid which formed was removed by . filtration and washed with Et,O (50 mL). The residue was triturated with MeOH (100 mL) and undissolved solid was removed by filtration. The solvent was - 5 concentrated to 25 mL and concentrated HCl (2 mL) was added. 90% #-BuONO (3.1 mL, 23.7 mmol) was added via syringe. The resulting olive green solution was stirred at room temperature for 20 minutes and then poured onto crushed ice (5 g). 10% Na, CO, (10 mL) was added and the mixture was extracted with EtOAc (3 x 50 mL). The combined organics were dried over Na,SO, and concentrated to give the title compound (3.6 g, 60%) as a green oil. 'H NMR (300 MHz, CDCL) 33.88 (t,] = 6.9 Hz, 2H), 2.25-2.95 (mult, 13H), 2.30 (s, 3H); "C NMR (75 MHz, CDCl,) § 62.5, 58.5,57.8, 51.5, 46.1, 36.4. 3e. 4-[5-(Methyl)-3-phenylisoxazol-4-yl]benzenesulfonamide.
This compound was synthesized as described in patent application WO 96/25405, Example 1, the disclosure of which is incorporated by reference herein in its entirety. mp 170 °C. '"H NMR (300 MHz, CD,CN) 6 7.90 (d, J = 8.4 Hz, 2 H), 7.39 — 7.49 (mult, 7 H), 5.48 (s, 2 H), 2.50 (s, 2 H); mass spectrum (API-TIS), m/z 315 , (MH). 3f. 2-[1-Methyl-4-(nitrosothio)-4-piperidyl]ethyl 3-(N-{[4-(5-methyl-3-phenyl isoxazol-4-yl)phenyljsulfonyl}jcarbamoyl)propanoate. :
To a stirred solution of the product of Example 3d (0.21 g, 1.03 mmol), the product of Example 3e (0.43 g, 1.03 mmol), and 4-(dimethylamino)pyridine (DMAP, 0.05 g) in CH,Cl, (10 mL) was added solid DCC (0.34 g, 164 mmol). The solution was stirred for 24 hours at room temperature. The precipitate which formed was removed by filtration and the filtrate was concentrated under reduced pressure. The crude product was chromatographed on silica gel eluting with 1:1
EtOAc:Hex followed by 1:9 MeOH:CH,Cl,. This gave the title compound (178 mg, 29 %) as a green foam. "H-NMR (300 MHz, CDCL) 6 7.94 (d, J = 8.2 Hz, 2H), 7.22- : 7.39 (mult, 7H), 4.47-4.57 (mult, 2H), 3.56-3.60 (mult, 2H), 3.15-3.25 (mult, 2H), 2.45-2.90 (mult, 10H), 2.42 (s, 6H); "C-NMR (75 MHz, CDCL) § 178.5, 173.4, 167.1, 161.0, 143.0, 133.5, 129.7, 129.5, 128.6, 128.5, 128.4, 126.7, 114.9, 60.0, 56.2, 51.7, 45.5, 41.0, 33.9, 31.8, 30.3, 11.6; mass spectrum (API-TIS), m/z 601 (MH). 3g. 2-[1-Methyl-4-(nitrosothio)-4-piperidyl]ethyl 3-(N-{[4-(5-methyl-3-pheny]
isoxazol-4-yl)phenyl]sulfonyljcarbamoyl)propanoate Citrate Sait.
Citric acid (65 mg, 0.34 mmol) in MeOH (0.2 mL) was added to the product . of Example 3f (170 mg, 0.28 mmol) dissolved in EtOAc (0.8 mL) and MeOH (0.4 mL). The green solution was left to crystallize at -20 °C for 48 hours. The solvent - 5 was decanted and the solid was dried under reduced pressure for 16 hours to give the title compound (124 mg, 55%) as shiny, olive green crystals. mp 82-84 °C (decom). "H-NMR (300 MHz, CDCL,) § 8.16 (d, J = 8.4 Hz, 2H), 7.52-7.60 (mult, 7H), 4.43 (t,] = 6.4 Hz, 2H), 3.15-3.25 (mult, 2H), 2.50-2.99 (mult, 22H); mass spectrum (API-TIS), m/z 601 (MH).
Example 4: (2-{1-[(4-Chlorophenyl)methyl]-5-methoxy-2-methylindol-3- yl}ethyDnitrooxy 4a. 2-{1-[(4-Chlorophenyl)methyl]-5-methoxy-2-methylindol-3-yl}ethan-1-ol
A solution of indomethacin (10 g, 28 mmol) in THF (90 mL) was immersed in an ice bath to maintain an internal temperature of 10-15 °C. To this solution was added BF-Et,0O (30 mL, 230 mmol) over 5 min, resulting in the formation of a precipitate. Sodium borohydride (4.2 g, 110 mmol) was added portionwise over 10 min resulting in vigorous effervescence. After gas evolution subsided the flask was : stoppered and allowed to warm to room temperature. After 1 hour the pressure was vented through a needle. The heterogeneous mixture was stirred for 6 hours.
The mixture was cooled in an ice bath and was quenched by adding saturated :
NaHCO,. To break the resultant emulsion the mixture was made acidic with IN
HCl and extracted with a 3:1 mixture of Et,0:Hexane (270 mL). The organic layer was washed with brine, dried over Na,SO,, and evaporated. The residue was taken up in a 3:1 mixture of hot Hex:EtOAc (80 mL). Upon cooling to room temperature, crystals began to form. Crystallization was completed by cooling to —20 °C. The solid was removed by filtration, washed with cold 3:1 Hex:EtOAc (2 X 25), Hexane (1 X 25) and dried in vacuo. This gave the title compound (4.5 g, 49%) as a white solid. mp 113-115 °C. "H-NMR (300 MHz, CDCL) § 7.24 (4, J = 8.4 Hz, 2H), 7.06 (d, . J=9.1 Hz, 1H), 7.03 (d, J = 3.5 Hz, 1H), 6.87 (d, J = 8.3 Hz, 2H), 6.78 (dd, ] = 2.4 and 8.7 Hz, 1H), 5.23 (s, 2H), 3.86 (s, 3H), 3.84 (1, J = 6.5 Hz, 2H), 2.99 (t,] = 6.5 Hz, 2H), : 2.29 (s, 3H); mass spectrum (API-TIS) m/z 330 (MH"). Anal calcd for C,H, CINO,:
C, 69.19; H, 6.11; N, 4.25; Cl, 10.75. Found: C, 68.98; H, 6.30; N, 4.08; Cl, 10.60. 4b. 3-(2-Bromoethyl)-1-[(4-chlorophenyl)methyl]-5-methoxy-2-methylindole _ 110 :
To the product of Example 4a (160 mg, 0.5 mmol) in toluene (1 mL) was added PBr, (17 ul, 0.18 mmol). The reaction mixture was heated to 100 °C for 10 i min then cooled to room temperature. The mixture was partitioned between
EtOAc and IN HCL. The aqueous layer was extracted with EtOAc (1 X10). The . 5 combined organic layers were washed with H,O (1 X 10), brine (2 X 10), dried over
Na,50,, and evaporated. This gave the title compound (170 mg, 87%) which solidified on standing. This material was used in the next reaction without further purification. "H-NMR (300 MHz, CDCL) § 7.24 (d, ] = 8.4 Hz, 2H), 7.06 (d,] = 9.1
Hz, 1H), 6.99 (d,J = 2.4 Hz, 1H), 6.86 (d, ] = 8.4 Hz, 2H), 6.78 (dd, ] = 2.4 and 8.8 Hz, 1H), 5.23 (s, 2H), 3.87 (s, 3H), 3.56 (t,] = 7.5 Hz, 2H), 3.28 (t,] = 7.5 Hz, 2H), 2.29 (s, 3H). 4c. (2-{1-[(4-Chlorophenyl)methyl]-5-methoxy-2-methylindol-3- yl}ethyl)nitrooxy
The product of Example 4b (170 mg, 0.43 mmol) was dissolved in CH,CN (6 mL). Addition of AgNO, (85 mg, 0.5 mmol) caused immediate formation of a precipitate. After 20 min, the reaction mixture was filtered through Celite and concentrated. The residue was purified by chromatography on silica gel eluting with 5:1 Hex:EtOAc. This gave the title compound (90 mg, 56%) as a white ; crystalline solid. mp 94-95 °C. "H-NMR (300 MHz, CDCl,) § 7.23 (d, J = 8.5 Hz, 2H), 7.07 (d,] = 8.9 Hz, 1H), 6.99 (d, J = 2.4 Hz, 1H), 6.86 (d, ] = 8.4 Hz, 2H), 6.79 3 (dd,J =2.4 and 8.4 Hz, 1H), 5.23 (s, 2H), 4.60 (t,] =7.2 Hz, 2H), 3.87 (s, 3H), 3.14 (t,] = 7.3 Hz, 2H), 2.28 (s, 3H); mass spectrum (API-TIS): m/z 375 (MH). Anal calcd for
C,H, CIN,O,: C, 60.88; H, 5.11; N, 7.47; Cl, 9.46. Found: C, 60.89; H, 5.23; N, 7.36;
Cl, 9.58. :
Example 5: 1-[3-(4-Fluorophenyl)-7-(nitrooxymethyl)(3a-hydroimidazolo[1,2-a] pyridin-2-y)]-4-(methylsulfonyl)benzene 5a. 1-[3-(4-Fluorophenyl)-7-(hydroxymethyl)(3a-hydroimidazolo[1,2-a]pyridin- 2-y1)]-4-(methylsulfonyl)benzene . This compound was prepared according to a procedure described in patent application WO 96/31509, (the disclosure of which is incorporated by reference ; herein in its entirety), Example 15. "H-NMR (300 MHz, CDCl,) § 7.80-7.87 (m, 5H), 7.40-7.46 (m, 2H), 7.20-7.33 (m, 3H), 6.82-6.86 (t, 2H, ] = 7.0 Hz), 5.11 (s, 2H), 3.04 (s, 3H); mass spectrum (API-TIS) m/z 397 (MH).
5b. 1-[3-(4-Fluorophenyl)-7-(nitrooxymethyl)(3a-hydroimidazolo{1,2-a]pyridin- 2-yD}-4-(methylsulfonyl)benzene . A suspension of the product of Example 5a (210 mg, 0.52 mmol) was added to an ice-cold mixture of acetic anhydride (393 pL, 4.16 mmol) and nitric acid (110 - 5 UL, 2.61 mmol). The resulting mixture was allowed to warm up to 10 °C and stirred for 1 hour. The mixture was then diluted with methylene chloride, washed with cold saturated sodium bicarbonate solution and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was suspended in hexane/ethyl acetate (2:1) mixture and filtered to give 230 mg (99 % yield) of the title compound as a yellow-orange solid. m.p. 145-147 °C. "H-NMR (300 MHz,
CDCl) $8.07-8.12 (d, 1 H, J = 7.0 Hz), 7.82-7.56 (m, 4 H), 7.48-7.56 (m, 2 H), 7.32- 7.39 (m, 2H), 6.95-7.01 (t,1 H, J = 7.0 Hz), 5.96 (s, 2 H), 3.12 (s, 3 H).
Example 6: Ethyl 6-chloro-8-[(nitrooxy)methyi]-2-(trifluoromethyl)-2H- chromene-3 carboxylate 6a. Ethyl 6-chloro-8-formyl-2-(trifluoromethyl)-2H-chromene-3 carboxylate
This compound was synthesized as described in patent application WO : 98/47890, (the disclosure of which is incorporated by reference herein in its : entirety), Example 76. "H-NMR (300 MHz, CDCL) 10.39 (s, 1H), 7.79 (s, 1H), 7.69 (s, 1H), 7.40 (s, 1H), 5.86 (q, ] = 6.6 Hz, 1H), 4.31-4.44 (mult, 2H), 1.37 (t,] = 7.1 Hz, : 3H); “C-NMR (75 MHz, CDCL) § 186.3, 163.0, 153.5, 134.4, 134.1, 130.1, 128.4, 125.0, “ 124.8,121.8,121.0, 119.2, 71.1 (q, J, = 134 Hz), 62.0, 14.1. 6b. Ethyl 6-chloro-8-(hydroxymethyl)-2-(trifluoromethyl)-2H-chromene-3 carboxylate
Na(OAc),BH (2.4 g, 11.2 mmol) was added to a stirred solution of the product of Example 6a (1.5 g, 4.5 mmol) in CH,CI, (50 mL) and the resulting solution was stirred at room temperature for 3 days. The solution was poured into water (100 mL), the CH,Cl, layer was separated and the aqueous layer was extracted with CHCl, (2 x 25 mL). The combined organic layers were dried over . Na,SO,. The solvent was evaporated under reduced pressure and the crude material was chromatographed on silica gel eluting with EtOAc:Hexane (1:5) to give the title compound (1.2 g, 79%) as a white solid. mp 98-100 °C. "H-NMR (300
MHz, CDCl) 7.66 (s, 1H), 7.41 (d,] = 2.3 Hz, 1H), 7.16 (d, J = 2.4 Hz, 1H), 5.76 (q, ] = 6.7 Hz, 1H), 4.71 (d, J = 5.5 Hz, 2H), 4.26-4.70 (mult, 2H), 2.06-2.10 (br mult, 1H),
I 112
'1.15-1.21 (mult, 3H); "C-NMR (75 MHz, CDCL,) 8 163.4, 146.7, 135.7, 131.2, 130.3, 127.7,127.6,121.3, 120.1, 118.0, 70:6 {q, J, = 133 Hz), 61.7, 59:6, 14.1; mass spectrum . (API-TIS) m/z 354 (M+NH,"). Anal. Caled for C,,H,,CIF,O,: C, 49.94; H, 3.59; F, 16.93; Cl, 10.53. Found: C, 49.83; H, 3.52; F, 17.10; Cl, 10.77. . 5 6c. Ethyl 6-chloro-8-[(nitrooxy)methyl]-2-(trifluoromethyl)-2H-chromene-3 carboxylate
Fuming HNO, (340 pL, 3.6 mmol) was added to a stirred solution of acetic anhydride (1.12 mL, 11.8 mmol) in EtOAc (10 mL) at 0 °C via syringe. The mixture was allowed to stir for 5 min at 0 °C. The product of Example 6b (0.5 g, 1.49 mmol) in EtOAc (10 mL) was then added and stirred for 15 min at 0 °C. The reaction mixture was poured into ice cold saturated NaHCO, (25 mL) and shaken well. The organic layer was separated and dried over Na,SO,. The solvent was evaporated under reduced pressure to afford a viscous oil which was dissolved in hexane (15 mL). The resulting solution was left in a freezer at -20 °C for 12 hours to give the title compound (0.44 g, 77%). mp 53 °C. "H-NMR (300 MHz, CDCl.) 87.65 (s, 1H), 7.34 (d,J=24Hz 1H), 7.25 (d, J = 24 Hz, 1H), 5.78 (q, ] = 6.6 Hz, 1H), 5.46 (s, 2H), 4.28-4.38 (mult, 3H), 1.35 (t, J = 7.1 Hz, 3H); *C-NMR (75 MHz, CDCL) § 163.0, 150.0, 135.0, 133.0, 130.0, 127.6, 125.0, 121.8, 121.1, 120.8, 118.8, 71.3 (q, J, = 133 Hz), 68.0, 61.8, 14; mass spectrum (API-TIS) m/z 399 (M+NH,"). Anal. Calcd for
CH, CIFO,: C, 44.06; H, 2.90; F, 14.93; C1, 9.29; N, 3.67. Found: C, 44.00; H, 2.85; F, . 14.83; Cl, 9.14; N, 3.57.
Example 7: 2-{1-[(4-Chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3- y1}-N-(2-methyl-2-(nitrosothio)propyl)acetamide 7a. 2-{1-[(4-Chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-y1}-N-(2- methyl-2-sulfanylpropyl)acetamide
A solution of indomethacin (3.6 g, 10 mmol) and Et,N (1.5 mL, 11 mmol) in
THF (50 mL) was cooled to 0 °C. i-Butyl chloroformate (1.5 mL, 11 mmol) was added dropwise and the reaction was allowed to stir for 20 min. To the resulting solution was added a slurry of 1-amino-2-methyl-2-propanethio.HCl1 (1.4 g, 10 mmol) and Et;N (1.5 mL, 11 mmol) in DMF (20 mL). The reaction mixture was kept cold for 2 hours, warmed to room temperature and stirred for 1 hour. The mixture was partitioned between Et,0 and dilute HCl. The organic layer was separated and washed with saturated NaHCQO,, brine, filtered and dried over Na,SO,. _ 113
Evaporation of the solvent gave a residue which was recrystallized from EtOActo give the title compound (1.1 g, 25%) as a white solid. mp 177-178 °C. "H-NMR (300
MHz, CDC) §7.67 (d, ] = 8.5 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 6.92 (d, ] = 2.3 Hz, 1H), 6.91 (d, J = 9.0 Hz, 1H), 6.71 (dd, J = 2.5 and 9.1 Hz, 1H), 6.10 (br t,] = 6.3 Hz, . 5 1H), 3.83(s, 3H), 3.69 (s, 2H), 3.27 (d, J. = 6.3 Hz, 2H), 2.42 (s, 3H), 1.36 (s, 1H), 1.26 (s, 6H); mass spectrum (API-TIS) m/z 445(447) MH" (1-Cl). 7b. -2-{1-[(4-Chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-y1}-N-(2- methyl-2-(nitrosothio)propyl)acetamide
The product of Example 7a (25 mg, 0.056 mmol) was dissolved in CH,C, (1 mL) and cooled to 0 °C. A solution of t+-BuONO (7.5 uL, 0.056 mmol) in CH,Cl, was added dropwise. The reaction mixture was allowed to warm to room temperature with stirring for 30 min. Evaporation of the solvent gave the title compound (25 mg, 100%) as a green crystalline solid. mp 122-125 °C dec. "H-NMR (300 MHz,
CDCl) 67.64 (d,] = 8.5 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 6.84 (d, ] = 9.1 Hz, 1H), 6.82 (d,] =25Hz, 1H), 6.78 (dd, J = 2.5 and 9.1 Hz, 1H), 5.96 (br t, ] = 6.4 Hz, 1H), 3.97 (d,J = 6.4 Hz, 2H), 3.79 (s, 3H), 3.67 (s, 2H), 2.32 (s, 3H), 1.78 (s, 6H); mass spectrum |, (API-TIS) m/z 491(493) M+NH" (1-Cl).
Example 8: Ethyl (2Z)-3-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-[2- (nitrooxy)ethyl]lprop-2-enoate 8a. Ethyl (2Z)-3-(4-chlorophenyl)-2-(2-hydroxyethyl)-3-[4- (methylsulfonyl)phenyl] prop-2-enoate
This compound was synthesized as described in U.S. Patent No. 5,807,873, (the disclosure of which is incorporated by reference herein in its entirety), Example 64. mp 126 °C. "H-NMR (300 MHz, CDCl,) § 7.93 (dd, J = 1.75 and 8.3 Hz, 2H), 7.46 (dd, J =1.78 and 6.7 Hz, 2H), 7.25-7.30 (mult, 2H), 7.04-7.09 (mult, 2H), 4.01 (q,] = 7.1 Hz, 2H), 3.76 (t, J = 6.2 Hz, 2H), 3.09 (s, 3H), 2.62 (t, ] = 6.1 Hz, 2H), 0.97 (t, J = 7.1
Hz, 3H); "C NMR (75 MHz, CDCl) 3 170.2, 145.6, 144.6, 140.0, 139.5, 134.2, 132.7, 130.3,129.9, 128.5, 127.6, 61.3, 61.1, 44.4, 35.0, 13.6; mass spectrum (API-TIS) m/z i 409 (MH"), 426 (MNH,"). Anal. Calcd for C,H, ClO.S: C, 58.75; H, 5.18; Cl, 8.67; S, 7.84. Found: C, 58.64; H, 5.02; C1, 8.80; S, 7.79. : 8b. Ethyl (2Z)-3-(4-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-[2- (nitrooxy)ethyl]prop-2-enoate
A suspension of the product of Example 8a (2.02 g, 4.95 mmol) in CHC], (20 mL) was added dropwise to a mixture of acetic anhydride (3.71 mL, 4.04 g, 39.6 mmol) and 90% fuming nitric acid (1.03 mL, 1.56 g, 24.8 mmol) at -12 °C. The } resultant solution was stirred at —12 °C for 1 hour. CH,Cl, (30 mL) was added, washed with ice cold saturated NaHCO,, dried over Na,SO, and filtered. : 5 Evaporation of the solvent gave a residue that was recrystallized from 1:2
Hexane:CH,(], to give the title compound (1.82 g, 82 %) as a white solid. mp 127- 128 °C. "H-NMR (300 MHz, CDCL,) §7.97 (d, J = 8.3 Hz, 2H), 7.41 (d, ] = 7.8 Hz, 2H), 7.27-7.31 (mult, 2H), 7.03-7.08 (mult, 2H), 4.59 (t, J = 6.4 Hz, 2H), 4.02 (q, J = 7.1
Hz, 2H), 3.09 (s, 3H), 2.76 (t, ] = 6.4 Hz, 2H), 0.98 (t, J] = 7.1 Hz, 3H); ®C NMR (75
MHz, CDCl,) 5 168.8, 147.6, 145.3, 140.5, 139.2, 134.6, 129.9, 129.8, 129.4, 128.7, 128.0, 70.8, 61.4, 44.5, 29.9, 13.6; mass spectrum (API-TIS) m/z 471 (MNH,"). Anal. Calcd tor C,H, CINO,S: C, 52.92; H, 4.44; N, 3.09; C1, 7.81; S, 7.06. Found: C, 52.91; H, 4.35; N, 2.93; Cl, 7.89, S, 7.20.
Example 9: (2Z)-3-(4-Chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-[2- (nitrooxy)ethyl]prop-2-enoic acid 9a. (2Z)-3-(4-Chlorophenyl)-2-(2-hydroxyethyl)-3-[4- (methylsulfonyl)phenyl}prop-2-enoic acid ;
NaOH (6.4 mL of 1.5N, 0.38 g, 9.6 mmol) was added dropwise to a solution p of the product of Example 8a (3.62 g, 8.87 mmol) in EtOH (80 mL) at 0 °C. The : resultant pale yellow solution was stirred at room temperature for 2 hours. The : residue, after evaporation of the solvent, was dissolved in water and washed with
EtOAc. Crushed ice was added to the aqueous layer which was then acidified with 10% HCl to ~pH=4 and extracted with EtOAc. The organic layer was dried over
Na,SO, and filtered. Evaporation of the solvent gave a residue that was recrystallized from EtOAc:Hex:CH,C], to give the title compound (2.79 g, 82 %) as a white solid. mp 144-145 °C. "H-NMR (300 MHz, CDCl,/MeOH-d,) 67.98 (d,J = 7.1
Hz, 2H), 7.53 (d,] = 7.0 Hz, 2H), 7.29-7.32 (mult, 2H), 7.16-7.19 (mult, 2H), 3.71 (t, J = 6.9 Hz, 2H), 3.15 (s, 3H), 2.56 (t, ] = 6.8 Hz, 2H); °C NMR (75 MHz, CDCl) § 173.1, : 147.4,145.1,141.4,141.2,134.9,134.3, 131.4, 131.3, 129.4, 128.7, 61.3, 61.3, 44.3, 36.3; mass spectrum (API-TIS) m/z 363 (M-H,0), 381 (MH), 398 (MNH,"). Anal. Calcd ) for C, H,,Cl0,S: C, 56.77; H, 4.50; C1, 9.31; S, 8.42. Found: C, 56.64; H, 4.44; Cl, 9.40;
S, 8.18. 9b. (2Z)-3-(4-Chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-[2-(nitrooxy)ethyl]
prop-2-enoic acid
A suspension of the product of Example 9a (1.37, 3:66 mmol) in CHCL, (54 ) mL) was added dropwise to a mixture of acetic anhydride (2.72 ml, 2.94 g, 28.8 mmol) and 90% fuming nitric acid (0.76 mL, 1.14 g, 18.0 mmol) at-12 °C. The . 5 resultant solution was stirred at 12 °C for 30 min. CH,CL, (25 mL) was added, washed with water, dried over Na, SO, and filtered. Evaporation of the solvent gave a residue that was recrystallized from EtOAc:Hexane:CH,CL, to give the title compound (0.9 g, 59 %) as a white solid. mp 143-144 °C. "H-NMR (300 MHz,
CDCl,) 67.98 (d, J = 8.2 Hz, 2H), 7.40 (d, J = 8.2 Hz, 2H), 7.27-7.32 (mult, 2H), 7.07-
Lo 7.11 (mult, 2H), 4.61 (t,] = 6.3 Hz, 2H), 3.10 (s, 3H), 2.78 (t, ] = 6.3 Hz, 2H); "C NMR (75 MHz, CDCl,) § 172.8, 150.9, 145.4, 140.7, 138.7, 135.1, 129.8, 129.7, 129.0, 128.1, 127.7, 70.8, 44.5, 30.0; mass spectrum (API-TIS) m/z 443 (MNH,"). Anal. Calcd for
C,H, CINO,S: C,50.77; H, 3.79; N, 3.29; Cl, 8.33; S, 7.53. Found: C, 50.87; H, 3.67; N, 3.13; Cl, 8.26, S, 7.43.
Example 10: (2Z)-3-(4-Chlorophenyl)-2-(2-hydroxyethyl)-N-[2-methyl-2 (nitrosothio)propyl]-3-[4-(methylsulfonyl)phenyljprop-2- enamide : 10a. (2Z)-3-(4-Chlorophenyl)-N-(2-methyl-2-sulfanylpropyl)-3-[4- : (methylsulfonyl)phenyl]-2-[2-(1,1,2,2,-tetramethyl-1-silapropoxy)ethyl]prop- ; 2-enamide
To a solution of the product of Example 9a (0.5 g, 1.32 mmol) and imidazole : (0.18 g, 2.63 mmol) in dry THF (10 mL) was added a solution of t-butyldimethyl- . chlorosilane (0.4 g, 2.63 mmol) in dry THF (10 mL) dropwise at room temperature.
The resulting white suspension was stirred at room temperature for 16 hours. The reaction mixture was partitioned between EtOAc and saturated NaHCO,. The organic layer was separated, washed with 10% HC], dried over Na,SO,, filtered and concentrated in vacuo to give 1:1 mono:disilylated product as a white foam which was used in the next step without further purification. Mass spectrum (API-TIS) : m/z 495 and 609 (MH"). The entire white foam was dissolved in THF (10 mL).
Bis(2-oxo0-3-oxazolidinyl)phosphonic chloride (0.70 g, 1.58 mmol) and 4- (dimethylamino)pyridine (0.16 g, 1.32 mmol) were added at room temperature.
After 5 min, 1-amino-2-methyl-2-propanethiol (0.15 g, 1.41 mmol) in THF (2 mL) was added dropwise. The resulting pale yellow solution was stirred at room temperature for 2.5 hours. Evaporation of the solvent gave a residue that was chromatographed on silica gel eluting with 1:1 EtOAc Hexane to give the title ] compound (0.28 g, 37%) as a white foam. "H-NMR (300 MHz, CDCL) 87.90 (4, ] = 8.3 Hz, 2H), 7.56 (d,] = 8.3 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 7.15 (d, ] = 6.7 Hz, 2H), - 5 591 (tJ = 6.2 Hz, 1H), 3.77 (t, J = 5.9 Hz, 2H), 3.15 (d, J = 6.2 Hz, 2H), 3.09 (s, 3H), 2.64 (t,] = 5.9 Hz, 2H), 1.28 (s, 1H), 1.11 (s, 6H), 0.96 (s, 9H), 0.09 (s, 6H); °C NMR (75 MHz, CDCl) $170.2, 145.9, 140.2, 139.8, 139.4, 137.9, 134.4, 130.9, 130.6, 129.1, 127.4, 60.6, 60.4, 53.5, 52.7, 44.6, 44.5, 35.0, 29.9, 26.1, 21.1, 18.4, 14.3, -5.2; mass spectrum (API-TIS) m/z 582 (MH). Anal. Calcd for C,H, CINO,S Si: C, 57.76; H, 6.92; N, 2.41. Found: C, 57.79; H, 6.67; N, 2.30. 10b. (2Z)-3-(4-Chlorophenyl)-2-(2-hydroxyethyl)-N-(2-methyl-2-sulfanylpropyl)- 3-[4-(methylsulfonyl)phenyl]prop-2-enamide
To a solution of the product of Example 10a (225 mg, 0.39 mmol) in THF (13 mL) was added dropwise trifluoroacetic acid (129 pL, 1.67 mmol) at 0 °C. To this was added tetrabutylammonium fluoride (385 pL of 1M solution in THF, 0.39 : mmol) dropwise. The resultant solution was gradually warmed to room temperature and stirred for 25 hours. The reaction mixture was partitioned between EtOAc (50 mL) and ice cold 1 % HCL. The organic layer was separated, : dried over Na,SO, and filtered. The solvent was evaporated and the residue was chromatographed on silica gel eluting with 5% MeOH:CH,(], to give the title ; compound (175 mg, 97%) as a white foam. mp 62-64 °C. "H-NMR (300 MHz,
CDCl) 87.93 (d,] = 8.2 Hz, 2H), 747 (d,] = 8.2 Hz, 2H), 7.28 (d, ] = 8.5 Hz, 2H), 7.16 (d, J =8.4Hz, 2H), 6.05 (t,] = 6.1 Hz, 1H), 3.72 (t, ] = 5.7 Hz, 2H), 3.14 (d,] = 6.1 Hz, 2H), 3.09 (s, 3H), 2.59 (t, ] = 5.7 Hz, 2H), 1.36 (s, 1H), 1.16 (s, 6H); °C NMR (75 MHz,
CDCl) 6171.1, 145.8, 141.1, 140.0, 138.8, 137.3, 134.7, 130.5, 130.4, 129.2, 127.8, 61.0, 52.9,44.7,44.6, 34.9, 30.0; mass spectrum (API-TIS) m/z 468 (MH). 10c. (2Z)-3-(4-Chlorophenyl)-2-(2-hydroxyethyl)-N-(2-methyl-2- (nitrosothio)propyl)-3-[4-(methylsulfonyl)phenyljprop-2-enamide
To a solution of t-butyl nitrite (0.2 mL of 90% solution, 158 mg, 1.53 mmol) in 1:1 MeOH:CH,C], (1.2 mL) was added dropwise a solution of the product of : : Example 10b (156 mg, 0.33 mmol) in 1:1 MeOH:CH,CL, (2 mL) at 0 °C. The resultant solution was stirred at 0 °C in the dark for 30 min. Additional t-butyl nitrite (0.15 mL of 90% solution, 118 mg, 1.15 mmol) was added and the resultant _ 117 green solution was stirred at 0 °C for a further 30 min and then at room temperature for 20 min. The volatiles were removed in vacuo and the residue was chromatographed on silica gel eluting with 1:1 BtOAc:CH,CL, to give the title compound (96 mg, 58%) as a green solid. mp 150-153 °C. "H-NMR (300 MHz, : 5 CDCL) 87.90 (d, J = 8.3 Hz, 2H), 7.45 (d, J] = 8.4 Hz, 2H), 7.24 (dd, J = 1.9 and 6.6 Hz, 2H), 7.09-7.12 (mult, 2H), 6.40 (br t, J = 6.3 Hz, 1H), 3.86 (d, J = 6.3 Hz, 2H), 3.66 (t,] = 5.9 Hz, 2H), 3.09 (s, 3H), 2.54 (t, ] = 5.8 Hz, 2H), 1.67 (s, 6H); °C NMR (75 MHz,
CDCL) 8171.4, 145.8, 141.2, 139.8, 138.8, 136.9, 134.5, 130.5, 130.3, 129.0, 127.6, 60.5, 56.5,44.5, 34.7, 26.8; mass spectrum (API-TIS) m/z 467 (M-NO), 497 (MH).
Example 11: 1-[5-methyl-1-(2-methyl-2-(nitrosothio)propyDpyrrol-2-yi}-4- : (methylsulfonyl)benzene 11a. 1-(4-Methylthiophenyl)pentane-1,4-dione 4-(Methylthio)benzaldehyde (20 mL, 150 mmol), 3-benzyl-5-(2- hydroxyethyl)-4-methylthiazolium chloride (7 g, 30 mmol), methyl vinyl ketone (15 mL, 180 mmol), and Et,N (21 mL, 150 mmol) were placed in a flask and immersed in an oil bath at 80 °C. The initial purple colored solution became orange over 30 = min. The solution was cooled to room temperature, EtOAc (30 mL) was added to Ce precipitate the thiazolium salt which was removed by filtration. The filter cake was washed with hot EtOAc (2x 30 mL). The combined mother liquor and washes were concentrated to give 43 g of residue. The residue was taken up in hot 1:1 Co
Hexane:EtOAc (100 mL), which upon cooling deposited a solid. This solid was isolated on a glass frit and washed with hot 4:1 Hexane:EtOAc (50 mL). From this hot wash was deposited the title compound (16.4 g, 49%) as a tan solid. mp 72-73 °C. "H-NMR (300 MHz, CDCL) § 7.88 (d, J = 8.4 Hz, 2H), 7.25 (d, ] = 8.4 Hz, 2H), 3.22 (t,] = 6.5 Hz, 2H), 2.87 (t, J = 6.2 Hz, 2H), 2.51 (s, 3H), 2.24 (s, 3H); mass . spectrum (API-TIS) m/z 223 (MH). Anal. Calcd. for C,H ,0,S: C, 64.84; H, 6.35; S, 14.42. Found C, 64.68; H, 6.19; S, 14.24.. 11b. 1-[4-(Methylsulphonyl)phenyl]pentane-1,4-dione . The product of Example 11a (16.4 g, 74 mmol) was dissolved in CH,CL (300 mL) and cooled to 0 °C. Solid 70 % m-chloroperbenzoic acid (37 g, 150 mmol) was : added portionwise over 5 min. After complete addition the cold bath was removed and the reaction mixture was allowed to warm to room temperature with stirring for 3 hours. The precipitate that had formed was removed by filtration and washed - 118 : i with CH,CL, (2 x 50 mL). The combined organic filtrates were washed with 1M
Na,CO,, dried over Na,50,, and concentrated. The residue was partitioned ] between EtOAc (200 mL) and 1M Na,CO, (50 mL). The solid was kept with the aqueous layer and the mixture was extracted with EtOAc (50 mL). The aqueous «5 layer was filtered to give the title compound (8.9 g) after drying in vacuo. The combined organic layers were washed with water, brine, dried over N a,50,, and concentrated to give additional title compound (6.5 g). Overall yield of the title compound was 15.4 g, 82%. mp 132-133 °C. "H-NMR (300 MHz, CDCI3) 38.15 (d, J = 8.4 Hz, 2H), 8.05 (d, ] = 8.3 Hz, 2H), 3.27 (t, 6.6 Hz, 2H), 3.07 (s, 3H), 2.93 (t,] = 6.4 lb Hz 2H), 2.26 (s, 3H); mass spectrum (API-TIS) m/z 255 (MH). Anal. Caled. for
CH, 0S: C, 56.68; H, 5.55; S, 12.61. Found: C, 56.39; 5.40; S, 13.36. llc. 1-[5-Methyl-1-(2-methyl-2-sulfanylpropyl)pyrrol-2-yl]-4-(methylsulfonyl) benzene
The product of Example 11b (2 g, 7.9 mmol), NaOAc (1.3 g, 16 mmol), and 1- t5 amino-2-methyl-2-propanethiol. HCI (1.2 g, 8.7 mmol) were added to HOAc (15mL) and heated to 80 °C for 3 hours. The reaction mixture was cooled to room : temperature and the HOAc was removed at reduced pressure. The residue was partitioned between EtOAc (40 mL) and IN Na,CO, (15 mL). The organic layer was separated and washed with 1N Na,CO,, brine, then dried over Na,SO, and concentrated. The residue was crystallized from hot MeOH (5 mL) to gave the title compound (1.6 g, 63%) as an orange-tan solid. mp 124-126 °C. "H-NMR (300 MHz,
CDCl) 67.93 (d,] = 8.4 Hz, 2H), 7.52 (d, ] = 8.4 Hz, 2H), 6.22 (d, ] = 3.6 Hz, 1H), 6.03 (d,J = 3.6 Hz, 1H), 4.24 (br, 2H), 3.08 (s, 3H), 2.41 (s, 3H), 1,55 (s, 1H), 1.04 (s, 6H); mass spectrum (API-TIS) m/z 324 (MH+). 11d. 1-[5-Methyl-1-(2-methyl-2-(nitrosothio)propyl)pyrrol-2-yl1]-4- (methylsulfonyl) benzene
The product of Example 11c (100 mg, 0.31 mmol) was dissolved in CH,Cl, and cooled to 0 °C. A solution of --BuONO (40 mL, 31 mmol) in CHCl, (1 mL) was added dropwise. After complete addition the reaction mixture was warmed to room temperature and allowed to stir 1 hour. The solvent was evaporated and the ’ residue was chromatographed on silica gel eluting with 2:1 Hexane:EtOAc. This gave a 1:3 mixture of starting material and desired product (67 mg, 61%). A small fraction of this mixture was reacted with --BuONO to give the title compound as a dark foam. "H-NMR (300 MHz, CDCL) § 7.89 (d, J = 8.5 Hz, 2H), 7.44 (d,] = 8.5 Hz, 2H), 6.22 (d, ] = 3.6 Hz, 11D), 6.05(d, |] = 3.5 Hz, 1H), 4.60-5.00 (br, 2H), 3.15 (s, 3H), . . 2.39 (s, 3H), 1.6-2.0 (br s, 6H); mass spectrum (API-TIS) m/z 353 (MH+).
Example 12: 3-{4-[1-Methyl-1-(nitrosothio)ethyl]-2-0x0-1,3-oxazolidin-3 yl} : - 5 propyl (2Z)-4-acetyloxy-2-(4-fluorophenyl)-3-[4 (methylsulfonyl) phenyl]but-2-enoate 12a. 3-(4-Fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-5-hydrofuran-2-one
This compound was synthesized as described in patent EP 0 788 476 B1, (the disclosure of which is incorporated by reference herein in its entirety), lactone 11. mp 163 °C. "H-NMR (300 MHz, CDCL) 87.94 (d, ] = 8.6 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 7.38-7.43 (mult, 2H), 7.06-7.27 (mult, 2H), 5.18 (s, 2H), 3.08 (s, 3H); °C NMR (75
MHz, CDCl) § 172.5,165.0,161.7,153.7, 142.2, 136.3, 131.4, 131.3, 128.6, 128.3, 128.0,125.3,125.2, 116.4, 116.1, 70.5, 44.4; mass spectrum (API-TIS) m/z 333 (MH), 350 (MNH,"). Anal. Calcd for C,H_FO,S: C, 61.44; H, 3.94; F, 5.72; S, 9.65. Found:
C, 61.24; H,3.89; F, 5.70; 5, 9.52. 12b. 1-[(1Z)-2-(4-Fluorophenyl)-3-hydroxy-1-(hydroxymethyl)prop-1-enyl}-4- (methylsulfonyl)benzene
A solution of diisobutylaluminium hydride (70.2 mL, 1M solution in THF, : 9.98 g, 70.2 mmol) was added dropwise to a solution of the product of Example12a : (4.68 g, 14.1 mmol) in THF (190 mL) at 0 °C. After stirring for 30 min at 0 °C and : then 1 hour at room temperature, the mixture was cooled to 0 °C. Additional
DIBAL (30 mL, 1M solution in THF, 4.27 g, 30 mmol) was added dropwise and stirred for 1 hour at room temperature. This reaction mixture was poured into a solution of 1M sodium potassium tartrate (200 mL) containing MeOH (50 mL). The aqueous mixture was extracted with EtOAc. The organic layer was dried over
Na,SO,, and filtered. The solvent was removed in vacuo to give the title compound (4.7 g, 99 %) as a colorless oil. "H-NMR (300 MHz, MeOH-d,) 87.73 (d,] = 8.5 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 7.07-7.12 (mult, 2H), 6.85-6.91 (mult, 2H), 4.64 (s, 2H), - 4.62 (s, 2H), 3.06 (s, 3H); mass spectrum (API-TIS) m/z 337 (MH), 354 (MNH,"). 12¢. (2Z)-3-(4-Fluorophenyl)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]but-2-enyl ’ acetate
Acetic anhydride (1.33 mL, 1.4 g, 14.0 mmol) was added dropwise to a solution of the product of Example 12b (4.7 g, 14.0 mmol), DMAP (56 mg, 0.46 _. 120 mmol) and triethylamine (5.89 mL, 42.3 mmol) in CH,Cl, (600 mL) at room temperature. The mixture was stirred for 1 hour at room-temperature, washed } with water and dried over Na,SO,. The residue, after evaporation of the solvent, was chromatographed on silica gel eluting with 1:1 to 3:2 EtOAc:Hexane to give the . 5 title compound (1.31 g, 25%) as a colorless oil, followed by its regio-isomer, (2Z)-2- (4-fluorophenyl)-4-hydroxy-3-[4-(methylsulfonyl)phenyl]but-2-enyl acetate (1.37 g, 26%) also as a colorless oil. (2Z)-3-(4-fluorophenyl)-4-hydroxy-2-[4- (methylsulfonyl)phenyl]but-2-enyl acetate: "H-NMR (300 MHz, CDCl) 87.73 (d,] = 8.4 Hz, 2H), 7.21 (d, J = 8.5 Hz, 2H), 7.02-7.06 (mult, 2H), 6.80-6.86 (mult, 2H), 5.17 (s, 2H), 4.63 (s, 2H), 3.01 (s, 3H), 1.99 (s, 3H); °C NMR (75 MHz, CDCL,) § 171.4, 163.6, 160.4, 145.9, 143.6, 139.0, 135.6 (J; = 3.4 Hz), 134.3, 131.0, 130.9, 130.5, 127.3, 115.5,115.2, 64.4, 63.4, 44.5, 21.0; mass spectrum (API-TIS) m/z 396 (MINH,"). (2Z)-2- (4-Fluorophenyl)-4-hydroxy-3-[4-(methylsulfonyl)phenyl]but-2-enyl acetate: 'H-
NMR (300 MHz, CDCl,) 6 7.70 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 6.82-6.97 (mult, 4H), 5.16 (s, 2H), 4.61 (s, 2H), 2.99 (s, 3H), 1.99 (s, 3H); *C NMR (75 MHz,
CDCl) 6 171.4,163.4, 160.1, 146.8, 141.0, 138.5, 136.7, 134.7 (J, = 3.5 Hz), 131.0, 130.9,130.1,126.9,115.4, 115.1, 64.4, 62.8, 44.3, 20.8; mass spectrum (API-TIS) m/z 396 (MNH,"). 12d. (2Z)-3-(4-Fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-4-oxobut-2-enyl acetate
A mixture of the product of Example 12c (1.31 g, 3.47 mmol) and MnO, (6.96 g, 80 mmol) in CH,Cl, (175 mL) was stirred for 16 hours at room temperature and then filtered through a pad of Celite. The filtrate was dried over Na,SO,, filtered and concentrated in vacuo to give the title compound (0.81 g, 62 %) as yellow solid.
H-NMR (300 MHz, CDCL,) § 10.39 (s, 1H), 7.79 (d, J = 10.3 Hz, 2H), 7.31 (d, J = 12.2
Hz, 2H), 6.88-6.91 (mult, 4H), 5.45 (s, 2H), 3.02 (s, 3H), 2.00 (s, 3H); "C NMR (75
MHz, CDCl) é 190.9,170.4, 164.1, 160.8, 149.6, 143.9, 141.3, 140.3, 132.4, 132.3, 130.0, 129.9, 127.4, 115.7, 115.5, 62.1, 44.4, 20.7; mass spectrum (API-TIS) m/z 394 . (MNH,"). 12e. (2Z)-4-Acetyloxy-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2- " enoic acid
To a solution of the product of Example 12d (0.81 g, 2.15 mmol) and 2- methyl-2-butene (28.9 mL, 19.1 g, 273 mmol) in {-butanol (170 mL), was added a solution of NaClO, (4.87 g, 53.9 mmol) and NaH,PO, (4.80 g, 40.1 mmol) in water " (10mL). The mixture was stirred for 2 hours at room temperature. The residue, . after evaporation of the solvent, was dissolved in pH = 7 buffer solution (250 mL) and extracted with EtOAc. The aqueous layer was acidified with 10% HCI (~pH = . 5 4-5) and extracted with EtOAc. The combined organic layers were dried over
Na,SO, and filtered. The residue after evaporation of the solvent was recrystallized from EtOAc:Hex:CH,Cl, to give the title compound (0.31 g, 37%) as a white solid. mp 187 °C. "H-NMR (300 MHz, THF-d,) 7.87 (d, J = 8.1 Hz, 2H), 7.47 (d,] = 8.1
Hz, 2H), 7.21-7.25 (mult, 2H), 6.97-7.03 (mult, 2H), 5.35 (mult, 2H), 3.08 (s, 3H), 1.97 (s, 3H); °C NMR (75 MHz, CDCL) § 170.8, 169.7, 165.2, 162.0, 144.9, 142.2, 141.9, 137.7,133.9 (J. = 3.5 Hz), 133.2, 133.1, 131.6, 128.4, 116.3, 116.0, 65.9, 44.5, 20.8; mass spectrum (API-TIS) m/z 333 (M-HOAC), 410 (M+NH,"). Anal. Calcd for
C,H FOSe1/2 HO: C, 56.85; H,4.52 F,473;S,799. Found: C, 56.83; H, 445;F, 5.07; S, 7.94. Rk 12f. 2-Amino-3-methyl-3-[(24,6-trimethoxyphenyl)methylthio]butanoic acid
A suspension of 2-amino-3-methyl-3-sulfanylbutanoic acid (D-penicillamine) : (5.0 g, 34 mmol) in CH,CL (150 mL} was cooled to 0 °C. Trifluoroacetic acid (54 mL, : 703 mmol) was added dropwise over a period of 5 min. Then 2,4,6-trimethoxy- benzyl alcohol (6.64 g, 34 mmol) in CH,Cl, (137 mL) was added dropwise at 0°C with stirring. Stirring was continued for 1 hour at 0 °C and then for 2 hours at room temperature. The solvent was removed in vacuo and the residue was dried under high vacuum for 3 hours. The crude red solid was recrystallized from 1:1:1
CH,C1,/MeOH/EtOAc to give the title compound (10.5 g, 95 %) as a white solid. "H-NMR (300 MHz, CDCl) § 6.10 (s, 2H), 3.84 (s, 6H), 3.76 (s, 3H), 3.40-4.10 (m, 3H), 1.69 (s, 3H), 1.23 (s, 3H); mass spectrum (API-TIS) m/z 330 (MH). 12g. 2-Amino-3-methyl-3-[(24,6-trimethoxyphenyl)methylthio]butan-1-ol
To a stirred solution of the product of Example 12f (10.5 g, 32 mmol) in THF (80 mL) was added dropwise lithium aluminum hydride (1 M in THF, 64 mL, 64 . mmol) at 0 °C under nitrogen. The resulting solution was stirred at 0 °C for 1 hour and then at room temperature for 2 hours. The excess reducing agent was ’ destroyed by careful portionwise addition of Na,5O,*10H,0 at 0 °C. The granular white precipitate was filtered and washed with 30% methanol in CH,CL,. The combined filtrate was dried over Na,SO,, filtered and evaporated to give the title compound (7.6 g, 76 %) as a yellow oil which was used for the next step without further purification. "H-NMR (300 MHz, CDCL)-8-6.10(s, 2H), 3:85 (s, 6H), 3.81 (s, 3H), 3.74 (s, 2H), 3.60-3.80 (mult, 2H), 3.37-3.43 (mult, 1H), 2.93-2.98 (mult, 1H), 1.45 (s, 3H), 1.30 (s, 3H); mass spectrum (API-TIS) m/z 316 (MH"). . 5 12h. 4-{1-Methyl-1-[(24,6-trimethoxyphenyl)methylthio]ethyl}-1,3-oxazolidin-2- one
A mixture of K.CO, (0.33 g, 2.4 mmol), diethylcarbonate (50 mL) and the product of Example 12g (7.6 g, 24 mmol) was heated at 100 °C for 24 hours. Excess diethylcarbonate was evaporated and the resultant light brown slurry was cooled to room temperature, diluted with CH,CL, and filtered to remove the K,CO,. The filtrate was evaporated and the residue was chromatographed on silica gel eluting with 1:1 EtOAc:Hexane to give the title compound 2.6 g (32 %) as a viscous yellow oil. "H-NMR (300 MHz, CDCL,) 8 6.13 (s, 2H), 6.07 (bs, 1H), 4.30-4.40 (mult, 1H), 4.25-4.28 (mult, 1H), 4.03-4.08 (mult, 1H), 3.86 (s, 6H), 3.83 (s, 2H), 3.81 (s, 3H), 1.32 (s, 3H), 1.27 (s, 3H); "C NMR (75 MHz, CDCl) § 160.7, 159.5, 158.7, 106.3, 90.9, 66.5, 59.5, 56.0, 55.5, 47.1, 23.8, 22.3, 20.3; mass spectrum (API-TIS) m/z 342 (MH), 359 (MNH,"). : 12i. 3-Bromo-1-(1,1,2,2-tetramethyl-1-silapropoxy)propane t-Butyldimethylchlorosilane (17.4 g, 115 mmol) in dry THF (50 mL) was added dropwise to a solution of 1,3-bromopropanol (16 g, 115 mmol) and imidazole (7.85 g, 115 mmol) in dry THF (50 mL) at room temperature. The resulting white suspension was stirred at room temperature for 16 hours. The reaction mixture was diluted with EtOAc (200 mL), washed with water, brine, dried over Na,SO,, filtered, and concentrated in vacuo at room temperature to give the title compound 28.5 g (98%) as a colorless volatile liquid. "H-NMR (300 MHz,
CDCl) 8 3.74 (t, J = 5.7 Hz, 2H), 3.52 (t, J = 6.5 Hz, 2H), 2.02-2.06 (mult, 2H), 0.90 (s, 9H), 0.07 (s, 6H); *C NMR (75 MHz, CDCL,) 8 60.6, 35.7, 30.8, 26.1, -5.2. 12j. 4-{1-Methyl-1-[(2,4,6-trimethoxyphenyl)methylthiolethyl}-3-[3-(1,1,2,2- . tetramethyl-1-silapropoxy)propyl]-1,3-oxazolidin-2-one
NaH (0.84 g, 35.3 mmol) was added portionwise to a solution of the product : of Example 12h (8.03 g, 23.5 mmol) in dry DMF (25 mL) under nitrogen at 0 °C.
The resulting suspension was stirred at 0 °C for 20 min to give a brown red solution. The product of Example 12i (7.14 g, 28.2 mmol) in DMF (7 mL) was added dropwise and stirred at room temperature for 16 hours and then the solvent was evaporated. The residue was treated with 1:1 EtOAc:water and the organic . layer was separated. The aqueous layer was extracted with EtOAc and the combined organic phases were washed with water, dried over Na,SO,, and filtered. . 5 Evaporation of the solvent left a residue that was chromatographed on silica gel eluting with 5% to 25% EtOAc:Hexane to give the title compound 6.2 g (51%) as a white foam. "H-NMR (300 MHz, CDCL,) § 6.11 (s, 2H), 4.38-4.42 (mult, 1H), 4.05- 4.11 (mult, 1H), 3.93-3.96 (mult, 1H), 3.83 (s, 6H), 3.80 (s, 3H), 3.77 (s, 2H), 3.65 (1,] = 6.1 Hz, 2H), 3.58-3.71 (mult, 1H), 3.34-3.44 (mult, 1H), 1.66-1.96 (mult, 2H), 1.56 (s, 3H), 1.24 (s, 3H), 0.89 (s, 9H), 0.04 (s, 6H); °C NMR (75 MHz, CDCL,) § 160.7, 159.5, 158.7, 107.0, 90.8, 65.7, 61.7, 60.6, 55.9, 55.4, 48.3, 42.6, 30.3, 26.8, 26.0, 22.2, 20.4, 18.4, -5.3; mass spectrum (API-TIS) m/z 514 (MH). 12k. 3-(3-Hydroxypropyl)-4-(1-methyl-1-sulfanylethyl)-1,3-oxazolidin-2-one
The product of Example 12j (5.0 g, 9.75 mmol) was treated with water (4.0 mL), phenol (4.0 g), anisole (4.0 mL) and finally trifluoroacetic acid (49 mL). The resultant solution was stirred at room temperature for 1 hour. The volatiles were evaporated to give a yellow oil. The crude yellow oil was chromatographed on - silica gel eluting with 1:1 EtOAc:Hexane to 5% MeOH:CH,C], to give the title compound 1.4 g (66%) as a pale yellow oil. "H-NMR (300 MHz, CDCL,) § 4.30-4.35 (mult, 2H), 3.50-3.82 (mult, 5H), 2.80-2.95 (bs, 1H), 1.83-1.89 (mult, 2H), 1.78 (s, 1H), 1.42 (s, 6H); *C NMR (75 MHz, CDCl) 8 160.5, 65.8, 65.4, 59.2, 47.2, 42.2, 30.1, 29.0, 28.0; mass spectrum (API-TIS) m/z 220 (MH), 237 (MNH,"). Anal. Calcd for
CH,_NO,S: C, 49.29; H, 7.81; N, 6.39. Found: C, 48.99; H, 7.71; N, 6.04. 121. 3-(3-Hydroxypropyl)-4-[1-methyl-1-(nitrosothio)ethyl]-1,3-oxazolidin-2-one
To a solution of :-BuONO (1.67 mL of 90% solution, 1.32 g, 12.8 mmol) in
CH,CI, (10 mL) was added dropwise a solution of the product of Example 12k (1.4 g, 6.4 mmol) in CHCl, (16 mL) at 0 °C. The resulting green solution was stirred at) - °C for 1 hour and then at room temperature for 20 min in the dark. Evaporation of - the solvent gave a residue that was chromatographed on silica gel eluting with 1:1
EtOAc:CH,CL, to 5% MeOH:CH,CI, to give the title compound 0.98 g (62%) as a : green oil. "H-NMR (300 MHz, CDCL) 8 4.61-4.66 (mult, 1H), 4.36-4.46 (mult, 2H), 3.42-3.75 (mult, 4H), 2.30-2.45 (br s, 1H), 1.97 (s, 3H), 1.96 (s, 3H), 1.74-1.80 (mult, 2H); ®C NMR (75 MHz, CDC),) § 160.2, 65.3, 63.3, 59.3, 58.8, 42.3, 29.8, 25.4, 25.0;
mass spectrum (API-TIS) m/z 219 (M-NO), 249 (MH"), 266 (MNH,"). Anal. Calcd for
CH,N,O,S: C, 43.54; H, 6.50; N, 11.28. Found: C, 43.61; H, 6:59; N, 16:99. . 12m. 3-{4-[1-Methyl-1-(nitrosothio)ethyl]-2-oxo-1,3-oxazolidin-3-yl}propyl (2Z)-4- acetyloxy-2-(4-flurophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-enoate . 5 Bis(2-oxo-3-oxazolidinyl)phosphonic chloride (0.14 g, 0.32 mmol) and 4- (dimethylamino)pyridine(19.0 mg, 0.16 mmol) were added to a solution of the product of Example 121 (100 mg, 0.40 mmol) and the product of Example 12e (61 mg, 0.16 mmol) in THF (2 mL) at 0 °C. The resulting solution was stirred at 0 °C for 1 hour and then at room temperature for 20 hours. Evaporation of the solvent gave a residue that was chromatographed on silica gel eluting with 1:1 EtOAc:CH,Cl, to give the title compound 68 mg (70%) as a green foam. "H-NMR (300 MHz, CDCL,) § 7.78 (d,] = 8.3 Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 6.99-7.03 (mult, 2H), 6.82-6.88 (mult, 2H), 5.17 (s, 2H), 4.53-4.57 (mult, 1H), 4.36-4.43 (m, 2H), 4.25 (t,] = 6.1 Hz, 2H), 3.64- 3.74 (mult, 1H), 3.18-3.28 (mult, 1H), 3.02 (s, 3H), 1.95 (s, 3H), 1.91 (s, 3H), 1.87 (s, 3H), 1.85-2.06 (mult, 2H); mass spectrum (API-TIS) m/z 593 (M-NO), 623 (MH"), 640 (MNH,").
Example 13: (2Z)-3-(4-Fluorophenyl)-3-{N-methyl-N-[2-methyl-2-(nitrosothio) propyllcarbamoyl}-2-[4-(methylsulfonyl)phenyllprop-2-enyl acetate : 13a. (2Z)-3-(4-Fluorophenyl)-3-[N-methyl-N-[2-methyl-2- sulfanylpropyl]carbamoyl]-2-[4-(methylsulfonyl)phenyllprop-2-enyl acetate :
Bis(2-oxo-3-oxazolidinyl)phosphonic chloride (0.242 g, 0.55 mmol) was added to a solution of the product of Example 12e (0.18 g, 0.46 mmol), triethylamine (0.62 mL, 0.45 g, 4.4 mmol) and 4-(dimethylamino)pyridine (56 mg, 0.46 mmol) in THF (6 mL) at room temperature. After 5 min, 1-amino-2-methyl-2- thiopropane (85.6 mg, 0.55 mmol) was added. The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with EtOAc (50 mL), washed with water, brine, dried over Na,SO,, and filtered. Evaporation of the solvent gave a residue that was chromatographed on silica gel eluting with 2% . MeOH:CH,(CI, to give the title compound (189 mg, 83 %) as a white foam. mp 45-47 °C. "H-NMR (300 MHz, DMSO-d,) 8 7.44 (d, J = 8.4 Hz, 2H), 7.44 (d, ] = 8.4 Hz, 2H), : 7.08-7.11 (mult, 4H), 4.95-5.05 (br s, 2H), 3.60 (s, 2H), 3.21 (s, 3H), 3.14 (s, 3H), 2.86 (s, 1H), 1.95 (s, 3H), 1.33 (s, 6H); °C NMR (75 MHz, CDCL,) § 170.6, 170.2, 160.9, 143.9, 141.0, 139.8, 132.7, 131.3, 131.2, 130.6, 127.6, 116.1, 115.8, 65.5, 60.6, 46.5, 44.6,
39.4, 31.7, 21.0; mass spectrum (API-TIS) m/z 494 (MH). 13b. (2Z)-3-(4-Fluorophenyl)-3-{N-methyl-N-[2-methyl-2-(nitrosothio)propyl] , carbamoyl}-2-[4-(methylsulfonyl)phenyl]prop-2-enyl acetate
To a solution of +-BuONO (141 pL of 90% solution, 111 mg, 1.08 mmol) in . 5 CHC, (1.4 mL) was added dropwise a solution of the product of Example 13a (163 mg, 0.33 mmol) in CH,CL, (4.3 mL) at 0 °C. The resulting green solution was stirred at 0 °C for 15 min and at room temperature and then for 15 min in the dark. The residue, after evaporation of the solvent, was chromatographed on silica gel eluting with 1:1 to 2:1 EtOAc:CH,CI, to give the title compound 60 mg (35 %) as a green foam. mp 37-38 °C. "H-NMR (300 MHz, CDCl,) $7.80 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.3 Hz, 2H), 7.04-7.08 (mult, 2H), 6.85-6.90 (mult, 2H), 4.96 (s, 2H), 4.25 (s, 2H), 3.04 (s, 3H), 2.95 (s, 3H), 2.04 (s, 3H), 1.92 (s, 6H); "C NMR (75 MHz, CDCL,) § 170.6, 170.5, 164.2, 160.9, 143.7, 140.6, 139.8, 133.0, 131.2, 131.1, 130.5, 130.2, 127.5, 116.1, 115.8, 65.4, 58.2, 57.8, 44.5, 39.3, 27.9, 20.9; mass spectrum (API-TIS) m/z 493 (M-
NO), 523 (MH), 540 (MNH,").
Example 14: 2-[1-Methyl-4-(nitrosothio)-4-piperidyllethyl (2Z)-3-(4-acetyloxy-2- By (4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-enoate 14a. 2-[1-Methyl-4-(nitrosothio)-4-piperidyl]ethyl (2Z)-3-(4-acetyloxy-2-(4- fluorophenyl)-3-[4-(methylsulfonyl)phenyljbut-2-enoate
DCC (0.11 g, 0.53 mmol) in CH,CL, (5 mL) was added dropwise to a stirred solution of the product of Example 12e (0.21 g, 0.53 mmol), 2-[1-methyl-4- (nitrosothio)-4-piperidyl]ethan-1ol (prepared as described in Patent Application
WO/025776, (the disclosure of which is incorporated by reference herein in its entirety) Example 13d, 0.132 g, 0.64 mmol) and 4-(dimethylamino)pyridine (33 mg, 0.27 mmol) in CH,CL, (5 mL) at room temperature. The resulting suspension was stirred at room temperature for 16 hours then the precipitate was filtered and washed with CH,CL, (10 mL). The combined organic phase was dried over Na, SO, and filtered. The residue after evaporation of the solvent was chromatographed on . silica gel eluting with 2% MeOH:CH,Cl, to give the title compound 13 mg (4%) as a green oil. "H-NMR (300 MHz, CDCL,) § 7.76 (d, ] = 8.4 Hz, 2H), 7.28 (d,] = 9.1 Hz, . 2H), 6.94-6.98 (mult, 2H), 6.81-6.86 (mult, 2H), 5.15 (s, 2H), 4.42 (t, ] = 6.7 Hz, 2H), 3.00 (s, 3H), 2.68 (t,] = 6.8 Hz, 2H), 2.30 (s, 3H), 2.15-2.43 (mult, 8H), 1.93 (s, 3H); mass spectrum (API-TIS) m/z 549 (M-NO), 579 (MH).
Example 15: (3Z)-4-(4-Chlorophenyl)-3-(ethoxycarbonyl)-4-[4-(methylsulfonyl) phenyllbut-3-eneic acid 15a. (3Z)-4-(4-Chlorophenyl)-3-(ethoxycarbonyl)-4-[4- (methylsulfonyl)phenyl]but-3-enoic acid . 5 This compound was synthesized as described in U. S. Patent No. 5,807,873, (the disclosure of which is incorporated by reference herein in its entirety),
Example 63. "H-NMR (300 MHz, CDCL,) § 7.96 (d, J = 8.2 Hz, 2H), 7.40 (d, J=83
Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.07 (d, ] = 8.4 Hz, 2H), 4.03 (q, ] = 7.1 Hz, 2H), 3.45 (s, 2H), 3.10 (s, 3H), 0.97 (t,] = 7.1 Hz, 3H); mass spectrum (API-TIS) m/z 377 (M-
CQO,), 423 (MH"), 440 (MNH,’), 445 (MNa"). 15b. 2-Bromo-1-(1,1,2,2-tetramethyl-1-silapropoxy)ethane t-Butyldimethylchlorosilane (21.7 g, 144 mmol) in dry THF (50 mL) was added dropwise to a solution of 1,2-bromoethanol (18 g, 144 mmol) and imidazole (9.81 g, 144 mmol) in dry THF (50 mL) at room temperature. The resulting white suspension was stirred at room temperature for 16 hours. The reaction mixture was diluted with EtOAc (200 mL), washed with water, brine, dried over Na,SO,, o filtered and concentrated in vacuo at room temperature to give the title compound . 33.2 g (96%) as a colorless liquid. "H-NMR (300 MHz, CDCL) 63.89 (t,] = 6.5 Hz, 2H), 3.39 (t,] = 6.6 Hz, 2H), 0.90 (s, 9H), 0.10 (s, 6H); °C NMR (75 MHz, CDCl) & : 63.7, 60.5, 33.4, 26.0, 21.2, 14.3, -5.1. : 15c. 4-{1-Methyl-1-[(24,6-trimethoxyphenyl)methylthio]ethyl}-3-[2-(1,1,2,2- tetramethyl-1-silapropoxy)ethyl]-1,3-oxazolidin-2-one
NaH (1.6 g, 66.7 mmol) was added portionwise to a solution of the product of Example 12h (15.3 g, 44.9 mmol) in dry DMF (50 mL) under nitrogen at 0 °C.
The resulting suspension was stirred at 0 °C for 20 min to give a brown red solution. The product of Example 15b (12.9 g, 53.8 mmol) in DMF (10 mL) was added dropwise and stirred at room temperature for 16 hours. The solvent was evaporated. The residue was partitioned with 1:1 EtOAc:water and the organic - layer was separated. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with water, dried over Na,SO,, and filtered. : The residue after evaporation of the solvent was chromatographed on silica gel eluting with 1:1 EtOAc:Hexane to give the title compound (18 g, 80%) as a white foam. "H-NMR (300 MHz, CDCL,) 8 6.12 (s, 2H), 4.38-4.47 (mult, 1H), 4.09-4.21
(mult, 3H), 3.83 (s, 9H), 3.79 (s, 2H), 3.71-3.79 (mult, 2H), 3.42-3.53 (m, 1H), 1.50 (5, 3H), 1.29 (s, 3H), 0.95(s, 9H), 0:08 (s, 6H); “C NMR (75 MHz, CBCL)$ 160.8, 159.7, } 158.9,106.5,90.9, 65.9, 62.3, 60.5, 56.0, 55.5, 48.6, 47.5, 26.4, 26.0, 22.6, 21.2, 20.3, 18.3, 14.4, -5.3; mass spectrum (API-TIS) m/z 500 (MH). . 5 15d. 3-(2-Hydroxyethyl)-4-(1-methyl-1-sulfanylethyl)-1,3-oxazolidin-2-one
The product of Example 15¢ (14.9 g, 29.8 mmol) was treated with water (11.8 mL), phenol (11.8 g), anisole (11.8 mL) and finally trifluoroacetic acid (147 mL).
The resultant solution was stirred at room temperature for 1 hour and then the solvent was evaporated to give a yellow oil which was chromatographed on silica gel eluting with 1:1 EtOAc:Hexane to 5% MeOH:CH,CL, to give the title compound 4.2 g (69%) as a pale yellow oil. "H-NMR (300 MHz, CDCL) § 4.33-4.43 (mult, 2H), 3.72-3.92 (mult, 4H), 3.50-3.59 (mult, 1H), 2.55-2.80 (br s, 1H), 1.78 (s, 1H), 1.41 (s, 6H); “C NMR (75 MHz, CDCL,) § 160.6, 66.2, 66.0, 60.4, 48.3, 47.6, 29.0, 27.8; mass spectrum (API-TIS) m/z 206 (MH), 223 (MNH,"). Anal. Calcd for C;H, ,NO,S: C, 46.81; H, 7.37; N, 6.82. Found: C, 46.81; H, 7.11; N, 6.61. 15e. 3~(2-Hydroxyethyl)-4-[1-methyl-1-(nitrosothio)ethyl]-1,3-oxazolidin-2-one
To a solution of t-butyl nitrite (4.45 mL of 90% solution, 3.5 g, 34.1 mmol) in Co
CH,C], (28 mL) was added dropwise a solution of the product of Example 15d (3.88 g, 18.9 mmol) in CH,Cl, (58 mL) at 0 °C. The resulting green solution was stirred at 0 °C for 1 hour and then at room temperature for 20 min in the dark. The residue after evaporation of the solvent was chromatographed on silica gel eluting with 1:1
EtOAc:CH,CI, to 5% MeOH:CH,CI, to give the title compound 3.7 g (84 %) as a green oil. 'H-NMR (300 MHz, CDCL,) § 4.70-4.74 (mult, 1H), 4.41-4.52 (mult, 2H), 3.77-3.89 (mult, 3H), 3.44-3.50 (mult, 1H), 1.99 (s, 3H), 1.96 (s, 3H); °C NMR (75
MHz, CDCl,) 6 160.4, 65.8, 63.9, 60.0, 59.3, 48.1, 25.7, 24.8; mass spectrum (API-TIS) m/z 205 (M-NO), 235 (MH), 252 (MNH,"). Anal. Caled for C,H, ,N,0,S: C, 41.02; H, 6.02; N, 11.96. Found: C, 41.30; H, 5.87; N, 11.68. 15f. (3Z)-4-(4-Chlorophenyl)-3-(ethoxycarbonyl)-4-[4- . (methylsulfonyl)phenyl]but-3-enoic acid
DCC (32 mg, 0.155 mmol) in CH,Cl, (0.5 mL) was added dropwise to a - stirred solution of the product of Example 15a (66 mg, 0.155 mmol), the product of
Example 15e (36 mg, 0.154 mmol) and 4-(dimethylamino)pyridine (19 mg, 0.155 mmol) in CH,CL (2 mL) at 0 °C. The resulting suspension was stirred at 0 °C for 15 min and then at room temperature for 1.5 hours. The precipitate was filtered and washed with CH,CL(5- mL). The combined organic phases were dried over Na,5C, . and filtered. The residue after evaporation of the solvent was chromatographed on silica gel eluting with 1:3 EtOAc:CH,C, to give the title compound 69 mg (70%) as a - 5 green solid. mp 40-42 °C. "H-NMR (300 MHz, CDCl) 8 7.96 (d, J = 6.7 Hz, 2H), 7.39 (d, J = 6.6 Hz, 2H), 7.28-7.31 (mult, 2H), 7.04-7.07 (mult, 2H), 4.69-4.73 (m, 1H), 4.01-4.47 (m, 2H+2H+1H), 3.98 (q, ] = 7.1 Hz, 2H), 3.42-3.50 (mult, 1H), 3.37 (s, 2F]), 3.09 (s, 3H), 1.96 (s, 3H), 1.93 (s, 3H), 0.93 (t, ] = 7.1 Hz, 3H); °C NMR (75 MHz,
CDCL) 6170.7, 168.3, 159.1, 149.3. 145.6. 149.7. 139.4, 134.6, 130.0, 128.6, 128.0, 126.9, 65.4, 62.6, 61.3, 61.3, 59.1, 44.5, 44.3, 37.9, 25.2, 25.1, 13.6; mass spectrum (API-TIS) m/z 609 (M-NO), 639 (MH), 659. (MNH,"). Anal. Calcd for C,;H, CIN,0O,S,: C, 52.62;
H, 4.89; N, 4.38; Cl, 5.55; S, 10.03. Found: C, 52.40; H, 4.98; N, 4.17; Cl, 5.68, S, 9.80.
Example 16: 3-Methyl-N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyllsulfonyl}-3- (nitrosothio)butanamide 16a. 3-Methyl-N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl}-3-{(2,4,6- trimethoxyphenyl)methylthiobutanamide 3-Methyl-3-[(2 4,6-trimethoxyphenyl)methylthio]butanoic acid (prepared as described in patent application WO 97/34871, (the disclosure of which is : incorporated by reference herein in its entirety), Example 1a, 1.05 g, 3.37 mmol) was added to a stirred solution of 4-(5-methyl-3-phenylisoxazol-4-yl)benzene sulfonamide (prepared as described by Talley et. al., J. Med. Chem. 43, 775 (2000), (the disclosure of which is incorporated by reference herein in its entirety), 0.85 g, 2.70 mmol), 4-(dimethylamino)pyridine (0.1 g) in THF (30 mL). The resulting solution was stirred at room temperature for 15 min and then solid DCC (0.84 g, 4.04 mmol) was added. The reaction mixture was stirred at room temperature for 3 hours, the solid was then removed by filtration. The filtrate was concentrated and the residue was chromatographed on silica gel eluting with 1:1 EtOAc:Hexane to give the title compound (0.92 g, 56%) as a white solid. mp 138-140 °C. "H-NMR . (300 MHz, CDCl,) 8 9.98 (s, 1H), 7.93 (d, J = 8.4 Hz, 2H), 7.25-7.42 (mult, 7H), 6.20 (s, 2H), 3.92(s, 6H), 3.83 (s, 3H), 3.79 (s, 2H), 2.54 (s, 2H), 2.45 (s, 3H), 1.20 (s, 6H); “C- : NMR (75 MHz, CDCL,) 6 168.8, 167.3, 161.0, 158.5, 138.0, 136.1, 129.8, 129.7, 128.9, 128.7,128.4,114.5,105.2,91.1, 56.1, 55.4, 47.3, 43.8, 29.0, 21.1, 11.7; mass spectrum - (API-TIS) m/z 611 (MH). i. 129
16b. 3-Methy!-N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl}-3- sulfanylbutanamide y The product of Example 16a (0.6 g, 0.98 mmol) in CH,CL (5 mL) was added to a stirred solution of cysteine (1.1 g, 9.07 mmol) in TFA (5 mL) and the resulting “ 5 pale yellow solution was stirred at room temperature for 1 hour. Crushed ice (~ 3 8) was added and the mixture neutralized with concentrated NH,OH (8 mL). The aqueous mixture was extracted with EtOAc (3 x 25 mL). The combined organic layers were dried over Na,SO, and concentrated to give the title compound (04 g, 95%) as a viscous oil. This material was used in the next reaction without further purification. mp 138-140 °C. "H-NMR (300 MHz, CDCL) § 8.05 (d, J = 8.3 Hz, 2H), 7.30-7.40 (mult, 7H), 2.57 (s, 2H), 2.49(s, 3H), 2.09 (s, 1H), 1.37 (s, 6H); "C-NMR (75
MHz, CDC) § 168.5, 167.5, 161.1,137.6, 136.3, 130.0, 129.7, 128.8,128.7, 128.4, 128.1, 114.4, 52.0, 42.0, 32.4, 11.7; mass spectrum (API-TIS), m/z 431 (MH). 16c. 3-Methyl-N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl}-3- (nitrosothio)butanamide
A few drops of HCl in ether was added to a stirred solution of product of
Example 16b (0.4 g, 0.93 mmol) in CH,Cl, (5 mL) and MeOH (5 mL). ¢-BuONO E (90%, 120 mL, 0.93 mmol) was then added. The resulting olive green solution was stirred at room temperature for 15 min under nitrogen. Cold water (25 mL) was added and the product was extracted into EtOAc (2 x 25 mL). The organic layer was dried over Na,SO, and concentrated. Flash chromatography of the residue on N silica gel eluting with 1:1 EtOAc/Hexane gave the title compound (0.32 g, 75%) asa green foam. "H-NMR (300 MHz, CDCL) 6 9.38 (s, 1H), 7.96 (d, J = 8.4 Hz, 2H), 7.28- 7.43 (mult, 7H), 3.22 (s, 2H), 2.52 (s, 3H), 1.98 (s, 6H); "C-NMR (75 MHz, CDCL,) 0167.8, 167.6, 161.1, 137.4, 136.2, 130.0, 129.8, 128.7,128.5, 128.0, 114.4, 53.6, 48.3, 27.8, 11.6; mass spectrum (API-TIS), m/z 460 (MH).
Example 17: 2-Methyl-2-(nitrosothio)propyl-5-(4-chlorophenyi)-1-(4- sulfamoylphenyl)pyrazole-3-carboxylate . 17a. Methyl 5-(4-chlorophenyl)-1-(4-sulfamoylphenyl)pyrazole-3-carboxylate
This compound was prepared as described in Penning et. al. J. Med. Chem. ’ 40, 1347-1365 (1997), (the disclosure of which is incorporated by reference herein in its entirety), Compound 3a. mp 186 °C. "H-NMR (300 MHz, DMSO-d.) § 7.89 (d, J = 8.6 Hz, 2H), 7.6-7 4 (m, 6H), 7.32 (d, J = 8.6 Hz, 2H), 7.21 (s, 1H), 3.87 (s, 3H); mass spectrum (API-TIS) m/z 392 (MH+). 17b. 5-(4-Chlorophenyl)-1-(4-sulfamoylphenyl)pyrazole-3-carboxylic acid , A stirred mixture of the product of Example 17a (9.75 g, 24.9 mmol), aqueous NaOH (1.5 N, 60 mL), and THF (200 mL) was heated to reflux for 5 hours. . 5 The reaction mixture was concentrated on a rotary evaporator. The residue was partitioned between EtOAc (200 mL) and 2N aqueous HCI (100 mL). The organic layer was separated and washed with water, dried over Na,SO,, filtered, and concentrated to give a solid material. Crystallization from EtOH/THEF (1:1) gave the title compound (8.8 g, 90%) as an off-white solid. mp 203 °C. '"H NMR (300 0 MHz, DMSO-d) 6 8.02 (d, J = 8.4 Hz, 2H), 7.7-7.6 (m, 4H), 7.45 (d, J = 8.4 Hz, 2H), 7.28 (s, 1H); mass spectrum (API-TIS) m/z 378 (MH+). 17c. 2-methyl-2-sulfanylpropan-1-ol
To 2-methylpropanal (3.53 g, 49 mmol) in carbon tetrachloride (30 ml) was added sulfur monochloride (2 ml, 25 mmol) and the reaction mixture was stirred at 55 °C for 2 hours. After cooling to room temperature, the volatiles were evaporated in vacuo to give 2-[(1,1-dimethyl-2-oxoethyl)disulfanyl]-2-methylpropanal. The disulfide (17.5 g, 85.7 mmol) was dissolved in THF (100 ml) and LiAlH, (86 ml,
IM/THF) was added slowly. After stirring at room temperature for 1 hour, the : mixture was poured onto ice, treated with 3N HCI (150 ml) and then extracted with : 0 EtOAc. The organic extracts were dried over sodium sulfate and the volatiles were : evaporated to yield 12.8 g (71%) of the title compound as a colorless oil. 'H NMR (300 MHz, CDCL) & 3.44 (s, 2H), 2.25 (brs, 1H), 1.63 (s, 1H), 1.36 (s, 6H); °C NMR (CDCl) 73.3, 46.3, 28.3. 17d. 2-methyl-2-(nitrosothio)propan-1-ol 5 To a solution of the product Example 17c (4.4 g, 41.5 mmol) in CH,CL (50 ml) was added t-BuONO (5.5 ml, 41.5 mmol). The reaction mixture was stirred at room temperature for 10 minutes and the volatiles were evaporated in vacuo at 40 °C to give 4.6 g (82%) of the title compound as a dark green oil. "'H NMR (300 MHz, . CDCl) 84.17 (s, 2H), 1.95 (brs, 1H), 1.90 (s, 6H); °C NMR (CDCL,) 70.5, 57.7, 25.1. 17e. 2-Methyl-2-(nitrosothio)propyl-5-(4-chlorophenyl)-1-(4-sulfamoylphenyl) : pyrazole-3-carboxylate
To a stirred solution of the product of Example 17b (3.78 g, 10.0 mmol), the product of Example 17d (1.35 g, 10 .0 mmol), 1-[3-(dimethylamino)propyl]-3-
ethylcarbodiimide hydrochloride (3.83 g, 20 .0 mmol), and 4- (dimethylamino)pyzridine (10 mg) in DMF-(80 mL) was-added triethylamine (2:79 ] mL, 20.0 mmol). After being stirred at room temperature for 4 hours, the mixture was diluted with EtOAc (200 mL), washed with 1N HCl, water, dried over Na,SO,, + 5 filtered, and concentrated. Chromatography of the residue on silica gel eluting with 1:4 EtOAc:Hexane gave the title compound (0.20 g, 4%) as a green solid. mp 153 °C (dec). "H NMR (300 MHz, DMSO-d,) 8 7.88 (d, J = 8.6 Hz, 2H), 7.55-7.49 (m, 4H), 7.32 (d, J = 8.6 Hz, 2H), 7.20 (s, 1H), 3.32 (s, 2H), 1.82 (5s, 6H); mass spectrum (API-TIS) m/z 495 (MH+). Anal. Caled. for C,H,,CIN,O,S,: C, 48.53; H, 3.87; N,
Lo 11.32; Cl, 7.16; S, 12.96. Found: C, 48.79; H, 4.12; N, 11.50; Cl, 6.81; S, 12.76.
Example 18: 4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyi]-2-({4- [(nitroxy)methyllphenyl}methyl)-2-hydroxypyridazin-3-one 18a. 4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-benzyl-2- hydropyridazin-3-one
This compound was synthesized as described in patent application WO 99/10331, (the disclosure of which is incorporated by reference herein in its entirety), Example 10. m.p. 151-153 °C. *H -NMR (300 MHz, CDCl3) § 7.85 (d, J = 8.4 Hz, 2H), 7.83 (m, 1H), 7.53 (m, 2H), 7.31 (m, 5H), 7.15 (m, 2H), 6.93 (m, 2H), 5.93 (s, 2H), 3.02 (s, 3H); "C-NMR (75 MHz, CDCL,) § 164.3, 161.0, 159.5, 140.5, 138.7, 13706, 135.8, 132.5, 132.4, 129.9, 129.1, 128.6, 128.1, 127.7, 115.2, 115.2, 56.1, 44.2; mass spectrum (API-TIS) m/z 435 (MEL). 18b. 4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-hydropyridazin-3-one
To the product of Example 18a (74 mg, 0.17 mmol) in toluene (20 mL) was added AlBr, (140 mg, 0.52 mmol). The reaction mixture was heated at 90 °C for 15 minutes and then cooled to 0 °C. The reaction mixture was then poured into ice cold water, acidified with 1 N HCl and extracted with ethyl acetate (2 x 50 mL).
The combined extracts were washed with water (2 x 25 mL) and brine (1 x 25 mL), dried over Na, SO, and filtered. Evaporation of the solvent gave a residue that was : purified by column chromatography on silica gel eluting with 5% methanol in - CHC, to give the title compound (45 mg, 76%). 'H NMR (300 MHz, CDCL) § 7.8- : 7.9 (m, 3H),7.35(d,J=9Hz,2H),7.2 (m,2H),7.0 (t, J =9 Hz, 2 H), 3.05 (5, 3H);
LRMS (APIMS) m/z 345 (M + H)*. 18c. Methyl 4-({5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]-6-oxohydro-
pyridazinyl}methyl)benzoate
The product of Example 18b (210 mg, 0.61 mmol) was dissolved-in . anhydrous DMF (3 mL) and then K,CO, (336 mg, 2.44 mmol) was added. To this reaction mixture was added methyl 4-(bromomethyl)benzoate (140 mg, 0.61 mmol) + 5 and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (2 x 50 mL). The combined extracts were washed with water (4 x 50 mL), brine (1 x 25 mL), and dried over sodium sulfate. Evaporation of the solvent gave a residue that was purified by column chromatography on silica gel eluting with 1:1 EtOAc:Hexane to 0 gave the title compound (210 mg, 70%) as a colorless foam. "H-NMR (300 MHz,
CDC) 88.02 (d, J = 7.8 Hz, 2H), 7.86 (d, J = 8.5 Hz, 2H), 7.84 (s, 1H), 7.58 (d,] = 7.8
Hz, 2H), 7.32 (t,] = 7.9 Hz, 2H), 7.15 (1, ] = 6.8 Hz, 2H), 6.94 (t, ] = 8.2 Hz, 2H), 5.43 (s, 2H), 3.89 (s, 3H), 3.03 (s, 3H); “C-NMR (75 MHz, CDCL,) § 166.7, 164.5, 159.5, 140.8, 140.7, 140.4, 138.8, 137 4, 137.3, 132.5, 132.4, 130.0, 129.9, 129.0, 128.3, 127.8, 127.4, 115.3, 55.8, 52.1, 44.3; mass spectrum (API-TIS)) m/z 493 (MH"). 18d. 4-(4-Fluorophenyl)-2-{4-(hydroxymethyl)phenyl}-5-[4- ; (methylsulfonyl)phenyl}-2-hydroxypyridazin-3-one :
The product of Example 18c (190 mg, 0.386 mmol) was dissolved in anhydrous CH,CI, (10 mL). The solution was cooled to 0 °C and 1M DIBAL-H (1.05 ml) was added dropwise under nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 30 minutes and then at room temperature for 15 minutes. It was then quenched with ice cold water, acidified with 1 N HC], and extracted with
CH, CL, (2 x 50 mL). The combined extracts were washed water (2 x 25 mL), brine (1 x 25 mL) and then dried over Na,SO,. Evaporation of the solvent gave a residue that was purified by column chromatography on silica gel eluting 5% methanol in
CHC], to give the title compound (100 mg, 54 %) as a colorless foam. mp 155-164 °C. "H-NMR (CDCL) 8 7.86 (d, J = 8.2 Hz, 2H), 7.82 (s, 1H), 7.52 (d, J = 7.8 Hz, 2H), 7.34 (d,] =7.9 Hz, 2H), 7.29 (d, ] = 8.1 Hz, 2H), 7.14 (t,] = 7.6 Hz, 2H), 6.93 (t, ] = 8.5 > Hz, 2H), 5.38 (s, 2H), 4.65 (s, 2H), 3.03 (s, 3H); “C-NMR (300 MHz, CDCL,) 5 164.4, 161.1,159.5, 140.9, 140.7, 140.5, 138.8, 137.2, 135.1, 132.4, 129.9, 129.4, 127.7, 127.6, . 115.6, 115.3, 64.8, 55.9, 44.3; mass spectrum (API-TIS) m/z 465 (MH"). 18e. 4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-({4-[(nitroxy)- - methyljphenylimethyl)-2-hydroxypyridazin-3-one
The product of Example 18d (30 mg, 0.065 mmol) was dissolved in anhydrous ethyl acetate (0.5-mL). In a separate flask the nitrating mixture was ; prepared by adding successively acetic anhydride (472 pL, 5.20 mmol) and fuming nitric acid (137 pL, 3.25 mmol) at 0 °C. From this mixture, 65 UL was added to the
Pp 5 above solution cooled to 0 °C. The reaction mixture was stirred at 0 °C for 5 minutes and quenched with water and then extracted with ethyl acetate. The organic layer was separated, washed with water, brine, and dried over Na,SO,.
Evaporation of the solvent gave a residue that was purified by preparative thin layer chromatography (0.25 mun thick silica gel plate) using 6:4 EtOAc:Hexane to give the title compound (5.5 mg, 17%) as a white solid. mp 78-87 °C. "H-NMR (300
MHz, CDCl) $7.86 (d, J = 8.2 Hz, 2H), 7.84 (s, 1H), 7.58 (d,] = 8.0 Hz, 2H), 7.39 (d, J =8.0 Hz, 2H), 7.31 (d, J = 8.2 Hz, 2H), 7.15 (t, ] = 6.4 Hz, 2H), 6.95 (t, ] = 8.6 Hz, 2H), 5.41 (s, 2H), 5.40 (s, 2H), 3.04 (s, 3H); mass spectrum (API-TIS) m/z 510 (MH).
Example 19: 4-(Methylsulfonyl)-i-{1-[2-(nitrooxy)ethyl}-4-benzylpyrazol-5- yl}benzene 19a. 1-(4-Methylthiophenyl)-3-phenylpropan-1-one :
To a stirred solution of 4-(methylthio)benzonitrile (25.0 g, 0.17 mol) in THF (100 mL) under N, atmosphere was added phenethylmagnesium chloride (1.0 M in
THF, 210 mL, 0.21 mol). The solution was heated to reflux for 4 hours, cooled to 0 °C, and quenched carefully with water (10 mL). The resulting slurry was treated . with 6 N hydrochloric acid (200 mL) and stirred at room temperature overnight. :
The THF was evaporated from the mixture, and the residue was extracted with
EtOAc (2 X 300. mL). The combined organic extracts were washed with 2M Na,CO,, dried over Na, SO, filtered, and concentrated to give a solid material.
Recrystallization from EtOAc-Hex (1:4) afforded the title compound (41.5 g, 96%) as greenish plates. mp 105 °C. 'H NMR (300 MHz, CDCL,) § 7.85 (d, J = 8.5 Hz, 2H), 7.32-7.19 (m, 7H), 3.24 (t, J = 6.8 Hz, 2H), 3.06 (t, J = 6.8 Hz, 2H), 2.50 (s, 3H); °C
NMR (75 MHz, CDCl) 6 198.2, 145.8, 141.3, 133.2, 128.48, 128.42, 128.38, 126.1, oN 125.0, 40.2, 30.2, 14.7; mass spectrum (API-TIS) m/z 257 (M+H). 19b. Mixture of 2-[3-(4-methylthiophenyl)-4-benzylpyrazolyl]ethan-1-ol and 2-[5- . (4-methylthiophenyl)-4-benzylpyrazolyl]ethan-1-ol
To a stirred solution of the product of Example 19a (850 mg, 3.3 mmol) in
THF (8 mL) at -78 °C under N, atmosphere was added lithium diisopropylamide oo 134 de Pe (1.5 M in cyclohexane, 2.66 mL, 4.0 mmol) dropwise. After 30 min, a solution of
HCO,Et (0.32 mL, 4.0 mmel)-in THF (1 mL) was added, and the reaction was . allowed to gradually warm to room temperature and stirred overnight. The mixture was poured into 1 N HCI (10 mL), and extracted with EtOAc (2 X 20 mL).
P) 5 The combined organic extracts were washed with saturated NaHCO, (10 mL), dried over Na,SO,, filtered, and concentrated to give an off-white solid (905 mg). A stirred solution of this solid and 2-hydoxyethylhydrazine (0.37 mL, 5.00 mmol) in
EtOH (15 mL) was heated to reflux under N, for 3 hours, and then concentrated.
The residue was dissolved in EtOAc (50 mL), washed with 1N HC}, dried over
Na,S0, filtered, and concentrated. The residue was chromatographed on silica gel eluting with EtOAc to. give two regioisomeric pyrazoles as an inseparable mixture (0.81 g, 75% over two steps). Ratio of isomers 3:2 as judged by the proton NMR. *H
NMR (300 MHz, CDCL,) 8 7.53-7.09 (m, ArH), 4.17 (t,] = 4.5 Hz), 4.08 (t,] = 4.5 Hz), 3.98 (t,] = 5.0 Hz), 3.96 (s), 3.91 (t, 5.0 Hz), 3.71 (s), 2.51 (s), 2.49 (s); mass spectrum (API-TIS) m/z 325 (M+H). 19c and 19d. 1-[1-(2-Hydroxyethyl)-4-benzylpyrazol-5-yl]-4- (methylsulfonyl)benzene and 1-[1-(2-Hydroxyethyl)-4-benzylpyrazol- 3-yl]-4-(methylsulfonyl)benzene
The product of Example 19b (810 mg, 2.50 mmol) was dissolved in MeOH (15 mL), and treated with oxone (4.61 g, 7.50 mmol) and water (10 ml). The slurry was stirred at room temperature for 30 min. The reaction mixture was poured into water (20 mL), neutralized with aqueous Na,CO,, and extracted with EtOAc (50 mL x 2). The combined organic extracts were dried over Na,SO,, filtered, and concentrated. The residue was chromatographed on silica gel eluting with EtOAc to give first compound Example 19¢ (450 mg, 50%) followed by Example 19d (260 mg, 29%). Physical data for Example 19c: R, 0.47 (EtOAc, silica gel). mp 96 °C. 'H
NMR (300 MHz, CDCL) 6 7.93 (d, J = 8.6 Hz, 2H), 7.81 (d, ] = 8.6 Hz, 2H), 7.31-7.17 (m, 6H), 4.23 (t,] = 4.5 Hz, 2H), 4.03 (t,] = 4.5 Hz, 2H), 4.00 (s, 2H), 3.05 (s, 3H); “C
L NMR (75 MHz, CDCl,) 6 147.7, 139.9, 139.1, 138.8, 131.8, 128.6, 128.3, 128.0, 127.4, 126.3, 118.6, 61.6, 54.0, 44.4, 30.7; mass spectrum (API-TIS) m/z 357 (M+H). Anal. : calcd for C,H, N,O,S: C, 64.02, H, 5.66; N, 7.86, S, 9.00. Found: C, 63.80; H, 5.76; N, 8.10; S, 8.98. Physical data for Example 19d: R; 0.38 (EtOAc, silica gel). mp 68 °C. "H NMR (300 MHz, CDCL) 8 7.99 (d, J = 8.2 Hz, 2H), 7.51 (d, J = 8.2 Hz, 2H), 7.41 (s,
tt WO 01/45703 PCT/US00/35014 1H), 7.25-7.14 (m, 3H), 7.06 (d, J = 7.2 Hz, 2H), 4.07 (t, J = 4.6 Hz, 2H), 3.93 (t,] = 4.6
Hz, 2H), 3.72 (s, 2H), 3.09 (s, 3H); °C NMR (75 MHz, CDCL,)-6 140.5; 140:3; 139.6, . 139.5,135.3, 130.9, 128.3, 128.1, 127.5, 126.0, 119.1, 61.3, 51.1, 44.2, 29.8; mass spectrum (API-TIS) m/z 357 (M+H). Anal. calcd for C,H, N,0,S: C, 64.02, H, 5.66; . 5 N, 7.86, 5, 9.00. Found: C, 64.18; H, 5.87; N, 7.79; S, 8.94. 19e. 4-(Methylsulfonyl)-1-{1-[2-(nitrooxy)ethyl]-4-benzylpyrazol-5-yljbenzene
Fuming HNO, (90%, 1 mL) was added to Ac,O (5 mL) at 0 °C, and the resulting mixture was stirred for 10 minutes. The product of Example 19d (235 mg, 0.66 mmol) in EtOAc (6 mL) was added, and the solution was stirred at 0 °C for 5 min. The mixture was poured into ice-cooled saturated NaHCO, (10 mL), extracted with EtOAc (2 X 20 mL). The combined organic extracts were repeatedly washed with brine, dried over Na,SO,, filtered, and concentrated to afford the title product as oil (259 mg, 96%). 'H NMR (300 MHz, CDCl.) $8.02 (d, J = 8.4 Hz, 2H), 7.47 (d,] = 8.4 Hz, 2H), 7.24-7.18 (m, 4H), 7.06 (m, 2H), 4.77 (t,] = 5.0 Hz, 2H), 4.31 (t,] = 5.0
Hz, 2H), 3.72 (s, 2H), 3.10 (s, 3H); mass spectrum (API-TIS) m/z 402 (M+H).
Example 20: 4-{1-Cyclohexyl-3-[(nitrooxy)methyl]pyrazol-5-yl}-1-methylsulfonyl) . benzene | : 20a. Methyl (2Z)-2-hydroxy-4-(4-methylthiophenyl)-4-oxobut-2-enoate Rg
Dimethyloxalate (26 g, 180.7 mmol) was added to a stirred suspension of x sodium methoxide (9.75 g, 180.7 mmol) in dry toluene (200 mL) at 0 °C. The white : suspension was stirred for 15 min at 0 °C. A solution of 4’- (methylthio)acetophenone (15 g, 90.4 mmol) in dry toluene (150 mL) was then added dropwise over 15 min giving a yellow suspension which was stirred for 2 hours at room temperature. The thick yellow suspension was transferred to a 2 liter flask and stirred vigorously with 10% HCl (250 mL) and EtOAc (200 mL) to dissolve all the solids present. The organic layer was separated and the aqueous layer was extracted with EtOAc (100 mL). The combined organic extracts were washed with water (250 mL), dried over Na, SO, and the solvent was evaporated ' under reduced pressure to give thick brown oil. The brown oil was dissolved in
CH,C], (25 mL) and hexane (125 mL) and left in a freezer at —20 °C for 16 hours to ) give the title compound (18 g, 79%) as orange color solid. mp 81 °C. "H-NMR (300
MHz, CDCl) 67.83 (d, J = 8.6 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 6.97 (s, 1H), 3.89 (s, 3H), 2.47 (s, 3H); “C-NMR (75 MHz, CDCL); mass spectrum (API-TIS) m/z 253 i. 136 te WO 01/45703 PCT/US00/35014 (MH") 20b. Methyl-1-cyclohexyl-5-(4-methylthiephenyl)pyrazole-3-carboxylate. . A mixture of the product of Example 20a (1.98 g, 7.8 mmol) and cyclohexylhydrazine hydrochloride (1.54 g, 10.2 mmol) in methanol (40 mL) was + 5 heated at 70 °C for 3 hours and cooled to room temperature. The mixture was made basic with 10% Na,CO, and extracted with EtOAc (3 x 25 mL). The organic extracts were dried over Na, SO, and the solvent was evaporated under reduced pressure to give a thick oil. The oil was dissolved in CH,CL, (4 mL) and hexane (20 mL) and left in a freezer at — 10 °C for 16 hours to give the title compound (2.2 g, 85%) asa white solid. mp 84 °C. ‘H-NMR (300 MHz, CDCL) 8 7.33 (d, ] = 8.3 Hz, 2H), 7.26 (d, J = 8.3 Hz, 2H), 6.76 (s, 1H), 4.08—4.13 (mult, 1H), 3.93 (s, 3H), 2.54 (s, 3H), 2.07-2.20 (mult, 2H), 1.80-1.95 (mult, 4H), 1.62-1.72 (mult, 1H), 1.20-1.30 (mult, 3H); "C-NMR (75 MHz, CDCL) 5 163.1, 143.6, 142.3, 140.1, 129.4, 126.4, 126.2, 108.8, 58.7, 51.9, 33.1, 25.5, 24.8, 15.3; mass spectrum (API-TIS), m/z 331 (MH").
Anal. calcd for C,H, N,0,S: C, 65.43; H, 6.71; N, 8.48; S, 9.70 Found: C, 65.28; H, 6.66; N, 8.47; S, 9.61. 20c. 1-Cyclohexyl-5-(4-methylthiophenyl)pyrazole-3-yljmethan-1-ol.
A solution of lithium aluminum hydride (2 mL at 1 M, 2 mmol) was added to a stirred solution of the product of Example 20b (0.7 g, 2.1 mmol) in THF (15 mL) at 0 °C. The resulting clear solution was stirred at room temperature for 1 hour.
Solid Na,50,.10H,O (2 g) was added in small portions with stirring until a thick precipitate formed. Methanol in CH,CL, (10%, 50 mL) was added and the mixture was filtered. The solid was washed with additional methanol in CH,CL, (10% , 50 mL) and the combined filtrates were evaporated to give the title compound (0.61 g, 95%) as a white solid. mp 97 °C. "H-NMR (300 MHz, CDCL) § 7.31 (d,] = 8.3 Hz, 2H), 7.24 (d,] = 8.3 Hz, 2H), 6.20 (s, 1H), 4.71 (d, J = 4.8 Hz, 2H), 4.00—4.15 (mult, 1H), 2.53 (s, 3H), 1.65-2.10 (mult, 7H), 1.15-1.30 (mult, 3H); “C-NMR (75 MHz,
CDCl,) § 151.0, 143.2, 139.3, 129.3, 127.5, 126.3, 104.1, 59.0, 57.7, 33.2, 25.6, 25.1, 15.4; 4 mass spectrum (API-TIS) m/z 303 (MH). 20d. 4-[1-Cyclohexyl-3-(hydroxymethyl)pyrazol-5-yl]-1-(methylsulfonyl)benzene ' The product of Example 20c (0.6 g, 2.0 mmol) was dissolved in a mixture of
MeOH (20 mL) and water (8 mL) and cooled to 0 °C. Solid oxone (3 g) was added and the resulting suspension was stirred at 0 °C for 1hr. Water (25 mL) and 15%
i WO 01/45703 PCT/US00/3501+4
NH,OH (25 mL) were added. The mixture was extracted with EtOAC (3 x 25 mL) and the organic extracts were dried over Na,SO,. The-solvent was evaporated . under reduced pressure to give white solid which was recrystallized from CH,CL (5 mL) and hexane (20 mL) to give the title compound (0.62 g, 94%) as a white solid. . 5 mp 148 °C. "H-NMR (300 MHz, CDCL,) 8 8.03 (d, J = 8.3 Hz, 2H), 7.56 (d, J = 8.3 Hz, 2H), 6.31 (s, 1H), 4.73 (s, 2H), 3.90-4.10 (mult, 1H), 3.13 (s, 3H), 2.45 (s, 1H, OH), 1.66-2.05 (mult, 7H), 1.10~1.25 (mult, 3H); "C-NMR (75 MHz, CDCL,) 8 151.4, 141.7, 140.4, 136.5, 129.7, 127.9, 105.0, 59.0, 58.2, 44.4, 33.3, 25.6, 25.0; mass spectrum (API
TIS), m/z 335 (MH). 20e. 4-{I-Cyclohexyl-3-(nitrooxy)methyl]pyrazol-5-yl}-1-(methylsulfonyl)benzene
Fuming HNO, (0.76 mL, 18 mmol) was added to Ac,0 (2.7 mL, 28.8 mmol) at 0 °C via syringe and stirred for 5 min at 0 °C. The mixture was then transferred with a pasteur pipette to a stirred suspension of the product of Example 20d (1.2 g, 3.6 mmol) in EtOAc (40 mL) at room temperature and the mixture was stirred for 45 minutes at room temperature. Cold saturated NaHCO, (40 mL) was added and shaken well in a separatory funnel. The organic layer was separated and dried over Na,SO,. The solvent was evaporated under reduced pressure to afford a co viscous oil which was dissolved in CH,CL, (5 mL) and hexane (25 mL). The : resulting clear solution was left in a freezer at -10 °C for 4 hours to give title 2 compound (1.05 g, 77%) as a yellow solid. mp 104 °C. "H-NMR (300 MHz, CDCl) : 88.05 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 6.39 (s, 1H), 5.50 (s, 2H), 3.95-4.10 (mult, 1H), 3.13 (s, 3H), 1.60-2.10 (mult, 7H), 1.15-1.30 (mult, 3H); “C-NMR (75
MHz, CDCL) 6 143.1, 142.1, 140.7, 136.0, 129.8, 127.9, 107.3, 68.6, 58.6, 44.4, 33.3, 25.5, 25.0; mass spectrum (API-TIS) m/z 380 (MH"). Anal. caled for C,H, N,O.S: C, 53.81; H, 5.58; N, 11.07; S, 8.45 Found C, 53.55; H, 5.55; N, 10.83; S, 8.36.
Example 21: Assay for Ovine COX-1 and COX-2 activity
The ovine COX-1 and COX-2 activities and the measurement of the prostaglandin products synthesized were performed using the COX Inhibitor ' Screening Assay (Cayman Chemical, Ann Arbor, MI, which also contained the
Prostaglandin Screening EIA Kit, used for prostaglandin quantification). The test ’ compounds were dissolved at 50 times the highest final reaction concentration in
DMSO or any other suitable solvent as stock solutions. These stock solutions were then diluted in the same solvent. Eight glass test tubes (13 x 100 mm) were placed i 138 in a 37 °C water bath. To each test tube was added 950 pL of reaction buffer (0.1 M
Tris-HCl, pH 8.0, containing 5 mM EDTA, and 2 mM phenol), 10-4L of 100-M- heme ) solution, and 10 pL (5 units) of either ovine COX-1 or COX-2 and the resulting mixture was incubated with the enzyme for 2 minutes. Twenty pL of the solvent + 5 was added to one tube (100% initial activity or solvent control) and 20 pL of each dilution of the test compound was added to one tube each. Each tube was vortexed immediately after the addition. The enzyme was incubated with the inhibitor for 3.5 minutes at 37 °C. The enzymatic reaction was then initiated by the addition of pL of freshly prepared 10 mM arachidonic acid (neutralized with KOH), 0 vortexed and then incubated for 2 minutes at 37 °C. The reaction was terminated by the addition of 50. uL of 1 M HCI, vortexed and placed at room temperature.
One hundred microliters of a saturated stannous chloride solution (50 mg/mL of 0.1 M HCI) was added and the reaction mixture was allowed to stand at room temperature for at least 5 minutes.
The prostaglandins (PG) produced in the reactions were assayed, after a 2,000- fold dilution, using the Prostaglandin Screening EIA Kit (Cayman Chemical,
Ann Arbor, MI). The assay contains an antibody with broad specificity for all the prostaglandin families (PGF, PGE, PGD, and thromboxane B-type) synthesized in the COX-1/COX 2 reactions. The synthesized prostaglandin competes with a PG- : tagged acetylcholine esterase tracer for binding to the PG antibody. Binding of synthesized PG lowers the colorimetric development of the Ellman’s Reagent (computed as %B/B,). The actual amount of synthesized PG was interpolated from a standard curve using known amounts of supplied prostaglandin E2 (PGE,) (PGE, concentration vs. %B/B,). The data generated were the mean + standard deviation of triplicate wells in the EIA for a single reaction at a given inhibitor concentration.
A plot of % of control (i.e., the solvent control without inhibitor) vs. test compound inhibitor concentration for both isoenzymes was used to determine the IC,, ‘s for
COX-1 and COX-2 for that test compound. The IC, for the compounds are given in ' Table 1.
TABLE 1 1C,, VALUES FOR-COX-1 and -COX-2
IC, (uM) IC, (uM)
The NSAID, indomethacin, did not show selectivity for either COX-1 or
COX-2. Celecoxib, a selective COX-2 inhibitor, used as a control, was selective for :
COX-2. The results show that the nitrosated compounds (i.e., Examples 1b, 2b and 5b) have similar COX-2 selectivity as their parent non-nitrosated compound (i.e., 8
Example 1a, 2a and 5a respectively). Hence, nitrosation did not effect the COX-2 inhibition properties. The results show that the nitrosylated compound (i.e.,
Example 3g) was not as potent as the parent non-nitrosylated compound (i.e.,
Example 3e). The nitrosylation of the sulfonamide group on the parent COX-2 inhibitor probably effected the COX-2 inhibition properties of the nitrosylated compound.
Example 22: Assay for Human COX-1 and COX-2 activity
The human COX-1 and COX-2 activities and the measurement of the prostaglandin products synthesized were performed using the COX Inhibitor
Screening Assay (Cayman Chemical, Ann Arbor, MI, which also contained the . Prostaglandin Screening EIA Kit, used for prostaglandin quantification). The test compounds were dissolved at 50 times the highest final reaction concentration in
DMSO or any other suitable solvent as stock solutions. These stock solutions were then diluted in the same solvent. Eight glass test tubes (13 x 100 mm) were placed i 146 in a 25 °C water bath. To each test tube was added 950 pL of reaction buffer (0.1 M
Tris-HCI, pH 8.0, containing 5 mM EDTA, and 2 mM phenol), 10-4L of 100-M heme . solution, and 10 pL (5 units) of either human COX-1 or COX-2 and the resulting mixture incubated with the enzyme for 2 minutes. Twenty pL of the solvent was added to one tube (100% initial activity or solvent control) and 20 pL of each dilution of the test compound was added to one tube each. Each tube was vortexed immediately after the addition. The enzyme was incubated with the inhibitor for 20 minutes at 25 °C. The enzymatic reaction was then initiated by the addition of 10 nL of freshly prepared 10 mM arachidonic acid (neutralized with KOH), vortexed and then incubated for 2 minutes (or, in some cases as indicated, 30 seconds) at 37 °C. The reaction was terminated by the addition of 50 pL of 1 M HCl, vortexed and placed at room temperature. One hundred microliters of a saturated stannous chloride solution (50 mg/mL of 0.1 M HCI) was added and the reaction mixture was allowed to stand at room temperature for at least 5 min.
The prostaglandins (PG) produced in the reactions were assayed, after a 2,000- fold dilution, using the Prostaglandin Screening EIA Kit (Cayman Chemical,
Ann Arbor, MI). The assay contains an antibody with broad specificity for all the h prostaglandin families (PGF, PGE, PGD, and thromboxane B-type) synthesized in the COX-1/COX 2 reactions. The synthesized prostaglandin competes with a PG- tagged acetylcholine esterase tracer for binding to the PG antibody. Binding of synthesized PG lowers the colorimetric development of the Ellman’s Reagent (computed as %B/B,). The actual amount of synthesized PG was interpolated from a standard curve using known amounts of supplied prostaglandin E2 (PGE,) (PGE, concentration vs. %B/B,). The data generated were the mean + standard deviation of triplicate wells in the EIA for a single reaction at a given inhibitor concentration.
A plot of % of control (i.e., the solvent control without inhibitor) vs. test compound inhibitor concentration for both isoenzymes was used to determine the IC;, ’s for
COX-1 and COX-2 for that test compound, when IC's were calculated. The % ’ inhibition for selected concentrations of inhibitors tested are given in Table 2.
TABLE 2
Yo INFHBITION-OF HHUMAN-COX-1 AND-COX-2 (% at 100 uM) (% at 10 uM)
Bampeza | 0 [0 es
Bamps | 0 | wo
Bamplesa | ow | er
Bampleve | oo | iw
Bampleoe | 0 | x a = Ovine COX-1 b = 30 second incubation with arachidonic acid substrate
The results show that the nitrosated compounds (i.e., Examples 2b, 5b, 19e ’ and 20e) have similar or slightly improved COX-2 selectivity compared to their parent non-nitrosated compound (i.e., Example 2a, 4a, 19d and 20d, respectively).
Hence, nitrosation did not effect the COX-2 inhibition properties and might g improve the COX-2 inhibition properties.
Example 23: Preparation of rat aortic smooth muscle rings
Male Sprague-Dawley rats (Charles River Laboratories (Wilmington, MA) : were euthanized by intraperiton injection of a high dose of sodium pentobarbitone (80-100 mg/kg). The thoracic aorta was rapidly excised and immediately placed in a Petri dish containing warm (37 °C) oxygenated (95% O, and 5% CO,) Krebs buffer (composition per millimolar: NaCl (119); KCl (4.69); CaCL.H,O (2.52); MgSO,.7H,0 (0.57); NaHCO, (25); Nat,PO,.H,0 (1.01) and glucose (11.1). Under a stereoscopic dissecting microscope, the aorta was cleaned, freed from adhering fat and connective tissues. The tissue was cut into ring segments, each approximately 2-3 . mm in length.
For experiments to measure relaxation of the tissue under various conditions, a stainless steel tissue holder and an U-shaped stainless steel wire were inserted into the lumen of the aortic ring. The tissue holder anchored the ring at a 142 the bottom of the organ bath whereas the end of the U-shaped steel wire was tied with fine silk thread so that it connected to the FT-202 transducer. The tissue . holder and the steel wire along with the aortic ring were then suspended in a 5-mL double-jacketed temperature-controlled glass organ bath (Radnoti Glass ‘ 5 Technology, Inc., Monrovia, CA) filled with fresh Kreb’s buffer. A mixture of 95%
O, and 5% CO, was bubbled through a porous sintered disc at the bottom of the bath. The rings were given an initial resting tension of 1.5 g and the preparation was allowed to equilibrate at the initial tension for about 90 minutes. During this equilibration period, the bath fluid was changed every 15 minutes and replaced with fresh prewarmed (37 ‘C) Kreb’s buffer. The isometric tension of the aortic muscle at rest and its response to different stimuli were recorded on a Power
Macintosh 6100 computer via a MacLab 8/S computer interface (CB Sciences, Inc,
Milford, MA) after an initial amplification through a low-noise ETH-400 bioamplifier (CB Sciences, Inc, Milford, MA). Contractile responsiveness of the tissue strips was established with 10 uM phenylephrine and the strips were incubated with the drug for 20 minutes to establish a steady level of contraction.
To test the relaxation effects, test compounds were added to the phenylephrine- precontracted strips in the tissue bath at cumulative concentrations of 0.1 uM to 0.1 mM. Concentration of test compounds was increased only after relaxation at the previous concentration had reached a plateau level. :
Example 24: Relaxation of aortic smooth muscle ring by Example 1 :
The tissue was prepared according to Example 23. The percent contraction of phenylephrine-contracted aortic smooth muscle rings induced by isosorbide dinitrate (ISDN), Example 1a and Example 1b (nitrate) was measured. Fig. 1 shows that the parent non-nitrosated compound, Example 1a, did not relax the aortic ring. The nitrosated compound, Example 1b, induced the relaxation of the aortic ring. The observed relaxation was more potent than that obtained by the nitrate compound, isosorbide dinitrate. : Example 25: Relaxation of aortic smooth muscle ring by Example 2
The tissue was prepared according to Example 23. The percent contraction of phenylephrine-contracted aortic smooth muscle rings induced by isosorbide dinitrate (ISDN), Example 2a and Example 2b (nitrate) was measured. Fig. 2 shows that the parent non-nitrosated compound, Example 2a, did not relax the i WO 01/45703 PCT/US00/3501+4 aortic ring. The nitrosated compound, Example 2b, induced the relaxation of the aortic ring. The ob served relaxation was similar to that obtained by the nitrate . compound, isosorbide dinitrate.
Example 26: Relaxation of aortic smooth muscle ring by Example 3 + 5 The tissue was prepared according to Example 23. The percent contraction of phenylephrine-contracted aortic smooth muscle rings induced by S- nitrosoglutathione (GSNO), Example 3e and Example 3h (nitrosothiol) was measured. Fig. 3 shows that the parent non-nitrosylated compound, Example 3e, did not relax the aortic ring. The nitrosylated compound, Example 3h, induced the relaxation of the aortic ring. The observed relaxation was similar to that obtained by the nitrosothiol compound, S-nitrosoglutathione.
Example 27: Relaxation of aortic smooth muscle ring by Example 20
The tissue was prepared according to Example 23. The percent contraction of phenylephrine-contracted aortic smooth muscle rings induced by isosorbide dinitrate (ISDN), Example 20d and Example 20e (nitrate) was measured. Fig. 4 shows that the parent non-nitrosylated compound, Example 20d, did not relax the aortic ring. The nitrosated compound, Example 20e, induced the relaxation of the aortic ring. The observed relaxation was similar to that obtained by the nitrate compound, isosorbide dinitrate.
Example 28: Anti-inflammatory paw edema test for Example 2
The carrageenan-induced rat paw edema test was used to measure antiinflammatory activity. The paw edema test was performed according to the method of Winter et al, Proc. Soc. Exp. Biol. Med. 111: 544-547, 1962. Male Sprague-
Dawley rats (200-250 g) were fasted for 24 hours with water ad libitum. The rats were dosed intragastrically with test compounds in a volume of 5 mL /kg. One hour after dosing the paw volume was measured. Then each rat received a subplantar injection of 50 ul of 1% suspension of carrageenan. Three hours later, the paw volume was measured and compared with the initial volume measured ‘ immediately after carrageenan injection. The increase in paw volume is presented as the mean + SEM for 5 rats per group. Data were analyzed by performing an
ANOVA test followed by a Student-Keuls post hoc test.
Figure 5 shows that the parent non-nitrosated compound Example 2a, the nitrosated compound Example 2b and Celecoxib all reduced the paw volume and,
hence, these compounds have antiinflammatory activity. Thus, nitrosation did not effect the COX-2 inhibition properties of the compounds. -- -
The disclosure of each patent, patent application and publication cited or described in the present specification is hereby incorporated by reference herein in » 5 its entirety.
Although the invention has been set forth in detail, one skilled in the art will appreciate that numerous changes and modifications can be made to the invention, and that such changes and modifications can be made without departing from the spirit and scope of the present invention.
Claims (1)
- CLAIMS What is claimed is: :1. A compound of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (IX), formula (X), formula (XI), : 5 formula (XI), formula (XIII), formula (XIV), formula (XV) or formula (XVI), or a pharmaceutically acceptable salt thereof: wherein the compound of formula (I) is: R R" =Tp . / R2 a XI . wherein: ) when side b is a double bond, and sides a and c are single bonds, -X-Y'-Z'- is: (a) -CRYR’)-CR*(R*)-CR(R’)~; (b) -C(O)-CR'R")-CR(R")-; (c) -CRY(R")-CR*(R")-C(O)~; (d) ~(CR*(R™)),-O-C(0)-; (e) -C(0)-O-(CR°R™),; (f) - CR'(R*")-NR*-CR’(R*)-; (g) -CR’(R™)-NR*-C(O)-; (h) -CR*=CR"-S-; : (i) -5-CR*=CR"-; (j) -S-N=CR*-; : (k) -CR*=N-S-; (1) -N=CR*-O-; (m) -O-CR’=N-; I 146 i i WO 01/45703 PCT/US00/35014 (n) -NR*-CR*=N-; (0) -N=CR"S-; : (p) -S-CR*=N-; (9) -C(O)-NR*-CR*(R™)-; . 5 (r) R'N-CR°=C R*; (s) -CR*=CR>-NR’*; (t) -O-N=CR*; (u) -CR*=N-O-; (v) -N=N-S-; 0 (w) -S-N=N-; (x) -R°N-CR*=N-; (y) -N=CR*NR>; (z) -R*N-N=N-; (aa) -N=N-NR’-; (bb) -CRY(R*)-O-CR(R™)-; (cc) -CRY(R*)-S-CR’(R*)-; : (dd) -CRY(R")- C(O)-CR’(R*)-; (ee) -CR(RY)-CR(R*)-C(S)-; (ff) -(CR’(R™)),-O-C(S)-; 0 (88) -C(S)-O-(CR'(R")),~ (hh) (CR°(R)),-NR*-C(S)-; (ii) -C(S)-NR-(CR’(R™)),~ (ji) ~(CR°(R™)),-S-C(O)-; ) (kk) -C(O)-5-(CR°(R™)),~; 5 (11) -O-CR'=CR’-; (mm) -CR*=CR*-O-; (nn) -C(O)- NR>-S-; (00) -5-NR*-C(O)-; (pp) -C(O)-NR*-O-; (qq) -O-NR-C(0)-; (rr) -NR’-CR'=CR’~; (ss) -CR*=N-NR’-; (tt) -NRN=CR*;i ’ WO 01/45703 PCT/US00/35014 (uu) -C(O)-NR-NR’; (vv) -NR-NR>-C(O)-; . (ww) -C(O)-O-NR>; (xx) -NR*-O-C(0)~; . 5 (yy) -CRR*CRR%; (zz) -C(O)-CR'R*- (aaa) -CR'R*-C(O)-; (bbb) -C(S)-CR'R*-; (ccc) -CRRE-C(S)-; 0 (ddd) -C(=NR*)-CR'R"; or (eee) -CR'R*-C(=NR%)-; when sides 4 and c are double bonds and side b is a single bond, -X*-Y-Z'- is: (a) =CR*-O-CR’=; (b) =CR-NR-CR’=; (c) =N-S-CR’=; (d) =CR*-S-N=; : (e) =N-O-CR'=; : (f) =CR*-O-N=; (8) =N-5-N=; 0 (h) =N-O-N=; (1) =N-NR-CR'=; (j) =CR“NR*-N=; (k) =N-NR-N=; (1) =CR*-S-CR’=; or 5 (m) =CR*-CR'(R*)-CR’=; R'is: (a) -5(0) CH; (b) -5(0),-NR’(D"); (c) -5(0),-N(D")-C(0)-CF;; (d) -S(O)-(NH)-NH(D'); (e) -S(0)-(NH)-N(D")-C(O)-CF;; (f) -P(O)(CH,NH(D"); (8) -P(O)CH,),;(h) -C(S)-NH(D"); (i) -S(O)NH)CH,; (j) -P(O)(CH,)OD'; or (k) -P(O)(CH,)NH(D"); . 5 R'is: (a) hydrogen; (b) halogen; : (c) methyl; or (d) CH,OH; 0 R?is: (a) lower alkyl; (b) cycloalkyl; (c) mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently: (1) hydrogen; (2) halo; (3) alkoxy; (4) alkylthio; (6) CN; 0 (6) haloalkyl; (7) lower alkyl; (8) Ny; (9) -CO,D; (10) -CO,-lower alkyl; 5 (11) «(C(R*)(R%),-OD%; (12) ~(C(R’)(R),-O-lower alkyl; (13) lower alkyl-CO,-R’; (14) -OD}; : : (15) haloalkoxy; (16) amino; ) (17) nitro; (18) alkylsulfinyl; or (19) heteroaryl;(d) mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, . 5 optionally, 1, 2, 3, or 4 additional N atoms; wherein the substituents are each independently: (1) hydrogen; (2) halo; (3) lower alkyl; (4) alkoxy; (5) alkylthio; (6) CN; (7) haloalkyl; (8) N,; (9) -C(R°)(R%)-ODY; (10) -C(R’(R")-O-lower alkyl; or (11) alkylsulfinyl; (e) benzoheteroaryl which includes the benzo fused analogs of (d); ; (f) NR” RY; : (g) SR”; (h) -ORY; (i) -RY (j) alkenyl; (k) alkynyl; (1) unsubstituted, mono-, di-, tri- or tetra-substituted cycloalkenyl, wherein the substituents are each independently: (1) halo; (2) alkoxy; . (3) alkylthio; (4) CN; (5) haloalkyl; (6) lower alkyl; (7) N,;a. 150(8)-CO,D"; (9) -CO,-lower alkyl; (10) -C(R®*)(R®)-OD%; (11) -CR*)R")-O-lower alkyl; : 5 (12) lower alkyl-CO,-R"” ; (13) benzyloxy; (14) -O-(lower alkyl)-CO,R%; (15) -O-(lower alkyl)-NR"” R” ; or (16) alkylsulfinyl;(m) mono-, di-, tri- or tetra-substituted heterocycloalkyl group of 5, 6 or 7 members, or a benzoheterocycle, wherein said heterocycloalkyl or benzoheterocycle contains 1 or 2 heteroatoms selected from O, S, or N and, optionally, contains a carbonyl group or a sulfonyl group, and wherein said substituents are each independently:(1) halo;(2) lower alkyl;(3) alkoxy;(4) alkylthio;(4) CN;(6) haloalkyl; (7) Ny;(8) -C(R*)(R")-OD’;(9) -CR®)(R")-O-lower alkyl; or (10) alkylsulfinyl;(n) styryl, mono or di-substituted styryl, wherein the substituent are each independently:(1) halo; (2) alkoxy;: (3) alkylthio;(4) CN;‘ (5) haloalkyl; (6) lower alkyl; (7) Ny oo 151Co WO 01/45703 PCT/USO00/35014 (8) -CO,D’;(9). -CO,-lower alkyl; . (10) -C(R*)(R®)-OD"; (11) -C(R™)(R®)-O-lower alkyl; - 5 (12) lower alkyl-CO,-R*; (13) benzyloxy; (14) -O-(lower alkyl)-CO,R"; or (15) -O-(lower alkyl)-NR"R"”; (0) phenylacetylene, mono- or di-substituted phenylacetylene, wherein the substituents are each independently: (1) halo; (2) alkoxy; (3) alkylthio; (4) CN; (5) haloalkyl; (6) lower alkyl; : (7) N;; (8) -CO,D'; (9) -CO,-lower alkyl; (10) -C(R™)(R*)-OD%; (11) -C(R®*)(R")-O-lower alkyl; (12) lower alkyl-CO,-R*; (13) benzyloxy; (14) -O-(lower alkyl)-CO,R*; or (15) -O-(lower alkyl)-NR”R"; (p) fluoroalkenyl; (9) mono- or di-substituted bicyclic heteroaryl of 8,9 or 10 members, containing 2, 3, 4 or 5 heteroatoms, wherein at least one heteroatom resides on each : ring of said bicyclic heteroaryl, said heteroatoms are each independently O, S and N and said substituents are each independently: ’ (1) hydrogen; (2) halo; (3) lower alkyl; oo 152(4) alkoxy; (5) alkylthio; . (6) CN; (7) haloalkyl; - 5 (8) N,; (9) -C(R’)(R%)-OD"; or : (10) -C(R’)(R°)-O-lower alkyl; (r) K; (s) aryl; (t) arylalkyl; (u) cycloalkylalkyl; (v) -C(O)RY; (u) hydrogen; (v) arylalkenyl; (w) arylalkoxy; (x) alkoxy; (y) aryloxy; : (z) cycloalkoxy; R (aa) arylthio; (bb) alkylthio; (cc) arylalkylthio; or (dd) cycloalkylthio; R’ is: (a) hydrogen; (b) haloalkyl; : (c) CN; (d) lower alkyl; (e) (CRIR)), UV; : OK (g) unsubstituted or substituted: ’ (1) lower alkyl-Q; (2) lower alkyl-O- lower alkyl-Q; (3) lower alkyl-S-lower alkyl-G;(4) lower alkyl-O-Q; (5) lower alkyl-S-Q; . (6) lower alkyl-O-V; (7) lower alkyl-S-V; ‘ 5 (8) lower alkyl-O-K; or (9) lower alkyl-S-K; wherein the substituent(s) reside on the lower alkyl group; (h) (i) alkylcarbonyl;10 . (j) arylcarbonyl; (k) alkylarylcarbonyl; (1) arylalkylcarbonyl; (m) carboxylic ester; (n) carboxamido; (0) cycloalkyl; (p) mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently: ; (1) hydrogen; . (2) halo; (3) alkoxy; (4) alkylthio; (5) CN; (6) haloalkyl; (7) lower alkyl; } B)N,; (9) -CO,D%; (10) -CO,-lower alkyl; (I) HCR)(R)), OD} : (12) (C(R*)(R")),-O-lower alkyl; (13) lower alkyl-CO,R’; ’ (14) -OD%; (15) haloalkoxy; (16) amino;(17) nitro; or (18)-alkylsulfinyl; . (q) alkenyl; (r) alkynyl; (s) arylalkyl; (t) lower alkyl-OD%; (u) alkoxyalkyl; (v) aminoalkyl; (w) lower alkyl-CO,R"; (x) lower alkyl-C(O)NR*(R™); (y) heterocyclicalkyl; or (z) heterocyclic ring-C(O)-; R!, R¥, R°and R” are each independently: (a) hydrogen; (b) amino; (c) CN; (d) lower alkyl; (e) haloalkyl; (f) alkoxy; : (g) alkylthio; ; (h) Q (i) -O-Q; 4) -S-Q x) XK; (1) cycloalkoxy; (m) cycloalkylthio; (n) unsubstituted, mono-, or di-substituted phenyl or unsubstituted, mono-, or di-substituted benzyl, wherein the substituents are each independently: : (1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; (5) CN;(6) haloalkyl; @N,; 6 Q (9) nitro; or (10) amino; (0) unsubstituted, mono-, or di-substituted heteroaryl or unsubstituted, mono-, or di-substituted heteroarylmethyl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1, 2, 3, or 4 additional N atoms; said substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; (5) CN; (6) haloalkyl; (7) Ny (8) -C(R*)(R")-OD%; ; (9) -C(R)(R")-O-lower alkyl; or (10) alkylsulfinyl (p) -CONRO)(RY); (q) - CHLOR®; (r) -CH,OCN; (s) unsubstituted or substituted: (1) lower alkyl-Q; (2) -O-lower alkyl-Q); : (3) -S-lower alkyl-Q3; (4) lower alkyl-O-lower alkyl-Q; (5) lower alkyl-S-lower alkyl-Q; (6) lower alkyl-O-Q; (7) lower alkyl-S-Q;(8) lower alkyl-O-K; (9) lower alkyl-S-K; . (10) lower alkyl-O-V; or (11) lower alkyl-S-V; : 5 wherein the substituent(s) resides on the lower alkyl; (t) cycloalkyl; (u) aryl; (v) arylalkyl; (w) cycloalkylalkyl; (x) aryloxy; (y) arylalkoxy; : (z) arylalkylthio; (aa) cycloalkylalkoxy; (bb) heterocycloalkyl; (cc) alkylsulfonyloxy; (dd) alkylsulfonyl; (ee) arylsulfonyl; (ff) arylsulfonyloxy; : (88) -C(O)R"; (hh) nitro; (ii) amino; (jj) aminoalkyl; (kk) -C(O)-alkyl-heterocyclic ring; (11) halo; (mm) heterocyclic ring; (nn) -CO,D"; (00) carboxyl; : (pp) amidyl; or : (qq) alkoxyalkyl; alternatively, R* and R’ together with the carbons to which they are attached are: (a) cycloalkyl; (b) aryl; or(c) heterocyclic ring; alternatively, R'and R* or R* and R” taken together with the carbon to which } they are attached are: (a) cycloalkyl; or : 5 (b) heterocyclic ring; alternatively, R'and R’, R*and R®, R*and R’, or R*and R® when substituents on adjacent carbon atoms taken together with the carbons to which they are attached are: (a) cycloalkyl; (b) heterocyclic ring; or (c) aryl; R’ and R’ are each independently: (a) hydrogen; (b) unsubstituted, mono- or di-substituted phenyl; unsubstituted,mono- or di-substituted benzyl; unsubstituted, mono- or di-substituted heteroaryl; mono- or di-substituted heteroarylmethyl, wherein said substituents are each independently: ;(1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; (0) CN; (6) haloalkyl; (7) N; (8) -C(R*)(R®)-OD’; or (9) -C(R*)(R®)-O-lower alkyl; (c) lower alkyl; (d) -CH,OR’; : (e) CN; (f) -CHLN; : (g) haloalkyl; (h) -CONR)(R’); (1) halo; or _ 158() -OR? Ris: ) (a) hydrogen; (b) K; or : : 5 ©R; alternatively, R°and R”, R® and R” or R” and R® together with the carbon to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms; optionally containing up to two heteroatoms selected from oxygen, S(O), or NR; R’ is: (a) lower alkyl; (b) lower alkyl-CO,D’; (c) lower alkyl-NHD’; (d) phenyl or mono-, di- or tri-substituted phenyl, wherein the substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy; : (4) alkylthio; (5) lower alkyl-CO,D’; (6) lower alkyl-NHD'; (7) CN; (8) COD’; or : (9) haloalkyl; (e) benzyl, mono-, di- or tri-substituted benzyl, wherein the substituents are each independently: : (1) halo; (2) lower alkyl; (3) alkoxy; . (4) alkylthio; (5) lower alkyl-CO,D’; (6) lower alkyl-NHD'; (7) CN; (8) -CO,D; or oo 159(9) haloalkyl; (f) cycloalkyl; . (8) K; or (h) benzoyl, mono-, di-, or trisubstituted benzoyl, wherein the - 5 substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; (5) lower alkyl-CO,D’; (6) lower alkyl-NHD; (7) CN; (8) -CO,D’; or (9) haloalkyl; R" and R' are each independently: (a) hydrogen; or (b) RY; : R" is: : (a) lower alkyl; (b) cycloalkyl; CL (c) unsubstituted, mono-, di- or tri-substituted phenyl or naphthyl, - wherein the substituents are each independently: : (1) halo; (2) alkoxy; (3) alkylthio; (4) CN; (5) haloalkyl; (6) lower alkyl; (7) N;; | (8)-CO,D; (9) -CO,-lower alkyl; (10) -C(R*)(R")-OD’; , (11) -C(R™)(R®)-O-lower alkyl; i 160.Tr WO 01/45703 PCT/US00/35014 (12) lower alkyl-CO,D’; (13) lower alkyl-CO,R"; (14) benzyloxy; (15) -O-(lower alkyl)-CO,D’; . 5 (16) -O-(lower alkyl)-CO,R"; or (17) -O-(lower alkyl)-NR"R"; (d) unsubstituted, mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or said heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally 1, 2, or 3 additional N atoms, and wherein said substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; (5) CN; (6) haloalkyl; (7) N;; (8) -C(R™)(R®)-OD’; or : (9) -C(R®)(R™)-O-lower alkyl; a (e) unsubstituted, mono- or di-substituted benzoheterocycle, wherein the benzoheterocycle is a 5, 6, or 7-membered ring which contains 1 or 2 heteroatoms independently selected from O, S, or N, and, optionally, a carbonyl group or a sulfonyl group, wherein said substituents are each independently: (1) halo; (2) lower alkyl; (3) alkoxy; : (4) alkylthio; (5) CN; } (6) haloalkyl; (7) N;; (8) -C(R*)(R¥)-OD’; or) ° WO 01/45703 PCT/US00/35014 (9) -C(R*)(R®)-O-lower alkyl; (f)- unsubstituted, mono- or di-substituted-benzocarboeyele, wherein . the carbocycle is a 5, 6, or 7-membered ring which optionally contains a carbonyl group, wherein said substituents are each independently : : 5 (1) halo; (2) lower alkyl; (3) alkoxy; (4) alkylthio; (5) CN; (6) haloalkyl; (7) Ny (8) -C(R®)(R®)-OD’; or (9) -C(R™)(R®)-O-lower alkyl; (g) hydrogen; or h)K R* and R® are each independently: (a) hydrogen; - (b) lower alkyl; or (c) aryl; or R* and R” together with the atom to which they are attached form a : saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms; R" and R" are each independently : (a) hydrogen; or (b) lower alkyl]; or R" and R” together with the atom to which they are attached form a carbonyl, a thial, or a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms; D'is: (a) hydrogen or (b) D; : Dis: . (@) V; or : (b) K; Uis:TT WO 01/45703 PCT/US00/35014 (a) oxygen; (b) sulfur; or : (©) -NR)R-; Vis: : 5 (a) -NO; (b) -NO,; or (c) hydrogen K is “W,-E-(CR JR), -EACRIR)),-W,-(CR)R)),-W-EWACRYR)),U- Vv; wherein aa, b, ¢, d, g, i and j are each independently an integer from 0 to 3; p,X, y and z are each independently an integer from 0 to 10; W at each occurrence is independently: (a) -C(O)- (b) -C(S)-; (© -T-; (d) (CRIR)), (e) alkyl; (f) aryl; (g) heterocyclic ring; ; (h) arylheterocyclic ring, or (i) -(CH,CH)0)~; : E at each occurrence is independently: (a) -T (b) alkyl; (c) aryl; (d) (CRIR), (e) heterocyclic ring; (f) arylheterocyclic ring; or (8) (CHCHO): h is an integer form 1 to 10; q is an integer from 1 to 5; R, and R, are each independently: (a) hydrogen;) ° WO 01/45703 PCT/US00/35014 (b) alkyl; (c) cycloalkoxy; . (d) halogen; (e) hydroxy; : 5 (f) hydroxyalkyl; (g) alkoxyalkyl; (h) arylheterocyclic ring; (i) cycloalkylalkyl; (§) heterocyclicalkyl; (k) alkoxy; (1) haloalkoxy; (m) amino; (n) alkylamino; (0) dialkylamino; (p) arylamino; (q) diarylamino; (r) alkylarylamino; : (s) alkoxyhaloalkyl; (t) haloalkoxy; (u) sulfonic acid; (v) alkylsulfonic acid; (w) arylsulfonic acid; (x) arylalkoxy; (y) alkylthio; (z) arylthio; (aa) cyano; (bb) aminoalkyl; (cc) aminoaryl; : (dd) alkoxy; (ee) aryl; (ff) arylalkyl; (gg) carboxamido; (hh) alkylcarboxamido;© WO 01/45703 PCT/US00/35014 (ii) arylcarboxamido; (jj) -amidyl; - . (kk) carboxyl; (II) carbamoyl; : 5 (mm) alkylcarboxylic acid; (nn) arylcarboxylic acid; (00) alkylcarbonyl; (pp) arylcarbonyl; (qq) ester; (rr) carboxylic ester; (ss) alkylcarboxylic ester; (tt) arylcarboxylic ester; (uu) haloalkoxy; (vv) sulfonamido; (ww) alkylsulfonamido; (xx) arylsulfonamido; (vy) alkylsulfonyl, (zz) alkylsulfonyloxy, (aaa) arylsulfonyl, (bbb) arylsulphonyloxy (ccc) sulfonic ester; (ddd) carbamoyl; (eee) urea; (fff) nitro; or (ggg) -U-V; or R, and R, taken together are: (@) oxo; (b) thial; or : R, and R; taken together with the carbon to which they are attached are: (a) heterocyclic ring; ’ (b) cycloalkyl group; or (c) bridged cycloalkyl group; k is an integer from 1 to 2;cr WO 01/45703 PCT/US00/3501+4 T at each occurrence is independently: (a) a covalent bond, Lo : (b) carbonyl, (c) an oxygen, : 5 (d) -S(O).-; or (e) -NR)R; 0 is an integer from 0 to 2; Qis: (a) -C(O)-U-D’; (b) -CO,-lower alkyl; (c) tetrazolyl-5-yl; (d) -CR)R’)(S-DY; (e) -CR)(R)(O-DY); or (f) -CR)R’)(O-lower alkyl); R, is: (a) alone pair of electron; (b) hydrogen; or (c) lower alkyl; : R, is: ) (a) hydrogen; (b) alkyl; (c) aryl; (d) alkylcarboxylic acid; (e) arylcarboxylic acid; (f) alkylcarboxylic ester; (g) arylcarboxylic ester; (h) alkylcarboxamido; (i) arylcarboxamido; : (§) alkylsulfinyl; (k) alkylsulfonyl; (1) alkylsulfonyloxy, (m) arylsulfinyl; (n) arylsulfonyl; _ 166 to WO 01/45703 PCT/US00/35014 (0) arylsulphonyloxy; (p)_sulfonamido; == = oo oo (q) carboxamido; (r) carboxylic ester; : 5 (s) aminoalkyl; (t) aminoaryl; (0) -CH-CU-V)(R)R); (v) abond to an adjacent atom creating a double bond to that atom; or (w) -(IN,O,-)*M’, wherein M" is an organic or inorganic cation; with the proviso that the compounds of formula I must contain at least one nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of formula (II) is: R! RY Je AN g __72 re” =eI wherein: A-Bis: (a) N-C; (b) C-N; or (c) N-N; when sides d and f are double bonds, and sides e and g are single bonds, XYZ is: (2) =CR-CR*=CR>; (b) =N-CR’=CR*-; (c) =N-CR'=N-;Co WO 01/45703 PCT/USO0/35014 (d) =CR*-N=CR"-; (e)=CR:-N=N-; = . (f) =N-N=CR"-; (8) =N-N=N-; : 5 (h) =CR*-CR’=N-; or (i) =CR*-CR’=N-; R’and R taken together are: (a) RS o ZN(b) So F _ or R” and R’ taken together with the carbon atoms to which they are attached are: (a) cycloalkyl; or (b) heterocyclic ring; R” is: (a) hydrogen; (b) alkylthio; : (c) alkylsulfinyl; (d) alkylsulfonyl; (e) cyano; (f) carboxyl; (g) amino;Co WO 01/45703 PCT/US00/35014 (h) lower alkyl; (i) haloalkyl; - : : () hydroxy; (k) alkoxy; : (1) haloalkoxy; (m) alkylarylalkylamino; (n) aminoalkyl; (0) aminoaryl; (p) sulfonamido; (9) alkylsulfonamido; (r) arylsulfonamido; (s) heterocyclic ring; (t) hydroxyalkyl; or (u) nitro; a is an integer from 1 to 3; when sides ¢ and g are double bonds, and sides d and f are single bonds, XYZ is: (a) -CR*=N-N=; (b) -N=N-CR's; (c) -CR*=N-CR"=; : (d) -N=CR’-N=; (e) -CR'=CR"-N=; (f) -N=CR-CR’=; (8) -CR'=CR’-CR’=; or (h) -N=N-N=; when side g is a double bond, and sides d, e and f are single bonds, -XE-YAZE- is: (a) -C(O)-O-CR's; : | (b) -C(O)-NR-CR'=; (c) -C(O)-S-CR'=; or (d) -CH)R-C(OH)R-N=; when sides d is a double bond, and sides ¢, f and g are single bonds, XYZ is:© WO 01/45703 PCT/US00/35014 (a) =CR*-O-C(O)~; by =CRENR-CO)5—— — Ce eee } (c) =CR*-S-C(O)-; or (d) =N-C(OH)R-C(H)R’>-; ’ 5 when sides fis a double bond, and sides d, e and g are single bonds, “XYZ is: (a) -CH(R*-CR’=N-; or (b) -C(O)-CR'=CR’; when sides e is a double bond, and sides d, f and g are single bonds, XYZ is: (a) -N=CR*-CH(R%)-; or (b) -CR*=CR*-C(O)-; when sides d, e, f and g are single bonds, XYZ is: (a) -C(O)-CR'(R")-C(O)-; RY, RY, RR, RY RY, R® and R” are as defined herein; with the proviso that the compounds of formula II must contain at least one ’ nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of formula (II) is: : ; = AN v3 R2 X* III wherein: Xis: : (a) -C(O)-U-D}; BY: (b) -CH,-U-DY (c) -CH,-C(O)-CH; (d) -CH,-CH,-C(0)-U-D}oo WO 01/45703 PCT/US00/35014 (e) -CH,-O-D’; or H-coH EE — . Yeis: (a) (CR(R*),- UD; (b) -CH,; (c) -CH,OC(O)R’; or (d) -C(O)H; alternatively, X* and Y° taken together are -CR®(R*)-CR*(R®)-; R™ R¥, R® and R¥ are each independently: (a) hydrogen; (b) hydroxy; (0) alkyl; (d) alkoxy; } (e) lower alkyl-OD%; (f) alkylthio; (g) CN; (h) -C(O)R*; or (i) -OC(O)R*; Ris: . (a) hydrogen; (b) lower alkyl; or (c) alkoxy; R® is: (a) lower alkyl; (b) alkoxy (c) unsubstituted, mono-, di- or tri-substituted phenyl or pyridyl, wherein the substituents are each independently: (1) halo; (2) alkoxy; (3) haloalkyl; (4) CN; (3)-CORY (6) lower alkyl;bo WO 01/45703 PCT/US00/35014 (7) -5(0),-lower alkyl; or (8) -OD’; : alternatively, R® and R” or R* and R* taken together are: (a) oxo; ' 5 (b) thial; (c) =CR¥*RY; or (d) =NR™; R* and R” are each independently: (a) hydrogen; (b) lower alkyl; (c) lower alkyl-OD’; (d) CN; or ~~ (e)-C(OR%; R* is: (a) OD} (b) alkoxy; (c) lower alkyl; or (d) unsubstituted, mono-, di- or tri-substituted phenyl or pyridyl, 4 wherein the substituents are each independently: : (1) halo; ; (2) alkoxy; (3) haloalkyl; (4) CN; (5) -C(O)R%; (6) lower alkyl; : (7) -5(O)-lower alkyl; or (8) -OD%; R, RR, RY, R%, U, DD}, 0 and k are as defined herein; with the proviso that the compounds of formula III must contain at least one nitrite, nitrate, thionitrite or thionitrate group.; _ 172I WO 01/45703 PCT/US00/35014 wherein the compound of formula (IV) is: PN R20 Y SN | x RT: AZ | R22 Iv wherein: X* and Z' are each independently: . (@N;or (b) CR*; R” is: (a) -S(O),-CH,; (b) -S(0),NR*(D"); or (c) -5(0),-N(D")-C(O)-CF; R” and R™ are each independently: (a) hydrogen; (b) lower alkyl; (c) alkoxy; (d) alkylthio; (e) haloalkyl; (f) haloalkoxy; (g) CN; (h) -CO,D; (i) -CO,R¥, (j) lower alkyl-O-D’; (k) lower alkyl-CO,D’; . 25 (1) lower alkyl-CO,R"; (m) halo; (n) -O-D; (0) -N,;Co WO 01/45703 PCT/US00/35014 (p) -NO,; (@-NR*D, ; (r) -N(D)C(O)R™; (s) -NHK; ; 5 (t) aryl; (uw) arylalkylthio; (v) arylalkoxy; (w) alkylamino; (x) aryloxy; (y) alkylarylalkylamino; (2) cycloalkylalkylamino; or (aa) cycloalkylalkoxy; R” is: (a) mono-, di- or tri-substituted phenyl or pyridinyl (or the N-oxide thereof), wherein the substituent are each independently: (1) hydrogen; (2) halo; (3) alkoxy; (4) alkylthio; (5) CN; (6) lower alkyl; (7) haloalkyl; (8) N,; (9) -CO,D’; (10) -CO lower alkyl; (11) -C(R*)(R™)-OD’; (12) -OD’; (13) lower alkyl-CO,-R*; or : (14) lower alkyl-CO,-D’; (b) -T-C(R®)(R*)~(C(R*)(R¥))-C(R")(R*)-U-D’;CT WO 01/45703 PCT/US00/35014 (© iN TT Hols no! (d) arylalkyl; or - (e) cycloalkylalkyl; wherein:R" and R” are each independently: (a) hydrogen; or (b) lower alkyl;R®, R* R” R*, R”, R* are each independently:(a) hydrogen; or(b) lower alkyl; or :R® and R”, or R” and R* together with the atoms to which they are attached form a carbocyclic ring of 3, 4, 5, 6 or 7 atoms, or R® and R”are joined to form a ; covalent bond; :Y’ is: (a) CR®R%; (b) oxygen; or (c) sulfur; R” and R” are each independently: (a) hydrogen; (b) lower alkyl; (0) (CH,),OD}; ] (d) halo; or R” and R” taken together are an oxo group; s is an integer from 2 to 4; R}, D', T, U, K and o are as defined herein;with the proviso that the compounds of formula IV must contain at least one nitrite, nitrate, thionitrite or thionitrate group.to WO 01/45703 PCT/US00/35014 wherein the compound of formula (V) is: Lo = CA Ce em » RE i} he n ; — K R3 R® 1 v \ CHs R38 0 = Co \ fx Re RH AY wherein: : XC is: (a) oxygen; or (b) sulfur; RY is: (a) alkoxy; (b) haloalkoxy; : (c) alkylthio; (d) haloalkyl; (e) halo; or } (f) lower alkyl; R” R® R* R* R* and R” are each independently : (a) hydrogen; (b) halo; (c) lower alkyl; . (d) cycloalkyl; (e) haloalkyl; "20 (f) -OD%; (g) -OR%; (h) -SD’;(i) -SR*; : - HSORE ee : (k) -S(O)R; (1) unsubstituted, mono- or di-substituted benzyl, wherein the : 5 substituents are each independently: (1) haloalkyl; (2) CN; (3) halo; (4) lower alkyl; (5) -OR%; (6) SR”; (7) -S(O)R®; or (8) -S(O),RY; (m) phenyl or mono- or di-substituted phenyl, wherein the substituents are each independently: (1) haloalkyl; (2) CN; i (3) halo; (4) lower alkyl; (5) -OR%; (6) -SR*; (7) -S(O)R”; or (8) -S(O),RY; or R* together with R” form an oxo group; or R* together with R* form an oxo group; or R* together with R” form an oxo group; or R* and R® are joined so that, together with the carbon atom to which they are attached, they form a saturated monocyclic ring of 3, 4, 5, 6 or 7 members, and, optionally, contain one heteroatom; or R® and R* are joined so that, together with the carbon atoms to which they are attached, they form a saturated or aromatic monocyclic ring of 3, 4,5, 6 or 7 members; or R® and R* are joined so that, together with the carbon atoms to which they oo 177 ee WO 01/45703 PCT/US00/35014 are attached, they form a saturated or aromatic monocyclic ring of 3,4, 5, 6 or 7 members; or - EE . R* and R” are joined so that, together with the carbon atom to which they are attached, they form a saturated monocyclic ring of 3, 4, 5, 6 or 7 members, and ’ 5 optionally, contain one heteroatom; or R* and R* are joined so that, together with the carbon atoms to which they are attached, they form a saturated or aromatic monocyclic ring of 3, 4,5, 6 or 7 + members; or R* and R” are joined so that, together with the carbon atom to which they are attached, they form a saturated monocyclic ring of 3, 4, 5, 6 or 7 members, and, optionally, contain one heteroatom; R* and R” are hydrogen or R* and R® when taken together are oxo; R®, R" and R” are each independently: (c) hydrogen; (d) halo; (c) lower alkyl; (d) alkoxy; (e) alkylthio; (f) -S(O)-lower alkyl; : (g) haloalkyl; (h) CN; (i) Ny 0) -NO,; : (k) -SCF,; or (1) -OCF;; R®is: (a) lower alkyl; or (b) benzyl, optionally mono- or di-substituted, wherein the substituents are each independently: (1) haloalkyl; (2) CN; (3) halo; or (4) lower alkyl;Te WO 01/45703 PCT/US00/35014 alternatively, X* and U taken together with the carbon atom to which they are attached form a 5-,6--or 7-membered heterocyclic ring; - ~~ - ) n at each occurrence is an integer from 0 to 1; and D', U and K are as defined herein; ’ 5 with the proviso that the compounds of formula V must contain at least one nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of formula (VI) is: I a5 6 R Ty Pr o SN Rr RYVI wherein: X° is: (a) oxygen; (b) sulfur; (c) CH,; (d) -5(0), (e) -NH; or (f) -C(O); Z' is: (@) K; (b) -C(O)CH;; or (c) hydrogen; R® is: (a) lower alkyl; or ere WO 01/45703 PCT/US00/35014 (b) mono-, di-, tri-, tetra- or per-substituted lower alkyl, wherein the substituentis halo; ~~ _ . R¥ is: (a) mono or disubstituted aromatic ring of 5 atoms containing one O, ) 5 S or N atom, and, optionally, 1, 2 or 3 additional N atoms, wherein the substituents are each independently: (1) hydrogen; (2) lower alkyl; (3) halo; (4) -O-lower alkyl; (5) -S-lower alkyl; (6) haloalkyl; (7) -COCH,; or (8) -5(0),-lower alkyl; ] (b) mono or disubstituted aromatic ring of 6 atoms containing 0, 1, 2, 3or4 nitrogen atoms, wherein the substituents are each independently: (1) hydrogen; uy : (2) lower alkyl; (3) halo; : (4) -O-lower alkyl; (5) -S-lower alkyl; (4) -O-haloalkyl; (5) -S-haloalkyl; (6) haloalkyl; (7) CN; (8) -N,; (9) -COCH; (10) -5(O),-lower alkyl; : (11) alkenyl; or (12) alkynyl; ’ (c) cycloalkylalkyl; (d) unsubstituted, mono-, di-, tri-, or tetra substituted phenyl or naphthyl, wherein the substituents are each independently:th WO 01/45703 PCT/US00/35014 (1) halo; DCN; —- F (3) haloalkyl; 4) -N; ’ 5 (5) vinyl; (6) acetylenyl; (7) lower alkyl; (8) alkoxy; (9) haloalkoxy; Lo (10) alkylthio; or (11) haloalkylthio; (e) unsubstituted, mono-, di-, tri-, or tetra substituted benzoheteroaryl, wherein the substituents are each independently: (1) halo; (2) CN; or : (3) haloalkyl; (f) substituted lower alkyl; (g) substituted alkenyl; ) (h) cycloalkyl; or : (i) lower alkyl-O-lower alkyl; . RY is: : (a) -C(O)-lower alkyl; (b) CN; (c) -CO,D’ | (d) -CO,-lower alkyl ester; (e) -C(O)-NHD; (f) -S(O)-lower alkyl; (g) -S(O) lower alkyl; (h) -NO,; (i) haloalkyl; ' G) halo; x) XK; (1) -S(O).NR"R"; orLE WO 01/45703 PCT/US00/35014 (m) -5(O) NR"R”; R®is: LL p (a) hydrogen; or (b) lower alkyl}; or * 5 R” and R” taken together with the atoms to which they are attached form a 5, 6, or 7-membered unsubstituted, mono-, di-, or trisubstituted saturated or unsaturated cyclic ring optionally containing a ~5(O),-group, wherein the substituents are each independently: (a) oxo; (b) lower alkyl; (c) OD'; or (d) =N-OD' R” R", R% R"® K, D' and o are as defined herein; with the proviso that the compounds of formula VI must contain at least one nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of formula (VII) is: 1 y? IN ~ RE XN ~~RE . NE X7 va wherein: X is: (a) oxygen; . (b) sulfur; (c) NR’; (d) -N-O-R* or (e) -N-NR"R;oho WO 01/45703 PCT/US00/35014 Y is: (a) hydrogen, ~~ ~~ ¢ (b) halo; : (c) lower alkyl; ¢ 5 (d) alkenyl; or (e) alkynyl; 7’ is: (a) -C(O); (b) oxygen; (©) (0), (d) -NR”-; or (e) covalent bond; R” is: (a) R%; or (b)R R” and R™ are each independently: (a) hydrogen; . (b) halo; (c) lower alkyl; : (d) aryl; (e) arylalkyl; (f) cycloalkyl; : (g) cycloalkylalkyl; (h) -ODY; (i) lower alkyl-OD’; (j) carboxamido; (k) amidyl; or OK; ‘ R* is: (a) lower alkyl; Vt (b) alkenyl; (c) cycloalkyl; (d) cycloalkylalkyl;(e) aryl; (Harylalkyl; : Co (g) heterocyclic ring; or : ‘ (h) lower alkyl-heterocyclic ring; , 5 R” and R” are each independently: (a) lower alkyl; (b) cycloalkyl; (c) cycloalkylalkyl; Cd aryl (e) arylalkyl; (f) heterocyclic ring; or (8) heterocyclicalkyl; R” is: (a) hydrogen; or (b) lower alkyl; RY, R’, RY, K, D' and o are as defined herein; : with the proviso that the compounds of formula VII must contain at least ) one nitrite, nitrate, thionitrite or thionitrate group. wherein the compound of formula (VIII) is: : R56 1 R55 p2 x Ne x8 rRVIII wherein: ’ Xt is: (a) oxygen; g (b) sulfur; (c) NR; or (d) -CR*R>;Al, A’, A’, and A‘are each independently carbon or nitrogen, with the proviso that at least two of A’, A*, A’, and A’are carbon atoms; = R* is: ’ (a) haloalkylalkyl; gy 5 (b) halo; (c) alkylthio; (d) alkoxy; (e) -NO; (f) CN; (g) lower alkyl-CN; (h) heterocyclic ring; (i) lower alkyl; (j) arylalkyl; (k) cycloalkyl; or (1) phenyl or mono- or di-substituted phenyl, wherein the substituents are each independently: (1) alkylthio; (2) nitro; or (3) alkylsulfonyl; a.R” is: (a) -CO,D%; (b) -C(O)-NR) RY); (c) -CO,- lower alkyl; (d) -C(O)-N(D'}S(0)-CRIR)),-U-V; or (e) -CO lower alkyl-U-V; R* is: (a) hydrogen; (b) phenyl; . (c) thienyl; (d) alkynyl; ¢ (e) alkenyl; or (f) alkyl; Ris:(a) hydrogen; ~__(b) lower alkyl; Co (c) arylalkyl; : ) (d) alkoxy; (e) aryloxy; (f) arylalkoxy; (g) haloalkyl; (h) haloalkoxy; (i) alkylamino; (j) arylamino; (k) arylalkylamino; (1) nitro; (m) sulfonamido; (n) carboxamido; (0) aryl; (p) -C(O)-ary]; or (q) -C(O)-alkyl; alternatively, R and the monocyclic ring radical of which A', A> A® and A* comprise four of the six atoms are: . (a) naphthyl; (b) quinolyl; (c) isoquinolyl; (d) quinolizinyl; (e) quinoxalinyl; or (f) dibenzofuryl; R* and R” are each independently: (a) hydrogen; (b) lower alkyl; ) (c) lower alkyl-phenyl; (d) haloalkyl; (e) halo; (f) -NO,; (8) CN;(h) lower alkyl-CN; (j) alkylthio; or ’ (k) alkenyl; alternatively, R*and R” taken together along with the atoms to which they are attached are cycloalkyl; R,R,R,R,D, U,V, aand p are as defined herein; with the proviso that the compounds of formula VIII must contain at least one nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of formula (IX) is: R! R2 ) wherein: X’ is -C(O)'UD' and Y’ is -CH,-CR’(R*)' UD or X’ is -CH, CR’ (R*) UD" and Y’ is -C(O)UD’; or X’ and Y’ taken together are: (a) -C(O)-O-CRYR")-CR’(R")-; (b) -(CR'(R")),-CR(R’)-CR'(R")-; (c) -C(OHCR'R)),-CR(R)~; (d) -(CR'R")),-CR’(R®)-C(O)-; or (e) -C(O)-CR'(R") -CR°(R%)~; ] wherein X is the first carbon atom of a, b, ¢, d and e; RY, R:, RY, RY, R’, R¥, U, D' and k are as defined herein; . with the proviso that the compounds of formula IX contain at least one nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of formula (X) is:R’ : g J _z10 > I N\\ro A : > 10 "2 Xx wherein: when side h, k, and j are single bonds, and side i and I are a double bond, - Xeyr_ ze. is: (a) ~~ ps i J h N - / . / : or \ i” \ IN R61 : (b) j 10 ~ EN g10 SW cio SN k pid when sides i, k and ] are single bonds, and sides h and j are double bonds, - he Xoylo. zw. is:D2 NE) Ur / Ara _ _ BE k ny Jj XK RON / md when side h and j are single bonds, and side k and i is a single or a double bond, -X"-Y"-Z"- is: (a) SNA \ B10’ or J h P10 p'’(b) 61 od, gh TN k R60 P” is: (a) -N=; (b) -NR*; (c) -O-; or (d)-5- Q"* and Q" are each independently: (a) CR"; or . 15 (b) nitrogen; ALB C10. ja: . (a) -CR*=CR"-CR’=CR’-; (b) -CR'(R)-CR’(R")-CR'(R)-C(O)-; (c) -CR(R")-CR(R°)-C(O)-CR'(R")-;(d) -CR'(R")-C(O)-CR(R*)-CR(R%)-; ~ (e)-C(O)-CRYR)-CR(R’)-CR'R")-; = EE (f) -CR'(R")-CR(R’)-C(O)-; ) (g) -CR(R)-C(O)-CR’(R°); , 5 (h) -C(O)-CR*R-CR(R”) -; (i) -CRYR")-CR*(R)-0-C(O)-; (j) -CR(R)-0-C(O)-CR'(R") -; (k) -O-C(O)-CR‘(R")-CR’(R") -; (1) -CRYR*)-CR’(R’)-C(O)-O-; (m) -CRY(R*)-C(O)-O-CR¥(R°)-; (n) -C(O)-O-CR'(R")-CR¥(R®)-; (0) -CR*(R")-O-C(O)~ (p) -C(O)-O-CR*(R")-; (q) -O-C(O)-CR*(R")-; (1) -CR¥R®)-C(O)-O-; (5) N=CR*-CR*=CR’; (t) -CR'=N-CR‘=CR>-; (u) -CR'=CR*-N=CR’-; (v) -CR*=CR’-CR°=N-; (w) -N=CR-CR*=N-; (x) -N=CR*-N=CR*-; (y) -CR'=N-CR*=N-; (z) -S-CR*=N-; (aa) -S-N=CR’-; (bb) -N=N-NR’- (cc) -CR*=N-S-; (dd) -N=CR*-S-; (ee) -O-CR*=N-; (£6) -O-N=CR-; or (gg) -N=CR"-O-; . ~AY=BD% js: (a) -CR'=CR>-CR’= (b) -CR*R*)-CR*(R’)-CR'(R")-;(c) -C(O)-CR{RY)-CR¥(R’); @)-CRRH-CR®)-CO); oo (e) -N=CR-CR’=; ) (g) -N=N-CR'=; a: (h) -N=N-NR*-; (i) -N=N-N=; j) -N=CR*NR>-; (k) -N=CR*N=; (1) -CR‘=N-NR>; C10 (m) -CR’=N-N=; : (n) -CR*=N-CR’=; (0) -CR*=CR-NR*; (p) -CR*=CR*-N=; (q) -S-CR*=CR’-; (r) -O-CR*=CR’; (s) -CR‘=CR*-O-; (t) -CR*=CR>-S-; (u) -CR'=N-S-; (v) -CR'=N-O-; (w) -N=CR*S-; : } (x) -N=CR-O-; (y) S-CR'=N-; (2) -O-CR=N; (aa) -N=N-5-; (bb) -N=N-O-; (cc) -S5-N=N-; (dd) -O-N=N-; (ee) -CR'=CR’-S; (ff) -CR(R*)-CR°(R%)-S-; (88) -CR'(R")-CR’(R")-O-; . (hh) -S-CRY(R*)-CR*(R%)~; or (ii) -O-CRARY)-CR*(R)-; © R“and R” are each independently:(a) lower alkyl; (b) haloalkyl; I (co) alkoxy; } (d) alkylthio; : (e) lower alkyl-OD%; (COOH; (h) ~(CH,) -CO,lower alkyl; : (i) (CH,)-CO,D’; (G) -O-(CH,)S-lower alkyl; (k) -(CH,) -S-lower alkyl; (1) -S(O),-lower alkyl; (m) -(CH,)-NR"R"; or (n) -CONR)R; R, RR, RY, RY RR’, RY, R? R? T, D' and q are as defined herein; with the proviso that the compounds of formula X must contain at least one nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of formula (XI) is: Re2 1 n 63 : Rosey) RES | R® 7 oo" Dn! XI ) wherein: X" is: . (a) oxygen; or (b) CH; Y" is:(a) oxygen; b-H, _ _ SL I _ (c) -N-OD*; (d) -N-O-lower alkyl; (e) -N-O-aryl; (f) -N-C(O)-O-lower alkyl; (8) -N-N(R*)(R’); or (h) -N-N(R%-S(0O),-lower alkyl; R?, R®, R* and R” are each independently: : (a) hydrogen; (b) lower alkyl; (c) alkoxy; (d) halo; (e) CN; (f) OD}; (g) aryloxy; (h) -NR"R%; (i) CF, - () -NO,; (k) alkylthio; (1) -S(O),-lower alkyl; (m) -C(ONR)(R’); (n) -CO,D! (0) -CO,- lower alkyl; or (p) -NR*-C(O)-lower alkyl; R¥is: (a) hydrogen; (b) lower alkyl; . (c) alkenyl; (d) alkoxyalkyl; or . (e) cycloalkylalkyl; R®, R? R”, 0, K and D' are as defined herein; with the proviso that the compounds of formula XI must contain at least one nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of the formula (XI)is: ~~ y12 aT zz ’ FZ 12 X11 wherein: XxX? is: (a) I R60 R70 (b) I or R70 Roe(c) NR; Y¥? is:(a) il A, (b) N R72 macadi o . R70 (©) 0 0} SOT p'o(d) 0 p 3 A RE0 R81 (e) -NR”(R™); (f) hydrogen; or eK oo Z2 is: (a) (b) RY; RY is:(a) hydrogen; ()loweralkyl, (c) lower alkyl-OD"; (d) -OD; (e) haloalkyl; or ®) X° Pi R7S 1 end R% is: (a) lower alkyl;(b) halo;(c) alkoxy(d) haloalkyl; (e) alkylthio;(f) haloalkylthio; .(8) -OCH,-(h) unsubstituted, mono-, or di-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or said heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally 1, 2, or 3 additional N atoms, and wherein said substituents are each independently:(1) halo; or (2) lower alkyl . 25 (i) -S(O),-lower alkyl; (j) -S(O),-lower haloalkyl; - (k) amino; (1) alkylamino; : (m) dialkylamino;: (n) -N(H)SO,- lower alkyl; (0) N(H)SO, lower haloalkyl; ~~ EE (p) nitro; (q) cyano; (r) -CO,D% (s) carboxylic ester; (t) lower alkyl-OD’; (q) carboxamide; or (r) -C(O)N(R*)D’; R% is: (a) lower alkyl; : : (b) hydrogen; (c) alkoxy (d) mono-, di-, tri, tetra- or penta-substituted phenyl, wherein the substituent are each independently: (1) hydrogen; (2) halo; ; (3) alkoxy; (4) alkylthio; . (5) -S(O).-lower alkyl; (6) lower alkyl; (7) haloalkyl; (8) -CO,D; (9) -lower alkyl-CO,D’; (10) -OD% (11) -lower alkyl-OD’; or (12) haloalkoxy; (e) mono-, di-, or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a . monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1,2, 3, or 4 additional N atoms; wherein the substituents are each independently: :(1) hydrogen; ~~ (Qhalo; : oo el (3) lower alkyl; (4) alkoxy; (5) alkylthio; (6) aryloxy; (7) arylthio; (8) -CO,D’; (9) -C(O)NH(D") (10) haloalkyl; or (11) -OD%; R” is: (a) lower alkyl; (b) hydrogen; or : (c) mono- or di-substituted phenyl, wherein the substituent are each independently: (1) hydrogen; : (2) halo; (3) alkoxy; (4) haloalkyl; or (5) lower alkyl; R" is: (a) benzoyl, or mono-, or disubstituted benzoyl, wherein the substituents are each independently: (1) halo; (2) lower alkyl; or (3) alkoxy; .(b) benzyl, mono- or disubstituted benzyl, wherein the substituents ] are each independently: (1) halo; (2) lower alkyl; or (3) alkoxy; (c) lower alkyl-pyridinyl, or unsubstituted, mono-, or disubstituted pyridinyl, wherein the substituents are each independently: (2) lower alkyl; or (3) alkoxy; (d) -C(O)-pyridinyl, or mono-, or disubstituted -C(O)-pyridinyl wherein the substituents are each independently: (3) halo; (4) lower alkyl; or (3) alkoxy; (e) hydrogen; (6) aryl; (g) cycloalkyl; (h) cycloalkylalkyl; R™ is: (a) lower alkenyl-CO,D’; or © K R” is unsubstituted or mono substituted lower alkyl, wherein the substituents are each independently: (a) hydroxy; Ek (b) alkoxy; (c) nitro; (c) -NH,; (d) alkylamino; (e) dialkylamino; (f) carboxyl; (g) carboxylic ester; or (h) carboxamide; R™ is: ] (a) hydrogen; (b) lower alkyl; or (c) -C(O)R; R” is: (a) lower alkyl;(b) haloalkyl (c) substituted lower alkyl, (d) cycloalkyl; (e) unsubstituted, mono-, di- or tri-substituted phenyl or naphthyl, wherein the substituents are each independently: : (1) halo; (2) alkoxy; (3) -S(O) lower alkyl; (4) hydroxy; (5) -S(0O) -haloalkyl; (6) lower alkyl; (7) haloalkyl; (8) -CO,D'; (9) -CO,-lower alkyl; : (10) -S(O),NR*D"); (11) -lower alkyl-O-lower alkyl; (12) -CN; : (13) lower alkyl-OD’; (14) arylalkoxy; (15) -C(O)NR¥(D'; or (16) aryl; (f) mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is selected from S, O, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1, 2, 3, or 4 additional N atoms; wherein the substituents are each independently: (1) halo; } (2) alkoxy; (3) -S(O) lower alkyl; . (4) hydroxy; (5) -5(0),-haloalkyl; (6) lower alkyl;(7) haloalkyl; @®cop; (9) -CO, lower alkyl; (10) -S(O),NR*(D'); (11) -lower alkyl-O-lower alkyl; (12) -N(D")S(O),-lower alkyl; (13) lower alkyl-OD’; (14) -N(D")S(O),-haloalky}; (15) -C(O)NR¥D"); or (16) aryl; - Ris: (a) alkyl; (b) substituted alkyl; ’ (c) alkyl-N(D")S(O),-aryl; : (d) substituted alkyl-cycloalkyl; (e) substituted alkyl-heterocyclic ring; or (f) arylalkoxy; R” is: (a) -OD; (b) alkoxy; or (c) -NR"R”; R” and R” are each independently: (a) hydrogen; (b) hydroxy; (c) alkoxy; (d) lower alkyl; or (e) substituted lower alkyl; or R” and R” taken together with the nitrogen to which they are attached form } a heterocyclic ring; R* and R" are each independently: . (a) hydrogen; (b) lower alkyl; or : (c) halo;R® and R* are each independently: (a8 hydrogen;or (b) lower alkyl; or R” and R” taken together with the carbon to which they are attached form a cycloalkyl ring; m is an integer from 0 to 6; DY, RR’, R% K, XC, a, p and o are as defined herein; and with the proviso that the compounds of formula XII must contain at least one nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of formula (XII) is: R x13 To R = y13 \ R oo XII wherein: X* and Y” are each independently: (a) =C(H)-; or (b) =N-; R* is: (a) lower alkyl; (b) lower alkyl-OD'; (c) alkenyl; (d) lower alkyl-CN; (e) lower alkyl-CO,D’; (f) aryl; (g) heterocyclic ring; or . 25 (i) heterocyclicalkyl; R” is: (a) mono-, di- or tri-substituted phenyl, wherein the substituents are each independently: ~~ _(Mhydrogen; ~~ _ (2) halo; (3) alkoxy; (4) alkylthio; (5) CN; (6) haloalkyl; (7) lower alkyl; (8) -CO,D; (9) -CO,- lower alkyl; (10) lower alkyl-OD"; (11) lower alkyl-NR”R"; (12) lower alkyl-CO,D’; or (13) -OD%; (b) mono-, di- or tri-substituted heteroaryl, wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is 5, 0, or N, and, optionally, 1, 2, or 3 additional N atoms; or the heteroarylis a . monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, : optionally, 1, 2, 3, or 4 additional N atoms; wherein the substituents are each . independently: : (1) hydrogen; (2) halo; (3) alkoxy; (4) alkylthio; (5) CN; (6) haloalkyl; (7) lower alkyl; (8) -CO,D’; (9) -CO,-lower alkyl; (10) lower alkyl-OD%; (11) lower alkyl-NR"”R"; (12) lower alkyl-CO,D' ; or (13) -OD;DY, RY, R? and R®, are as defined herein; and ~ with the proviso that the compounds of formula XIII must contain at least one nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of formula (XIV) is: rR Ie jo. A ” 0 NL Xv wherein: X* is: (a) -C(O)-; or (b) -C(S)-; : Y" is: (a) -O-; or . (b) 5+ A¥=B=D" is: (a) -CR*=CR*-CR’=CR’-; (b) -CR(R*)-CR*(R")-C(O)-; (c) -CR'(R*)-C(O)-CR’(R%)-; (d) -C(O)-CRR")-CR'(R’) ~;20 . (e) -CR'(R)-O-C(0)-; (f) -C(O)-O-CR'(R%)—; (g) -O-C(O)-CR(R’) (h) -5-N=CR*-; (i) -O-N=CR*; os (j) -CRYR®)-NR*-C(O)-; (k) -C(O)-NR*-CR*(R’)--;(1) -NR*-C(O)-CR'(R)-; (m) -CR'(R)-S-C(O)-; CLL (n) -C(O)-S-CR(R)-; (0) S-C(O)-CR'(R)-; Cs (p) -CR*=CR*-C(O)-; (q) -C(O)- CR*=CR*; (r) -O-CR*=CR*-; (s) -S-CR*=CR*~; (t) -NR-CR'=CR’-; (un) -S-NR’-C(O)-; (v) -O-NR>-C(O)-; or (w) -NR’-N=CR*; R, RR’, R*, RY R’and R’ are as defined herein; and with the proviso that the compounds of formula XIV must contain at least one nitrite, nitrate, thionitrite or thionitrate group; wherein the compound of formula (XV) is: oo : 215(I . R XV wherein: X* is: (a) C(O); (b) CH, (c) -CH(OD'); (d) -C=N-O-lower alkyl-; _ 25 (e)-O-; (f) -5(0).~ (g) NR”; or(g) covalent bond; Yous (a) aryl; or (b) cycloalkyl; Zz" is: (a) hydrogen;(b) alkyl; (c) haloalkyl; (d) cycloalkyl; _(e) alkoxy; (f) alkylthio; (g) cycloalkylalkylthio; (h) cycloalkylalkoxy;(i) -OD%(j) halo; (k) cyano; : 1) -C(O)OD'; (m) -C(O)-lower alkyl;R* is:(a) hydrogen; (b) lower alkyl; (c) -C(O)-lower alkyl; or (d) K;R', DY, K and o are as defined herein; and with the proviso that the compounds of formula XV contain at least one nitrite, nitrate, thionitrite or thionitrate group;wherein the compound of formula (XVI) is: Cl oo Ll ye. = (0) AX XVI wherein: X* is: (a) EEO R98 . (b) [=i R% Re EN ] \ Gs RY Y* is: (a) hydrogen; (b) halogen; . 15 (c) methyl; or (d) ethyl; Z is:* oo oo ~~ PCT/US00/35014. oo B (2) hydrogen; or (b) methyl; | : _ ”s (a) chloro; or - . | oo : (b) fluores; | oo oo R* and R* are each independently: oT : : (a) hydrogen; or oo (b) fluoro; = - RPis: | So : (a) chloro; N : (b) fluoro; - (c) hydrogen; (d) methyl; SE Co (e) ethyl; | oo oo | of (f) methoxy; (g) ethoxy; or I ; (i) hydroxy; : R*is: (a) chloro; . (b) fluoro; ~~ (c) trifluoromethyl; or : (@ methyl; i R*is: oo (a) lower alkyl; a : | (b) lower alkenyl; oo (c) alkoxy; or : (d) alkylthio; K and X* are as defined herein; and : with the proviso that the compounds of formula XVI must contain at least one nitrite, nitrate, thionitrite or thionitrate group.2. A composition comprising the compound of claim land a - oo pharmaceutically acceptable carrier. © 208 AMENDED SHEETPCT/US00/35014 oo 3, A method for preventing inflammation, pain or fever in a subject comprising - © administering to the subject an effective amount of the composition of claim 2.4. A method for preventing a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a subject comprising administering to the subject an effective amount of the composition of claim 2. oo5. The method of claim 4, wherein the gastrointestinal disorder is an inflammatory bowel disease, Crohn’s disease, gastritis, irritable bowel syndrome, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding ulcer, gastric hyperacidity, dyspepsia, : gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, a bacterial infection, short-bowel (anastomosis) syndrome, or a hypersecretory state associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia.6. Use of a compound of claim 1 in the manufacture of a medicament for facilitating wound healing in a patient in need thereof. :: 7. Use of claim 6, wherein the wound is an ulcer. oo8. Use of a compound of claim 1 in the manufacture of a medicament for treating Co © or reversing renal or other toxicities in a patient in need thereof.S. A method for preventing a disorder resulting from elevated levels of COX-2 - in a subject comprising administering to the subject an effective amount of a compound of claim 1.10. The method of claim 9, wherein the disorder resulting from elevated levels of 'COX-2 is angiogenesis, arthritis, asthma, bronchitis, menstrual cramps, premature labor, tendinitis, bursitis, skin-related condition, neoplasia, ‘inflammation in disease, ophthalmic disorder, pulmonary inflammation, central nervous system disorder, allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, inflammation and/or microbial infection, cardiovascular disorder, urinary and/or urological disorder, endothelial dysfunction, organ or tissue deterioration, activation, adhesion and/or infiltration of neutrophils at the site of inflammation, or platelet aggregation. 209 } AMENDED SHEET® : PCT/US00/35014 : Tt “Fhe-composition-of claim 2;-further comprising a ing-at-least-one-therapeutic-agent;12. The composition of claim 11, wherein the therapeutic agent is a steroid, a nonsteroidal antiinflammatory compound, a 5-lipoxygenase inhibitor, ‘a leukotriene B, receptor antagonist, a leukotriene A, hydrolase inhibitor, a 5-HT agonist, a 3-hydroxy-3- methylglutaryl coenzyme A inhibitor, a H, receptor antagonist, an antineoplastic agent, an : antiplatelet agent, a decongestant, a diuretic, a sedating or non-sedating anti-histamine, an inducible nitric oxide synthase inhibitor, an opioid, an analgesic, a Helicobacter pylori inhibitor, a proton pump inhibitor, an isoprostane inhibitor, or a mixture thereof.13. A method for preventing inflammation, pain or fever in a subject comprising administering to the subject an effective amount of the composition of claim 11. : 14. A method for preventing a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a subject comprising administering to the subject an effective amount of the composition of claim 11.15. The method of claim 14, wherein the gastrointestinal disorder is an inflammatory bowel disease, Crohn’s disease, gastritis, irritable bowel syndrome, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, a bacterial infection, short-bowel (anastomosis) syndrome, or a hypersecretory state associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia. oo 16. Use of the composition of claim 11 in the manufacture of a medicament for facilitating wound healing in a patient in need thereof.17. Use of claim 16, wherein the wound is an ulcer. :18. Use of the composition of claim 11 in the manufacture of a medicament for treating or reversing renal or other toxicities in a patient in need thereof.19.. A method for preventing a disorder resulting from elevated levels of COX-2 in a subject comprising administering to the subject an effective amount of the composition of claim 11. AMENDED SHEET® - IR | oo PCT/US00/35014 =20. The method of claim 19, wherein the disorder resulting from elevated © levels of COX-2 is angiogenesis, arthritis, asthma, bronchitis, menstrual qamps, premature labor, tendinitis, bursitis, skin-related condition, neoplasia, Lo inflammation in disease, ophthalmic disorder, pulmonary inflammation, central nervous system disorder, allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, inflammation and/or microbial infection, cardiovascular disorder, urinary and/or urological disorder, endothelial dysfunction, preservation of organs and tissues, inhibition and/or prevention of activation, adhesion and infiltration of neutrophils at the site of inflammation, or inhibition and/or prevention of platelet aggregation. : 21. © A composition comprising at least one compound of claimlora pharmaceutically acceptable salt thereof, and at least one compound that donates, - transfers or releases nitric oxide, or induces the production of endogenous nitric oxideor endothelium-derived relaxing factor, or is a substrate for nitric oxide22. The composition of claim 21 further comprising a pharmaceutically oo acceptable carrier. | }23. The composition of claim 21, wherein the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric - oxide or endothelium-derived relaxing factor or is a substrate for nitric oxide synthase is an S-nitrosothiol. ] 24. The composition of claim 23, wherein the S-ritrosothiol is S-nitroso- N-acetylcysteine, S-nitresc~captopril, S-nitroso-N-acetylpenicillamine, S-nitroso- homocysteine, S-nitroso-cysteine, S-nitroso-glutathione, or S-nitroso-cysteinyl- glycine. :25. The composition of claim 23, wherein the S-nitrosothiol is: () HESICRIR)SNO; | - () ONSCRIR)uR, cr (i) FLN-CE(COHN-CH)_-CONH-CH(CHSNOM-C(ONH-CH-COH;, wherein mm is an integer from 2 to 20; R, and R, are each independently a | ) hydrogen, an alkyl, a cycloalkoxy, a haleger, 2 hydroxy, an hydroxyalkyl,an alkoxyalkyl, an aryiheterocyclic ring, a cycloalkylalkyl, a heterocyclicalkyl, an } 211 AMENDED SHEET alkoxy, a haloalkoxy, an amino, an alkylamino, a dialkylamino, an arylamino, a diarylamino, an alkylarylamino, an alkoxyhaloalkyl, a haloalkoxy, a sulfonic acid, a sulfonic ester, an alkylsulfonic acid, an arylsulfonic acid, an arylalkoxy, an alkylthio, an arylthio, a cyano, an aminoalkyl, an aminoaryl, an alkoxy, an aryl, an arylalkyl, a carboxamido, a alkylcarboxamido, an arylcarboxamido, an amidyl, a carboxyl, a carbamoyl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarbonyl, an arylcarbonyl, an ester, a carboxylic ester, an alkylcarboxylic ester, an arylcarboxylic ester, a haloalkoxy, a sulfonamido, an alkylsulfonamido, an arylsulfonamido, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfonyl, an arylsulfonyloxy, a carbamoyl, a urea, a nitro, -T-Q-, or (C(R)(R),-T-Q, or R and R, taken together are an oxo, a methanthial, a heterocyclic ring, a cycloalkyl group or a bridged cycloalkyl group; Q is -NO or -NO,; and T is independently a covalent bond, a carbonyl, an oxygen, -S(O),- or -N(R,)R-, wherein o is an integer from 0 to 2, R_ is alone pair of electrons, a hydrogen or an alkyl group; R; is a hydrogen, an alkyl, an aryl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarboxylic ester, an arylcarboxylic ester, an alkylcarboxamido, an arylcarboxamido, an alkylsulfinyl, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfinyl, an ) arylsulfonyloxy, an arylsulfonyl, a sulfonamido, a carboxamido, a carboxylic ester, an aminoalkyl, an aminoaryl, -CH,-C(T-Q)(R )(R), or -(N,O,-) *M’, wherein M" is an organic or inorganic cation; with the proviso that when R, is -CH,-C(T-Q)(R))(R) or E -(N,O,-)*M’; then "-T-Q" can be a hydrogen, an alkyl group, an alkoxyalkyl group, an aminoalkyl group, a hydroxy group or an aryl group.26. The composition of claim 21, wherein the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase is L-arginine, L-homoarginine, N-hydroxy-L-arginine, nitrosated L- arginine, nitrosylated L-arginine, nitrosated N-hydroxy-L-arginine, nitrosylated N- hydroxy-L-arginine, citrulline, ornithine, glutamine, or an arginase inhibitor.27. The composition of claim 21, wherein the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric : . oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase is: (@ a compound that comprises at least one ON-O-, ON-N- or ON-C-PCT/US00/35014 - group; (ii) acompound that comprises at least one O,N-O-, O,N-N-, O,N-S- or -ON-C-growp; ~~ (ii) a N-oxo-N-nitrosoamnine having the formula: .RIR?N-N(O-M¥)-NO, wherein R' and R’ are each independently a polypeptide, an amino acid, a sugar, an oligonucleotide, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted hydrocarbon, or a heterocyclic group, and M’ is an organic or inorganic cation.28. The composition of claim 27, wherein the compound comprising at least one ON-O-, ON-N- or ON-C- group is an ON-O-polypeptide, an ON-N- polypeptide, an ON-C-polypeptide, an ON-O-amino acid, an ON-N-amino acid, an ON-C-amino acid, an ON-O-sugar, an ON-N-sugar, an ON-C-sugar, an ON-O- oligonucleotide, an ON-N-oligonucleotide, an ON-C-oligonucleotide, a straight or branched, saturated or unsaturated, substituted or unsubstituted, aliphatic or aromatic ON -O-hydrocarbon, a straight or branched, saturated or unsaturated, substituted or unsubstituted, aliphatic or aromatic ON-N-hydrocarbon, a straight or branched, saturated or unsaturated, substituted or unsubstituted, aliphatic or aromatic ON-C-hydrocarbon, an ON-O-heterocyclic compound, an ON-N- heterocyclic compound or a ON-C-heterocyclic compound.29. The composition of claim 27, wherein compound comprising at least one O,N-O-, O,N-N-, O,N-5- or O,N-C- group is an O,N-O-polypeptide, an O,N-N- polypeptide, an O,N-S-polypeptide, an ON-C-polypeptide, an O,N-O-amino acid, O,N-N-amino acid, O,N-S-amino acid, an O,N-C-amino acid, an O,N-O-sugar, an O,N-N-sugar, O,N-5-sugar, an O,N-C-sugar, an O,N-O-oligonucleotide, an O,N-N- oligonucleotide, an O,N-5-oligonucleotide, an O,N-C-oligonucleotide, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted O,N-O-hydrocarbon, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted O,N-N- hydrocarbon, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted O,N-S-hydrocarbon, a straight or branched, . saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted O,N-" C-hydrocarbon, an O,N-O-heterocyclic compound, an O,N-N-heterocyclic compound, an O,N-S-heterocyclic compound or an O,N-C-heterocyclic compound. 213 AMENDED SHEET@ PCT/US00/3501430.- —The-composition of claim 21, further comprising at least one therapeutic agent. : 31. The composition of claim 30, wherein the therapeutic agent is a steroid, a nonsteroidal antiinflammatory compound, a 5-lipoxygenase inhibitor, a leukotriene B, receptor antagonist, a leukotriene A, hydrolase inhibitor, a 5-HT agonist, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor, a H, receptor antagonist, an antineoplastic agent, an antiplatelet agent, a decongestant, a diuretic, a sedating or non-sedating anti-histamine, an inducible nitric oxide synthase inhibitor, an opioid, an analgesic, a Helicobacter pylori inhibitor, a proton pump inhibitor, an isoprostane inhibitor, or a mixture thereof. :32. A method for preventing inflammation, pain or fever in a subject comprising administering to the subject effective amount of the composition of claim 21 or 30.33. A method for preventing a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a subject comprising administering to the subject an effective amount of the composition of claim 21 or 30.34. The method of claim 33, wherein the gastrointestinal disorder is an inflammatory bowel disease, Crohn’s disease, gastritis, irritable bowel syndrome, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger- Ellison syndrome, gastroesophageal reflux disease, a bacterial infection, short-bowel (anastomosis) syndrome, or a hypersecretory state associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia. : :35. Use of the composition of claim 21 or 30 in the manufacture of a medicament for facilitating wound healing in a patient in need thereof.36. Use of claim 35, wherein the wound is an ulcer.37. Use of the composition of claim 21 or 30 in the manufacture of a medicament for treating or reversing renal or other toxicities in a patient in need thereof.38. A method for a preventing a disorder resulting from elevated levels of COX-2 in a subject comprising administering to the subject an effective amount of the composition of claim 21 or 30. AMENDED SHEET® . le ) PCT/US00/3501439. The method of claim 38, wherein the disorder resulting from elevated © levels of COX-2 is angiogenesis, arthritis, asthma, bronchitis, menstrual cramps, premature labor, tendinitis, bursitis, skin-related condition, neoplasia, : 5 inflammation in disease, ophthalmic disorder, pulmonary inflammation, central : nervous system disorder, allergic rhinitis, respiratory distress syndrome, endotoxin ; shock syndrome, atherosclerosis, inflammation and/or microbial infection, cardiovascular disorder, urinary and/or urological disorder, endothelial dysfunction, preservation of organs and tissues, inhibition and/or prevention of activation, adhesion and infiltration of neutrophils at the site of inflammation, or = inhibition and/or prevention of platelet aggregation. ) : oo40. A kit comprising at least one compound of claim 1 or a SE B pharmaceutically acceptable salt thereof. : oo oo 41. Akit comprising at least one compound of claim 1 or a oo pharmaceutically acceptable salt thereof, and at least one compound that donates, transfers or releases nitric oxide, or induces the production of endogenous nitric a. oxide or endothelium-cerived relaxing factor, or is a substrate for nitric oxide synthase. | | :42. TheXkit of claim 41, wherein the compound of claim lora pharmaceutically acceptable salt thereof, and the at least one compound that : donates, transfers or releases nitric oxide, induces the production of endogenous : nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase are separate compoerents in the kit or are in the form of a compesitionin N the kit. 43, A ldt comprising at least one compound of claimlora BN N pharmaceutically acceptable salt thereof, and at least one therapeutic agent. 44 The kit cf claim 43, wherein the compound of claim 1 or a pharmaceutically acceptable salt thereof, and the at least one therapeutic agent are : separate components in the kit or are in the form of a compesition in the lit.45. A compound selected from the group consisting of 4-{3H{4- oo chlorophenyl)-3-((nitrooxy)methyl)-3-hyropyrazolyl) benzenesulfonamide, 4- i {5((nitrooxy)methyl)-3-phenylisoxazol-4-yljbenzenesulfonamide, 2-(1-methyl4- (nitresothio)+-piperidyl) ethyl 3N-{(4-{5-methyl-3-phenylisoxazol-4- oo 215 : AMENDED SHEET ylphenyl)sulfonyl}carbamoyl)propanoate, (2-{1-((4-chlorophenyl)methyl)-5- methoxy-2-methylindol-3-yllethyl)nitrooxy, 1-(3-(4-fluorophenyl)-7- - (nitrooxymethyl)(3a-hydroimidazolo(1,2-a)pyridin-2-yl))-4- (methylsulfonyl)benzene, ethyl 6-chloro-8-((nitrooxy)methyl)-2-(trifluoromethyl)- 2H-chromene-3 carboxylate, 2-{1-((4-chlorophenyl)carbonyl)-5-methoxy-2- methylindol-3-y1}-N-(2-methyl-2-(nitrosothio)propyl)acetamide, ethyl (2Z)-3-(4- chlorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-(2-(nitrooxy)ethyl)prop-2-enoate, (2Z)-3-(4-chlorophenyl)-3-(4-(methylsulfonylyphenyl)-2-(2-(nitrooxy)ethyl)prop-2- enoic acid, (2Z)-3-(4-chlorophenyl)-2-(2-hydroxyethyl)-N-(2-methyl-2- (nitrosothio)propyl)-3-(4-(methylsulfonyl)phenyl)prop-2-enamide, 1-(5-methyl-1- (2-methyl-2-(nitrosothio) propyl)pyrrol-2-yl)-4-(methylsulfonyl) benzene, 3-{4-(1- methyl-1-(nitrosothio)ethyl)-2-oxo-1,3-oxazolidin-3-yl}propyl (2Z)-4-acetyloxy-2-(4- fluropheny!)-3-(4-(methylsulfonyl) phenyl)but-2-enoate, (2Z)-3-(4-fluorophenyl)-3- {N-methyl-N-(2-methyl-2-(nitrosothio) propyl)carbamoyl}-2-(4- (methylsulfonyl)phenyl)prop-2-enyl acetate, 2-(1-methyl-4-(nitrosothio)-4- piperidyl)ethyl (2Z)-3-(4-acetyloxy-2-(4-fluorophenyl)-3-(4- (methylsulfonyl)phenyl)but-2-enoate, (3Z2)-4-(4-chlorophenyl)-3-(ethoxycarbonyl)- 4-(4-(methylsulfonyl)phenyl)but-3-enoic acid, 3-methyl-N-{(4-(5-methyl-3- phenylisoxazol-4-yl)phenyl)sulfonyl}-3-(nitrosothio)butanamide, 2-methyl-2- (nitrosothio)propyl-5-(4-chlorophenyl)-1-(4-sulfamoylphenyl) pyrazole-3- : carboxylate, 4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-({4-((nitroxy)- methyl)phenyl}methyl)-2-hydroxypyridazin-3-one, 1-(1-(2-hydroxyethyl)-4- benzylpyrazol-3-yl)-4-(methylsulfonyl)benzene, 4-(methylsulfonyl)-1-{1-(2- (nitrooxy)ethyl)-4-benzylpyrazol-5-yl}benzene, 4-(1-cyclohexyl-3- (hydroxymethyl)pyrazol-5-yl)-1-(methylsulfonyl)benzene and 4-{1-cyclohexyl-3- (nitrooxy)methyl)pyrazol-5-yl}-1-(methylsulfonyl)benzene.46. A composition comprising at least one compound of claim 45 and a pharmaceutically acceptable carrier.47. A kit comprising at least one compound of claim 45.48. A composition comprising at least one parent COX-2 inhibitor of formula (I), formula (IT), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (IX), formula (X), formula (XI), formula (XI), ), formula (XI), formula (XIV), formula (XV) or formula (XVI), or a pharmaceutically acceptable salt thereof, and at least one compound that donates, transfers or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase.49. The composition of claim 48 further comprising a pharmaceutically acceptable carrier.50. The composition of claim 48, wherein the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor or is a substrate for nitric oxide synthase is an S-nitrosothiol.51. The composition of claim 50, wherein the S-nitrosothiol is S-nitroso- N-acetylcysteine, S-nitroso-captopril, S-nitroso-N-acetylpenicillamine, S-nitroso- homocysteine, S-nitroso-cysteine, S-nitroso-glutathione, or S-nitroso-cysteinyl- glycine. :52. The composition of claim 50, wherein the S-nitrosothiol is: (i) HS(C(R)(R)),..SNO; (ii) ONS(C(R)R))..R.;or (iii) HN-CH(CO,H)~(CH,),..-C(O)NH-CH(CH,SNO)-C(O)NH-CH,-CO,H; wherein mm is an integer from 2 to 20; R, and R, are each independently a - hydrogen, an alkyl, a cycloalkoxy, a halogen, a hydroxy, an hydroxyalkyl, an alkoxyalkyl, an arylheterocyclic ring, a cycloalkylalkyl, a heterocyclicalkyl, an - alkoxy, a haloalkoxy, an amino, an alkylamino, a dialkylamino, an arylamino, a diarylamino, an alkylarylamino, an alkoxyhaloalkyl, a haloalkoxy, a sulfonic acid, a sulfonic ester, an alkylsulfonic acid, an arylsulfonic acid, an arylalkoxy, an alkylthio, an arylthio, a cyano, an aminoalkyl, an aminoaryl, an alkoxy, an aryl, an arylalkyl, a carboxamido, a alkylcarboxamido, an arylcarboxamido, an amidyl, a carboxyl, a carbamoyl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarbonyl, an arylcarbonyl, an ester, a carboxylic ester, an alkylcarboxylic ester, an arylcarboxylic ester, a haloalkoxy, a sulfonamido, an alkylsulfonamido, an arylsulfonamido, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfonyl, an arylsulfonyloxy, a carbamoyl, a urea, a nitro, -T-Q-, or (C(R)(R)),-T-Q, or R, and . R, taken together are an oxo, a methanthial, a heterocyclic ring, a cycloalkyl group or a bridged cycloalkyl group; Q is -NO or -NO,; and T is independently a covalent bond, a carbonyl, an oxygen, -5(0),- or -N(R,)R-, wherein o is an integer from 0 toPCT/US00/35014 2, R, is a lone pair of electrons, a hydrogen or an alkyl group; R; is a hydrogen, an alkyl, an aryl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarboxylic ester, an arylcarboxylic ester, an alkylcarboxamido, an arylearboxamido, an N ] alkylsulfinyl, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfinyl, an arylsulfonyloxy, an arylsulfonyl, a sulfonamido, a carboxamido, a carboxylic ester, an aminoalkyl, an aminoaryl, -CH,-C(T-Q)(R )(R)), or -(N,0,-) eM", wherein M" is an : organic or inorganic cation; with the proviso that when R, is -CIH,-C(T-Q)(R (Ry) or -(N,O,-)*M’; then "-T-Q" can be a hydrogen, an alkyl group, an alkoxyalkyl group, an aminoalkyl group, a hydroxy group or an aryl group.53. The composition of claim 48, wherein the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide : synthase is L-arginine, L-homoarginine, N-hydroxy-L-arginine, nitrosated L- arginine, nitrosylated L-arginine, nitrosated N-hydroxy-L-arginine, nitrosylated N- hydroxy-L-arginine, citrulline, ornithine, glutamine, or an arginase inhibitor.54. The composition of claim 48, wherein the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase is: (i) a compound that comprises at least one ON-O-, ON-N- or ON-C- group; (i) acompound that comprises at least one O,N-O-, O,N-N-, O,N-5- or -O,N-C- group; (iii) a N-oxo-N-nitrosoamine having the formula: RIR?N-N(O-M*)-NO, wherein R' and R? are each independently a polypeptide, an amino acid, a sugar, an oligonucleotide, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted hydrocarbon, or a heterocyclic group, and M" is an organic or inorganic cation.55. The composition of claim 54, wherein the compound comprising at least one ON-O-, ON-N- or ON-C- group is an ON-O-polypeptide, an ON-N- polypeptide, an ON-C-polypeptide, an ON-O-amino acid, an ON-N-amino acid, an ON-C-amino acid, ‘an ON-O-sugar, an ON-N-sugar, an ON-C-sugar, an ON-O- oligonucleotide, an ON-N-oligonucleotide, an ON-C-oligonucleotide, a straight or 218 AMENDED SHEET® PCT/US00/35014 ‘branched, saturated—or unsaturated, substituted or unsubstituted, aliphatic or aromatic ON-O- ~ hydrocarbon, a straight or branched, saturated or unsaturated, substituted or unsubstituted, aliphatic . or aromatic ON-N-hydrocarbon, a straight or branched, saturated or unsaturated, substituted or unsubstituted, aliphatic or aromatic ON-C-hydrocarbon, an ON-O-heterocyclic compound, an ON- N-heterocyclic compound or a ON-C-heterocyclic compound. :56. The composition of claim 54, wherein compound comprising at least one O,N-O-, } O,N-N-, O,N-S- or O,N-C- group is an 0O,N-O-polypeptide, an O,N-N-polypeptide, an O,N-S- polypeptide, an O,N-C-polypeptide, an O,N-O-amino acid, O,N-N-amino acid, O,N-S-amino acid, O,N-C-amino acid, an O,N-O-sugar, an O,N-N-sugar, O,N-S-sugar, an O,N-C-sugar, an O,N-O- oligonucleotide, an O,N-N-oligonucleotide, an O,N-S-oligonucleotide, an O,N-C-oligonucleotide, oo a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted O,N-O-hydrocarbon, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted O,N-N-hydrocarbon, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted O,N-S-hydrocarbon, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted O,N-C-hydrocarbon, an O,N-O-heterocyclic compound, an O,N-N-heterocyclic compound, an O,N-S-heterocyclic compound or an O,N-C-heterocyclic compound. © 57. The composition of claim 48, further comprising at least one therapeutic agent.58. The composition of claim 57, wherein the therapeutic agent is a steroid, a nonsteroidal antiinflammatory compound, a 5-lipoxygenase inhibitor, a leukotriene B, receptor antagonist, a leukotriene A, hydrolase inhibitor, a 5-HT agonist, a 3-hydroxy-3-methylglutaryl _. coenzyme A inhibitor, a H, receptor antagonist, an antineoplastic agent, an antiplatelet agent, a decongestant, a diuretic, a sedating or non-sedating anti-histamine, an inducible nitric oxide synthase inhibitor, an opioid, an analgesic a Helicobacter pylori inhibitor, a proton pump inhibitor, an isoprostane inhibitor, or a mixture thereof.59. A method for preventing inflammation, pain or fever in a subject comprising administering to the subject an effective amount of the composition of claim 48 or 57. AMENDED SHEET® | : PCT/US00/3501460. A method for preventing a gastrointestinal disorder, or improving the gastrointestinal - properties of COX-2 inhibitor in a subject comprising administering to the subject an effective amount of the composition of claim 48 or 57.61. The method of claim 60, wherein the gastrointestinal disorder is an inflammatory bowel disease, Crohn’s disease, gastritis, irritable bowel syndrome, ulcerative colitis, a peptic ulcer, a stress ulcer, a bleeding ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger- Ellison syndrome, gastroesophageal reflux disease, a bacterial infection, short-bowel (anastomosis) syndrome, or a hypersecretory state associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia. : 62. Use of the composition of claim 48 or 57 in the manufacture of a medicament for - facilitating wound healing in a patient in need thereof.63. Use of claim 62, wherein the wound is an ulcer.64. Use of the composition of claim 48 or 57 in the manufacture of a medicament for treating or reversing renal or other toxicities in a patient in need thereof.65. A method for preventing a disorder resulting from elevated levels of COX-2 in a subject comprising administering to the subject an effective amount of the composition of claim 48 or 57.66. The method of claim 65, wherein the disorder resulting from elevated levels of COX-2 is angiogenesis, arthritis, asthma, bronchitis, menstrual cramps, premature labor, tendinitis, bursitis, skin-related condition, neoplasia, inflammation in disease, ophthalmic disorder, pulmonary inflammation, central nervous system disorder, allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, inflammation and/or microbial infection, cardiovascular disorder, urinary and/or urological disorder, endothelial dysfunction, preservation of organs and tissues, inhibition and/or prevention of activation, adhesion and infiltration of neutrophils at the site of inflammation, or inhibition and/or prevention of platelet aggregation.67. A kit comprising at least one parent COX-2 inhibitor and at least one compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, or a pharmaceutically acceptable salt thereof. | : AMENDED SHEET® PCT/USG0/3501468. The kit of claim 67, further comprising at least one therapeutic agent.69. The kit of claim 67, wherein the parent COX-2 inhibitor and the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase are separate components in the kit.70. The kit of claim 67, wherein the parent COX-2 inhibitor and the compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide ‘ or endothelium-derived relaxing factor, or is a substrate for nitric oxide synthase are in the form of a composition in the kit.71. Use of the compound of claim 1 in the manufacture of a medicament for treating, preventing or reducing inflammation, pain or fever in a patient in need thereof.72. Use of the compound of claim 1 in the manufacture of a medicament for treating or preventing a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a patient in need thereof.73. Use of claim 4, wherein the gastrointestinal disorder is as listed in claim 5.74. Use of a compound of claim 1 in the manufacture of a medicament for treating or preventing a disorder resulting from elevated levels of COX-2 in a patient in need thereof.75. Use of claim 74, wherein the disorder resulting from elevated levels of COX-2 is as listed in claim 10.76. Use of the composition of claim 11 in the manufacture of a medicament for treating, preventing or reducing inflammation, pain or fever in a patient in need thereof.77. Use of the composition of claim 11 in the manufacture of a medicament for treating or preventing a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a patient in need thereof.78. Use of claim 77, wherein the gastrointestinal disorder is as listed in claim 15.79. Use of the composition of claim 11 in the manufacture of a medicament for treating or preventing a disorder resulting from elevated levels of COX-2 in a patient in need thereof. : AMENDED SHEET® PCT/US00/3501480. Use of claim 79, wherein the disorder resulting from elevated levels of COX-2 is as listed in claim 20.81. Use of the composition of claim 21 or 30 in the manufacture of a medicament for treating, preventing or reducing inflammation, pain or fever in a patient in need thereof.82. Use of the composition of claim 21 or 30 in the manufacture of a medicament for treating or preventing a gastrointestinal disorder, or improving the gastrointestinal properties ofa COX-2 inhibitor in a patient in need thereof.83. Use of claim 82, wherein the gastrointestinal disorder is as listed in claim 34.84. Use of the composition of claim 21 or 30 in the manufacture of a medicament for treating or preventing a disorder resulting from elevated levels of COX-2 in a patient in need thereof. | :85. Use of claim 84, wherein the disorder resulting from elevated levels of COX-2 is as listed in claim 39.86. Use of the composition of claim 48 or 57 in the manufacture of a medicament for treating, preventing or reducing inflammation, pain or fever in a patient in need thereof. : 87. Use of the composition of claim 48 or 57 in the manufacture of a medicament for treating or preventing a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a patient in need thereof.88. Use of claim 87, wherein the gastrointestinal disorder is as listed in claim 61.89. Use of the composition of claim 48 or 57 in the manufacture of a medicament for treating or preventing a disorder resulting from elevated levels of COX-2 in a patient in need thereof.90. Use of claim 89 wherein the disorder resulting from elevated levels of COX-2 as listed in claim 66.91. A substance or composition for use in a method for treating, preventing or reducing inflammation, pain or fever in a patient in need thereof, said substance or composition comprising of a compound of claim 1, and said method comprising administering to the patient a : therapeutically effective amount of said substance or composition. AMENDED SHEET® a. PCT/US00/35014 : 92. A substance or composition for use in a method for treating or preventing a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a patient in need thereof, saib substance or composition comprising of a compound of claim 1, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.93. A substance or composition for use in a method of treatment of claim 92, wherein the gastrointestinal disorder is as listed in claim 5.94. A substance or composition for use in a method for facilitating wound healing in a patient in need thereof, said substance or composition comprising a compound of claim 1, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition. :95. A substance or composition for use in a method of treatment of claim 94, wherein the wound is an ulcer.96. A substance or composition for use in a method for treating or reversing renal or other toxicities in a patient in need thereof, said substance or composition comprising a compound of claim 1, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.97. A substance or composition for use in a method for treating or preventing a disorder resulting from elevated levels of COX-2 in a patient in need thereof, said substance or composition comprising a compound of claim 1, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.98. A substance or composition for use in a method of treatment of claim 97, wherein the disorder resulting from elevated levels of COX-2 is as listed in claim 10.99. A substance or composition for use in a method for treating, preventing or reducing inflammation, pain or fever in a patient in need thereof, said substance or composition comprising the composition of claim 11, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.100. A substance or composition for use in a method for treating or preventing a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a AMENDED SHEET® PCT/US00/35014 : ~ patient in need thereof, said substance or composition comprising the composition of claim 11, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.101. A substance or composition for use in a method of treatment of claim 100, wherein the gastrointestinal disorder is as listed in claim 15.102. A substance or composition for use in a method for facilitating wound healing in a patient in need thereof, said substance or composition comprising the composition of claim 11, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition. :103. A substance or composition for use in a method of treatment of claim 102, wherein the wound is an ulcer.104. A substance or composition for use in a method for treating or reversing renal or other toxicities in a patient in need thereof, said substance or composition comprising the composition of claim 11, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.105. A substance or composition for use in a method for treating or preventing a disorder resulting from elevated levels of COX-2 in a patient in need thereof, said substance or composition comprising the composition of claim 11, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.106. A substance or composition for use in a method of treatment of claim 105, wherein the disorder resulting from elevated levels of COX-2 is as listed in claim 20.107. A substance or composition for use in a method for treating, preventing or reducing ° inflammation, pain or fever in a patient in need thereof, said substance or composition comprising the composition of claim 21 or 30, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.108. A substance or composition for use in a method for treating or preventing a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a patient in need thereof, said substance or composition comprising the composition of claim 21 or : 30, and said method comprising administering to the patient a therapeutically effective amount of AMENDED SHEET® PCT/US00/35014 said substance or composition. : 109. A substance orcomposition-for-use-in-a-method-of treatment of claim-108, wherein the gastrointestinal disorder is as listed in claim 34.110. A substance or composition for use in a method for facilitating wound healing in a patient in need thereof, said substance or composition comprising the composition of claim 21 or 30, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition. :111. A substance or composition for use in a method of treatment of claim 110, wherein the wound is an ulcer.112. A substance or composition for use in a method for treating or reversing renal or other toxicities in a patient in need thereof, said substance or composition comprising the composition of claim 21 or 30, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.113. A substance or composition for use in a method for treating or preventing a disorder resulting from elevated levels of COX-2 in a patient in need thereof, said substance or composition : comprising the composition of claim 21 or 30, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.114. A substance or composition for use in a method of treatment of claim 113, wherein the disorder resulting from elevated levels of COX-2 is as listed in claim 39.115. A substance or composition for use in a method for treating, preventing or reducing inflammation, pain or fever in a patient in need thereof, said substance or composition comprising the composition of claim 48 or 57, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.116. A substance or composition for use in a method for treating or preventing a gastrointestinal disorder, or improving the gastrointestinal properties of a COX-2 inhibitor in a patient in need thereof, said substance or composition comprising the sermposidon of claim 48 or 57, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.117. A substance or composition for use in a method of treatment of claim 116, wherein the gastrointestinal disorder is as listed in claim 61. AMENDED SHEET® | PCT/US00/35014118. A substance or composition for use in a method for facilitating wound healing in a . patient in need thereof, said substance or composition comprising the composition of claim 48 or 57, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.119. A substance or composition for use in a method of treatment of claim 118, wherein the wound is an ulcer.120. A substance or composition for use in a method for treating or reversing renal or other toxicities in a patient in need thereof, said substance or composition comprising the composition of claim 48 or 57, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition. .121. A substance or composition for use in a method for treating or preventing a disorder resulting from elevated levels of COX-2 in a patient in need thereof, said substance or composition comprising the composition of claim 48 or 57, and said method comprising administering to the patient a therapeutically effective amount of said substance or composition.122. A substance or composition for use in a method of treatment of claim 121, wherein the disorder resulting from elevated levels of COX-2 is as listed in claim 66.123. A compound according to claim 1 or claim 45, substantially as herein described and illustrated.124. A composition according to anyone of claims 2, 21, 46, or 48, substantially as herein described and illustrated.125. A kit according to claim 40, or claim 41, or claim 43, or claim 47, or claim 67, substantially as herein described and illustrated.126. A method according to any one of claims 3, 4, 9, 13, 19, 32, 33, 38, 59, or 65, substantially as herein described and illustrated.127. Use according to any one of claims 6, 8, 16, 18, 35, 37, 62, 64, and 71 to 90, substantially as herein described and illustrated.128. A substance or composition for use in a method of treatment or prevention according to anyone of claims 91 to 122, substantially as herein described and illustrated. AMENDED SHEET@ PCT/US00/35014129. A new compound, a new composition, a new Kit, a new non-therapeutic method of treatment, a new use of a compound as claimed in claim 1, or a substance or composition for a new use in a method of treatment or prevention, substantially as herein described. AMENDED SHEET oo
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17162399P | 1999-12-23 | 1999-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200205707B true ZA200205707B (en) | 2003-11-11 |
Family
ID=32592404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200205707A ZA200205707B (en) | 1999-12-23 | 2002-07-17 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200205707B (en) |
-
2002
- 2002-07-17 ZA ZA200205707A patent/ZA200205707B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6649629B2 (en) | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | |
US20060194861A1 (en) | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | |
US7589124B2 (en) | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | |
EP1406609A2 (en) | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use | |
AU2002249812A1 (en) | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use | |
US20070155734A1 (en) | Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | |
US20070238735A1 (en) | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | |
US20020183366A1 (en) | Cyclooxygenase-2 inhibitors, compositions and methods of use | |
ZA200205707B (en) | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use. |